window.__IS_SSR__=true
window.__INITIAL_STATE__={
"attachmentsReducer": {
"audio_0": {
"type": "attachments",
"id": "audio_0",
"imgSizes": {
"kqedFullSize": {
"file": "https://ww2.kqed.org/news/wp-content/themes/KQED-unified/img/audio_bgs/background0.jpg"
}
}
},
"audio_1": {
"type": "attachments",
"id": "audio_1",
"imgSizes": {
"kqedFullSize": {
"file": "https://ww2.kqed.org/news/wp-content/themes/KQED-unified/img/audio_bgs/background1.jpg"
}
}
},
"audio_2": {
"type": "attachments",
"id": "audio_2",
"imgSizes": {
"kqedFullSize": {
"file": "https://ww2.kqed.org/news/wp-content/themes/KQED-unified/img/audio_bgs/background2.jpg"
}
}
},
"audio_3": {
"type": "attachments",
"id": "audio_3",
"imgSizes": {
"kqedFullSize": {
"file": "https://ww2.kqed.org/news/wp-content/themes/KQED-unified/img/audio_bgs/background3.jpg"
}
}
},
"audio_4": {
"type": "attachments",
"id": "audio_4",
"imgSizes": {
"kqedFullSize": {
"file": "https://ww2.kqed.org/news/wp-content/themes/KQED-unified/img/audio_bgs/background4.jpg"
}
}
},
"placeholder": {
"type": "attachments",
"id": "placeholder",
"imgSizes": {
"thumbnail": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-160x107.jpg",
"width": 160,
"height": 107,
"mimeType": "image/jpeg"
},
"medium": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-800x533.jpg",
"width": 800,
"height": 533,
"mimeType": "image/jpeg"
},
"medium_large": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-768x512.jpg",
"width": 768,
"height": 512,
"mimeType": "image/jpeg"
},
"large": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-1020x680.jpg",
"width": 1020,
"height": 680,
"mimeType": "image/jpeg"
},
"1536x1536": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-1536x1024.jpg",
"width": 1536,
"height": 1024,
"mimeType": "image/jpeg"
},
"fd-lrg": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-1536x1024.jpg",
"width": 1536,
"height": 1024,
"mimeType": "image/jpeg"
},
"fd-med": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-1020x680.jpg",
"width": 1020,
"height": 680,
"mimeType": "image/jpeg"
},
"fd-sm": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-800x533.jpg",
"width": 800,
"height": 533,
"mimeType": "image/jpeg"
},
"post-thumbnail": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-672x372.jpg",
"width": 672,
"height": 372,
"mimeType": "image/jpeg"
},
"twentyfourteen-full-width": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-1038x576.jpg",
"width": 1038,
"height": 576,
"mimeType": "image/jpeg"
},
"xxsmall": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-160x107.jpg",
"width": 160,
"height": 107,
"mimeType": "image/jpeg"
},
"xsmall": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-672x372.jpg",
"width": 672,
"height": 372,
"mimeType": "image/jpeg"
},
"small": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-672x372.jpg",
"width": 672,
"height": 372,
"mimeType": "image/jpeg"
},
"xlarge": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-1020x680.jpg",
"width": 1020,
"height": 680,
"mimeType": "image/jpeg"
},
"full-width": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1-1920x1280.jpg",
"width": 1920,
"height": 1280,
"mimeType": "image/jpeg"
},
"guest-author-32": {
"file": "https://cdn.kqed.org/wp-content/uploads/2025/01/KQED-Default-Image-816638274-1333x1333-1-160x160.jpg",
"width": 32,
"height": 32,
"mimeType": "image/jpeg"
},
"guest-author-50": {
"file": "https://cdn.kqed.org/wp-content/uploads/2025/01/KQED-Default-Image-816638274-1333x1333-1-160x160.jpg",
"width": 50,
"height": 50,
"mimeType": "image/jpeg"
},
"guest-author-64": {
"file": "https://cdn.kqed.org/wp-content/uploads/2025/01/KQED-Default-Image-816638274-1333x1333-1-160x160.jpg",
"width": 64,
"height": 64,
"mimeType": "image/jpeg"
},
"guest-author-96": {
"file": "https://cdn.kqed.org/wp-content/uploads/2025/01/KQED-Default-Image-816638274-1333x1333-1-160x160.jpg",
"width": 96,
"height": 96,
"mimeType": "image/jpeg"
},
"guest-author-128": {
"file": "https://cdn.kqed.org/wp-content/uploads/2025/01/KQED-Default-Image-816638274-1333x1333-1-160x160.jpg",
"width": 128,
"height": 128,
"mimeType": "image/jpeg"
},
"detail": {
"file": "https://cdn.kqed.org/wp-content/uploads/2025/01/KQED-Default-Image-816638274-1333x1333-1-160x160.jpg",
"width": 160,
"height": 160,
"mimeType": "image/jpeg"
},
"kqedFullSize": {
"file": "https://cdn.kqed.org/wp-content/uploads/2024/12/KQED-Default-Image-816638274-2000x1333-1.jpg",
"width": 2000,
"height": 1333
}
}
},
"futureofyou_203083": {
"type": "attachments",
"id": "futureofyou_203083",
"meta": {
"index": "attachments_1716263798",
"site": "futureofyou",
"id": "203083",
"found": true
},
"parent": 203018,
"imgSizes": {
"twentyfourteen-full-width": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/07/KQED_Theranos_FeaturedImage-1038x576.jpg",
"width": 1038,
"mimeType": "image/jpeg",
"height": 576
},
"thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/07/KQED_Theranos_FeaturedImage-400x240.jpg",
"width": 400,
"mimeType": "image/jpeg",
"height": 240
},
"fd-sm": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/07/KQED_Theranos_FeaturedImage-960x576.jpg",
"width": 960,
"mimeType": "image/jpeg",
"height": 576
},
"post-thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/07/KQED_Theranos_FeaturedImage-672x372.jpg",
"width": 672,
"mimeType": "image/jpeg",
"height": 372
},
"kqedFullSize": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/07/KQED_Theranos_FeaturedImage.jpg",
"width": 1920,
"height": 1151
},
"large": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/07/KQED_Theranos_FeaturedImage-1180x707.jpg",
"width": 1180,
"mimeType": "image/jpeg",
"height": 707
},
"guest-author-50": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/07/KQED_Theranos_FeaturedImage-50x50.jpg",
"width": 50,
"mimeType": "image/jpeg",
"height": 50
},
"guest-author-96": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/07/KQED_Theranos_FeaturedImage-96x96.jpg",
"width": 96,
"mimeType": "image/jpeg",
"height": 96
},
"medium": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/07/KQED_Theranos_FeaturedImage-800x480.jpg",
"width": 800,
"mimeType": "image/jpeg",
"height": 480
},
"guest-author-64": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/07/KQED_Theranos_FeaturedImage-64x64.jpg",
"width": 64,
"mimeType": "image/jpeg",
"height": 64
},
"guest-author-32": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/07/KQED_Theranos_FeaturedImage-32x32.jpg",
"width": 32,
"mimeType": "image/jpeg",
"height": 32
},
"fd-lrg": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/07/KQED_Theranos_FeaturedImage-1920x1151.jpg",
"width": 1920,
"mimeType": "image/jpeg",
"height": 1151
},
"fd-med": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/07/KQED_Theranos_FeaturedImage-1180x707.jpg",
"width": 1180,
"mimeType": "image/jpeg",
"height": 707
},
"detail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/07/KQED_Theranos_FeaturedImage-150x150.jpg",
"width": 150,
"mimeType": "image/jpeg",
"height": 150
},
"medium_large": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/07/KQED_Theranos_FeaturedImage-768x460.jpg",
"width": 768,
"mimeType": "image/jpeg",
"height": 460
},
"guest-author-128": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/07/KQED_Theranos_FeaturedImage-128x128.jpg",
"width": 128,
"mimeType": "image/jpeg",
"height": 128
}
},
"publishDate": 1468451121,
"modified": 1470171969,
"caption": null,
"description": "For the first time in public, Elizabeth Holmes will present evidence that Theranos says will show its technology works. Her presentation will be given at the American Association for Clinical Chemistry annual meeting in Philadelphia, Monday, Aug. 1.",
"title": "KQED_Theranos_FeaturedImage",
"credit": "Image by Mark Fiore, \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/07/14/the-rise-and-fall-of-theranos-a-cartoon-history/\">The Rise and Fall of Theranos: A Cartoon History\u003c/a>",
"status": "inherit",
"isLoading": false,
"fetchFailed": false
},
"futureofyou_152361": {
"type": "attachments",
"id": "futureofyou_152361",
"meta": {
"index": "attachments_1716263798",
"site": "futureofyou",
"id": "152361",
"found": true
},
"parent": 152359,
"imgSizes": {
"twentyfourteen-full-width": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/theranoshome-1038x576.jpg",
"width": 1038,
"mimeType": "image/jpeg",
"height": 576
},
"thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/theranoshome-400x346.jpg",
"width": 400,
"mimeType": "image/jpeg",
"height": 346
},
"fd-sm": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/theranoshome-960x829.jpg",
"width": 960,
"mimeType": "image/jpeg",
"height": 829
},
"post-thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/theranoshome-672x372.jpg",
"width": 672,
"mimeType": "image/jpeg",
"height": 372
},
"kqedFullSize": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/theranoshome-e1461624309161.jpg",
"width": 1920,
"height": 1658
},
"large": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/theranoshome-1180x1019.jpg",
"width": 1180,
"mimeType": "image/jpeg",
"height": 1019
},
"guest-author-96": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/theranoshome-96x96.jpg",
"width": 96,
"mimeType": "image/jpeg",
"height": 96
},
"medium": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/theranoshome-695x600.jpg",
"width": 695,
"mimeType": "image/jpeg",
"height": 600
},
"guest-author-64": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/theranoshome-64x64.jpg",
"width": 64,
"mimeType": "image/jpeg",
"height": 64
},
"guest-author-32": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/theranoshome-32x32.jpg",
"width": 32,
"mimeType": "image/jpeg",
"height": 32
},
"fd-lrg": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/theranoshome-1920x1658.jpg",
"width": 1920,
"mimeType": "image/jpeg",
"height": 1658
},
"fd-med": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/theranoshome-1180x1019.jpg",
"width": 1180,
"mimeType": "image/jpeg",
"height": 1019
},
"detail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/theranoshome-75x75.jpg",
"width": 75,
"mimeType": "image/jpeg",
"height": 75
},
"medium_large": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/theranoshome-768x663.jpg",
"width": 768,
"mimeType": "image/jpeg",
"height": 663
},
"guest-author-128": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/theranoshome-128x128.jpg",
"width": 128,
"mimeType": "image/jpeg",
"height": 128
}
},
"publishDate": 1461624188,
"modified": 1461625314,
"caption": null,
"description": null,
"title": "theranoshome",
"credit": "Photo by Steve Jurvetson/Flickr",
"status": "inherit",
"isLoading": false,
"fetchFailed": false
},
"futureofyou_216776": {
"type": "attachments",
"id": "futureofyou_216776",
"meta": {
"index": "attachments_1716263798",
"site": "futureofyou",
"id": "216776",
"found": true
},
"parent": 216744,
"imgSizes": {
"twentyfourteen-full-width": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/08/HolmesNPR-800x576.jpg",
"width": 800,
"mimeType": "image/jpeg",
"height": 576
},
"thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/08/HolmesNPR-400x300.jpg",
"width": 400,
"mimeType": "image/jpeg",
"height": 300
},
"post-thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/08/HolmesNPR-672x372.jpg",
"width": 672,
"mimeType": "image/jpeg",
"height": 372
},
"kqedFullSize": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/08/HolmesNPR.jpg",
"width": 800,
"height": 600
},
"guest-author-50": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/08/HolmesNPR-50x50.jpg",
"width": 50,
"mimeType": "image/jpeg",
"height": 50
},
"guest-author-96": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/08/HolmesNPR-96x96.jpg",
"width": 96,
"mimeType": "image/jpeg",
"height": 96
},
"guest-author-64": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/08/HolmesNPR-64x64.jpg",
"width": 64,
"mimeType": "image/jpeg",
"height": 64
},
"detail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/08/HolmesNPR-150x150.jpg",
"width": 150,
"mimeType": "image/jpeg",
"height": 150
},
"guest-author-32": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/08/HolmesNPR-32x32.jpg",
"width": 32,
"mimeType": "image/jpeg",
"height": 32
},
"medium_large": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/08/HolmesNPR-768x576.jpg",
"width": 768,
"mimeType": "image/jpeg",
"height": 576
},
"guest-author-128": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/08/HolmesNPR-128x128.jpg",
"width": 128,
"mimeType": "image/jpeg",
"height": 128
}
},
"publishDate": 1470356082,
"modified": 1470356097,
"caption": "Elizabeth Holmes, founder and CEO of Theranos, speaks at the Clinton Global Initiative's closing session Sept. 29, 2015, in New York City.\n",
"description": null,
"title": "HolmesNPR",
"credit": "Andrew Burton/Getty Images",
"status": "inherit",
"isLoading": false,
"fetchFailed": false
},
"futureofyou_145322": {
"type": "attachments",
"id": "futureofyou_145322",
"meta": {
"index": "attachments_1716263798",
"site": "futureofyou",
"id": "145322",
"found": true
},
"parent": 145291,
"imgSizes": {
"twentyfourteen-full-width": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-1038x576.jpg",
"width": 1038,
"mimeType": "image/jpeg",
"height": 576
},
"thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-400x266.jpg",
"width": 400,
"mimeType": "image/jpeg",
"height": 266
},
"fd-sm": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-960x639.jpg",
"width": 960,
"mimeType": "image/jpeg",
"height": 639
},
"post-thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-672x372.jpg",
"width": 672,
"mimeType": "image/jpeg",
"height": 372
},
"kqedFullSize": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-e1460580069776.jpg",
"width": 1920,
"height": 1278
},
"large": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-1180x785.jpg",
"width": 1180,
"mimeType": "image/jpeg",
"height": 785
},
"guest-author-96": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-96x96.jpg",
"width": 96,
"mimeType": "image/jpeg",
"height": 96
},
"medium": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-800x532.jpg",
"width": 800,
"mimeType": "image/jpeg",
"height": 532
},
"guest-author-64": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-64x64.jpg",
"width": 64,
"mimeType": "image/jpeg",
"height": 64
},
"guest-author-32": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-32x32.jpg",
"width": 32,
"mimeType": "image/jpeg",
"height": 32
},
"fd-lrg": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-1920x1278.jpg",
"width": 1920,
"mimeType": "image/jpeg",
"height": 1278
},
"fd-med": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-1180x785.jpg",
"width": 1180,
"mimeType": "image/jpeg",
"height": 785
},
"detail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-75x75.jpg",
"width": 75,
"mimeType": "image/jpeg",
"height": 75
},
"medium_large": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-768x511.jpg",
"width": 768,
"mimeType": "image/jpeg",
"height": 511
},
"guest-author-128": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-128x128.jpg",
"width": 128,
"mimeType": "image/jpeg",
"height": 128
}
},
"publishDate": 1460580012,
"modified": 1523548902,
"caption": "Theranos founder Elizabeth Holmes in 2015.",
"description": "Theranos founder Eliabeth Holmes at the Fortune Global Forum, November 2015.",
"title": "Holmes",
"credit": "Stuart Isett/Fortune Global Forum",
"status": "inherit",
"isLoading": false,
"fetchFailed": false
},
"futureofyou_190769": {
"type": "attachments",
"id": "futureofyou_190769",
"meta": {
"index": "attachments_1716263798",
"site": "futureofyou",
"id": "190769",
"found": true
},
"parent": 190748,
"imgSizes": {
"thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/06/buchanan-400x271.jpg",
"width": 400,
"mimeType": "image/jpeg",
"height": 271
},
"post-thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/06/buchanan-643x372.jpg",
"width": 643,
"mimeType": "image/jpeg",
"height": 372
},
"kqedFullSize": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/06/buchanan.jpg",
"width": 643,
"height": 436
},
"guest-author-50": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/06/buchanan-50x50.jpg",
"width": 50,
"mimeType": "image/jpeg",
"height": 50
},
"guest-author-96": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/06/buchanan-96x96.jpg",
"width": 96,
"mimeType": "image/jpeg",
"height": 96
},
"guest-author-64": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/06/buchanan-64x64.jpg",
"width": 64,
"mimeType": "image/jpeg",
"height": 64
},
"detail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/06/buchanan-150x150.jpg",
"width": 150,
"mimeType": "image/jpeg",
"height": 150
},
"guest-author-32": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/06/buchanan-32x32.jpg",
"width": 32,
"mimeType": "image/jpeg",
"height": 32
},
"guest-author-128": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/06/buchanan-128x128.jpg",
"width": 128,
"mimeType": "image/jpeg",
"height": 128
}
},
"publishDate": 1466802502,
"modified": 1466802544,
"caption": "Brooke Buchanan when she was John McCain's press aide in 2007.",
"description": null,
"title": "buchanan",
"credit": "YouTube screenshot",
"status": "inherit",
"isLoading": false,
"fetchFailed": false
},
"futureofyou_148281": {
"type": "attachments",
"id": "futureofyou_148281",
"meta": {
"index": "attachments_1716263798",
"site": "futureofyou",
"id": "148281",
"found": true
},
"parent": 148241,
"imgSizes": {
"thumbnail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-1-400x199.jpg",
"width": 400,
"mimeType": "image/jpeg",
"height": 199
},
"kqedFullSize": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-1.jpg",
"width": 632,
"height": 315
},
"guest-author-96": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-1-96x96.jpg",
"width": 96,
"mimeType": "image/jpeg",
"height": 96
},
"guest-author-64": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-1-64x64.jpg",
"width": 64,
"mimeType": "image/jpeg",
"height": 64
},
"detail": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-1-75x75.jpg",
"width": 75,
"mimeType": "image/jpeg",
"height": 75
},
"guest-author-32": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-1-32x32.jpg",
"width": 32,
"mimeType": "image/jpeg",
"height": 32
},
"guest-author-128": {
"file": "https://ww2.kqed.org/app/uploads/sites/13/2016/04/Holmes-1-128x128.jpg",
"width": 128,
"mimeType": "image/jpeg",
"height": 128
}
},
"publishDate": 1461002135,
"modified": 1464120443,
"caption": "Elizabeth Holmes discusses Theranos' problems on the 'Today' show in April.",
"description": null,
"title": "Holmes",
"credit": "Today show",
"status": "inherit",
"isLoading": false,
"fetchFailed": false
}
},
"audioPlayerReducer": {
"postId": "stream_live",
"isPaused": true,
"isPlaying": false,
"pfsActive": false,
"pledgeModalIsOpen": true,
"playerDrawerIsOpen": false,
"liveAudioPlayStartedAt": 0,
"liveAudioPlayContext": ""
},
"authorsReducer": {
"byline_futureofyou_216744": {
"type": "authors",
"id": "byline_futureofyou_216744",
"meta": {
"override": true
},
"slug": "byline_futureofyou_216744",
"name": "Laura Sydell\u003cbr />NPR",
"isLoading": false
},
"jbrooks": {
"type": "authors",
"id": "80",
"meta": {
"index": "authors_1716337520",
"id": "80",
"found": true
},
"name": "Jon Brooks",
"firstName": "Jon",
"lastName": "Brooks",
"slug": "jbrooks",
"email": "jbrooks@kqed.org",
"display_author_email": true,
"staff_mastheads": [
"science"
],
"title": "Digital Editor",
"bio": "Jon Brooks is a former Digital Editor for KQED Science. He is the former editor of KQED’s daily news blog, News Fix. In 2014, he won a California Journalism Award for his coverage of ride services like Uber and Lyft and the taxi industry. A veteran blogger, he previously worked for Yahoo! in various news writing and editing roles. Jon is also a playwright whose work has been produced in San Francisco, New York, Italy, and around the U.S. He has written about film for his own blog and studied film at Boston University.",
"avatar": "https://secure.gravatar.com/avatar/98887f7ed1c876ed414d4c915e969584?s=600&d=blank&r=g",
"twitter": "jbrooksfoy",
"facebook": null,
"instagram": null,
"linkedin": null,
"sites": [
{
"site": "arts",
"roles": [
"Contributor",
"editor"
]
},
{
"site": "news",
"roles": [
"author"
]
},
{
"site": "futureofyou",
"roles": [
"administrator"
]
},
{
"site": "mindshift",
"roles": [
"editor"
]
},
{
"site": "stateofhealth",
"roles": [
"editor"
]
},
{
"site": "science",
"roles": [
"administrator"
]
},
{
"site": "quest",
"roles": [
"editor"
]
}
],
"headData": {
"title": "Jon Brooks | KQED",
"description": "Digital Editor",
"ogImgSrc": "https://secure.gravatar.com/avatar/98887f7ed1c876ed414d4c915e969584?s=600&d=blank&r=g",
"twImgSrc": "https://secure.gravatar.com/avatar/98887f7ed1c876ed414d4c915e969584?s=600&d=blank&r=g"
},
"isLoading": false,
"link": "/author/jbrooks"
}
},
"pagesReducer": {
"futureofyou_tag_theranos": {
"type": "terms",
"id": "futureofyou_617",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "617",
"score": 9.108458
},
"featImg": null,
"name": "theranos",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "theranos Archives | KQED Arts",
"ogDescription": null
},
"ttid": 617,
"slug": "theranos",
"isLoading": false,
"title": "theranos",
"pageMeta": {
"site": "futureofyou",
"WpPageTemplate": "page-topic-editorial",
"currentPage": 2
},
"blocks": [
{
"blockName": "kqed/post-list",
"attrs": {
"layout": "cardArticle2",
"query": "posts/futureofyou?tag=theranos",
"seeMore": false,
"paginated": true,
"page": 2
}
},
{
"blockName": "kqed/ad"
}
]
}
},
"pfsSessionReducer": {},
"postsReducer": {
"stream_live": {
"type": "live",
"id": "stream_live",
"audioUrl": "https://hls.kqed.org/hls/kqed_app/playlist.m3u8",
"title": "Live Stream",
"excerpt": "Live Stream information currently unavailable.",
"link": "/radio",
"featImg": "",
"label": {
"name": "KQED Live",
"link": "/"
}
},
"stream_kqedNewscast": {
"type": "posts",
"id": "stream_kqedNewscast",
"audioUrl": "https://www.kqed.org/.stream/anon/radio/RDnews/newscast.mp3?_=1",
"title": "KQED Newscast",
"featImg": "",
"label": {
"name": "88.5 FM",
"link": "/"
}
},
"futureofyou_257644": {
"type": "posts",
"id": "futureofyou_257644",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "257644",
"score": null,
"sort": [
1475763815000
]
},
"parent": 0,
"labelTerm": {},
"blocks": [],
"publishDate": 1475763815,
"format": "standard",
"disqusTitle": "Theranos Shutting Down Blood-Testing Centers and Labs",
"title": "Theranos Shutting Down Blood-Testing Centers and Labs",
"headTitle": "KQED Future of You | KQED Science",
"content": "\u003cp>No news is good news when it comes to the fortunes of blood-testing company Theranos.\u003c/p>\n\u003cp>And yesterday, there was news.\u003c/p>\n\u003cp>Company CEO Elizabeth Holmes posted an \u003ca href=\"https://news.theranos.com/2016/10/05/an-open-letter-elizabeth-holmes/\" target=\"_blank\">open letter\u003c/a> Wednesday announcing that Theranos will shut down its two clinical labs and its handful of remaining blood-testing centers. That will result in layoffs for about 340 employees -- approximately 40 percent of the company's workforce -- in Arizona, California and Pennsylvania.\u003c/p>\n\u003cp>Holmes said in her letter, addressed to \"stakeholders,\" that the company will now focus on the development of a portable blood-testing device, which Holmes unveiled at a scientific conference in August.\u003c/p>\n\u003cp>Theranos calls that product a miniLab, and at least some lab experts who we and other media outlets spoke to \u003ca href=\"https://ww2.kqed.org/futureofyou/2016/07/29/theranos-elizabeth-holmes-will-face-1000-scientists-monday-can-she-say-anything-to-gain-their-trust/\" target=\"_blank\">did not think\u003c/a> it represented a significant advance in the field.\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\n\u003cp>Holmes' announcement yesterday comes in the midst of the company's appeal of severe sanctions imposed by the Centers for Medicare & Medicaid Services, which among other penalties banned Holmes from owning or running any clinical laboratory for two years. The sanctions stem from deficiencies at Theranos' Newark, California lab, including problems with a blood-clotting test that CMS judged to be life-threatening. That lab has been closed since July, when regulators revoked the company's license to operate it.\u003c/p>\n\u003cp>Theranos has another lab in Scottsdale, Arizona, so now that will be shuttered as well. But because the government's sanctions preclude Holmes from owning or operating any lab, it's unclear how Holmes could have stayed with the company should Theranos have wished to keep its Arizona lab open. And Holmes, apparently, isn't going anywhere. At least, that seemed to be the case in mid-July, when Theranos issued a sort of \u003ca href=\"https://news.theranos.com/2016/07/19/theranos-statement-on-cms-findings/\" target=\"_blank\">FAQ\u003c/a> about what the government's sanctions meant for its operations.\u003c/p>\n\u003cp>\"The clinical lab is just one of Theranos’ many opportunities to provide access to high-integrity, affordable and actionable health care information, and the company will continue to carry out its mission under the leadership of its founder and CEO, Elizabeth Holmes,\" the company said.\u003c/p>\n\u003cp>In her open letter yesterday, Holmes said Theranos had installed a new executive team \"leading our work toward obtaining FDA clearances, building commercial partnerships, and pursuing publications in scientific journals. We are fortunate to have supporters and investors who believe deeply in our mission of affordable, less invasive lab testing, and to have the runway to realize our vision.\"\u003c/p>\n\u003cp>We sent Theranos and Hill+Knowlton Strategies, which Theranos uses for media relations, a query as to how the shuttering of its consumer blood-testing business might affect its appeal of the sanctions. Hill+Knowlton said Theranos would have no comment beyond Holmes' open letter \"at this time.\"\u003c/p>\n\u003cp>CMS has said it routinely negotiates with companies that it penalizes, but the circumstances for which it lifts sanctions did not seem to apply to Theranos. CMS also said at one point that closing down its labs would not be enough to prevent the penalties from being implemented.\u003c/p>\n\u003cp>If Theranos has no further comment right now, here's someone who does: Wall Street Journal reporter John Carreyrou, whose \u003ca href=\"http://www.wsj.com/articles/theranos-has-struggled-with-blood-tests-1444881901\" target=\"_blank\">investigative reporting\u003c/a> heralded the beginning of the end for Theranos' status as a golden child of Silicon Valley \"disruption.\" Carreyrou yesterday indulged in a victory tweet:\u003c/p>\n\u003cp>https://twitter.com/JohnCarreyrou/status/783844650213715968\u003c/p>\n\u003cp>\u003cstrong>Litany of Woes\u003c/strong>\u003c/p>\n\u003cp>We won't go into the specifics of the many developments that have led to Theranos in just a year's time becoming -- it's probably fair to say -- a corporate pariah. (See our \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/07/14/the-rise-and-fall-of-theranos-a-cartoon-history/\" target=\"_blank\">cartoon history of the company here\u003c/a> for more.) Theranos made its name by touting what it said was a revolutionary diagnostic technology, which allowed for dozens of blood tests from just a few drops of blood, and for extremely low prices.\u003c/p>\n\u003cp>A high-profile partnership with Walgreens, opening dozens of Theranos blood-testing centers within the pharmacy chain’s stores, gave its technology the imprimatur of a major health care provider.\u003c/p>\n\u003cp>Investors piled on, bestowing the company with a $9 billion valuation, according to Forbes, $4.5 billion of which would accrue to Holmes.\u003c/p>\n\u003cp>But it all came tumbling down -- rapidly. The lab testing community had already been grumbling that Theranos had never published in a a single word of proof in a peer-reviewed journal that its methods worked. Then came \u003ca href=\"https://ww2.kqed.org/futureofyou/2016/01/26/for-theranos-the-bad-news-keeps-coming/\">Wall Street Journal articles alleging\u003c/a>, among other improprieties, that Theranos failed to report tests showing its vaunted tech may not be accurate. CMS soon threatened its sanctions, which were based on an unrelated lab inspection. Scientific studies emerged that showed Theranos' test results deviated from norms; \u003ca href=\"https://ww2.kqed.org/futureofyou/2016/06/12/walgreens-shutting-down-theranos-centers-immediately-as-it-ends-partnership/\">Walgreens bailed\u003c/a>; the company invalidated tens of thousands of patient blood tests; lawsuits proliferated; the SEC and U.S. Attorney's Office for Northern California opened investigations; and an attempted comeback at the annual meeting of the American Association for Clinical Chemistry was a bust: attendees had fully expected, at long last, some hard validating data, but instead got what some characterized as a marketing presentation for a not overly exciting new product.\u003c/p>\n\u003cp>Plus there's the whole \u003ca href=\"http://www.vanityfair.com/hollywood/2016/06/jennifer-lawrence-theranos-elizabeth-holmes\" target=\"_blank\">Jennifer Lawrence thing\u003c/a>. ...\u003c/p>\n\u003cp>More to come, we're sure.\u003c/p>\n\u003cp>Here's yesterday's full \u003ca href=\"https://news.theranos.com/2016/10/05/an-open-letter-elizabeth-holmes/\" target=\"_blank\">open letter \u003c/a>from Holmes on Theranos' website:\u003c/p>\n\u003cblockquote>\u003cp>For our stakeholders,\u003c/p>\n\u003cp>After many months spent assessing our strengths and addressing our weaknesses, we have moved to structure our company around the model best aligned with our core values and mission.\u003c/p>\n\u003cp>We have decided to close our clinical labs and Theranos Wellness Centers, which will impact approximately 340 employees in Arizona, California, and Pennsylvania. We are profoundly grateful to these team members, many of whom have devoted years to Theranos and our mission, for their commitment to our company and our guests.\u003c/p>\n\u003cp>We will return our undivided attention to our miniLab platform. Our ultimate goal is to commercialize miniaturized, automated laboratories capable of small-volume sample testing, with an emphasis on vulnerable patient populations, including oncology, pediatrics, and intensive care.\u003c/p>\n\u003cp>We have a new executive team leading our work toward obtaining FDA clearances, building commercial partnerships, and pursuing publications in scientific journals.\u003c/p>\n\u003cp>We are fortunate to have supporters and investors who believe deeply in our mission of affordable, less invasive lab testing, and to have the runway to realize our vision.\u003c/p>\n\u003cp>I look forward to sharing more with you as we progress along the way.\u003c/p>\n\u003cp>Sincerely,\u003c/p>\n\u003cp>Elizabeth Holmes\u003c/p>\u003c/blockquote>\n\u003cp>[ad floatright]\u003c/p>\n\u003cp>\u003cem>This posted has been edited. It originally said that Theranos does not have an in-house spokesperson, which it does. \u003c/em>\u003c/p>\n\n",
"disqusIdentifier": "257644 http://ww2.kqed.org/futureofyou/?p=257644",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/10/06/theranos-shutting-down-blood-testing-centers-and-labs/",
"stats": {
"hasVideo": false,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 1121,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 32
},
"modified": 1475788404,
"excerpt": "The company will lay off more than 40 percent of its full-time employees.",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "The company will lay off more than 40 percent of its full-time employees.",
"title": "Theranos Shutting Down Blood-Testing Centers and Labs | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "Theranos Shutting Down Blood-Testing Centers and Labs",
"datePublished": "2016-10-06T07:23:35-07:00",
"dateModified": "2016-10-06T14:13:24-07:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "theranos-shutting-down-blood-testing-centers-and-labs",
"status": "publish",
"customPermalink": "2016/10/05/theranos-labs/",
"source": "Future of You",
"path": "/futureofyou/257644/theranos-shutting-down-blood-testing-centers-and-labs",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>No news is good news when it comes to the fortunes of blood-testing company Theranos.\u003c/p>\n\u003cp>And yesterday, there was news.\u003c/p>\n\u003cp>Company CEO Elizabeth Holmes posted an \u003ca href=\"https://news.theranos.com/2016/10/05/an-open-letter-elizabeth-holmes/\" target=\"_blank\">open letter\u003c/a> Wednesday announcing that Theranos will shut down its two clinical labs and its handful of remaining blood-testing centers. That will result in layoffs for about 340 employees -- approximately 40 percent of the company's workforce -- in Arizona, California and Pennsylvania.\u003c/p>\n\u003cp>Holmes said in her letter, addressed to \"stakeholders,\" that the company will now focus on the development of a portable blood-testing device, which Holmes unveiled at a scientific conference in August.\u003c/p>\n\u003cp>Theranos calls that product a miniLab, and at least some lab experts who we and other media outlets spoke to \u003ca href=\"https://ww2.kqed.org/futureofyou/2016/07/29/theranos-elizabeth-holmes-will-face-1000-scientists-monday-can-she-say-anything-to-gain-their-trust/\" target=\"_blank\">did not think\u003c/a> it represented a significant advance in the field.\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>Holmes' announcement yesterday comes in the midst of the company's appeal of severe sanctions imposed by the Centers for Medicare & Medicaid Services, which among other penalties banned Holmes from owning or running any clinical laboratory for two years. The sanctions stem from deficiencies at Theranos' Newark, California lab, including problems with a blood-clotting test that CMS judged to be life-threatening. That lab has been closed since July, when regulators revoked the company's license to operate it.\u003c/p>\n\u003cp>Theranos has another lab in Scottsdale, Arizona, so now that will be shuttered as well. But because the government's sanctions preclude Holmes from owning or operating any lab, it's unclear how Holmes could have stayed with the company should Theranos have wished to keep its Arizona lab open. And Holmes, apparently, isn't going anywhere. At least, that seemed to be the case in mid-July, when Theranos issued a sort of \u003ca href=\"https://news.theranos.com/2016/07/19/theranos-statement-on-cms-findings/\" target=\"_blank\">FAQ\u003c/a> about what the government's sanctions meant for its operations.\u003c/p>\n\u003cp>\"The clinical lab is just one of Theranos’ many opportunities to provide access to high-integrity, affordable and actionable health care information, and the company will continue to carry out its mission under the leadership of its founder and CEO, Elizabeth Holmes,\" the company said.\u003c/p>\n\u003cp>In her open letter yesterday, Holmes said Theranos had installed a new executive team \"leading our work toward obtaining FDA clearances, building commercial partnerships, and pursuing publications in scientific journals. We are fortunate to have supporters and investors who believe deeply in our mission of affordable, less invasive lab testing, and to have the runway to realize our vision.\"\u003c/p>\n\u003cp>We sent Theranos and Hill+Knowlton Strategies, which Theranos uses for media relations, a query as to how the shuttering of its consumer blood-testing business might affect its appeal of the sanctions. Hill+Knowlton said Theranos would have no comment beyond Holmes' open letter \"at this time.\"\u003c/p>\n\u003cp>CMS has said it routinely negotiates with companies that it penalizes, but the circumstances for which it lifts sanctions did not seem to apply to Theranos. CMS also said at one point that closing down its labs would not be enough to prevent the penalties from being implemented.\u003c/p>\n\u003cp>If Theranos has no further comment right now, here's someone who does: Wall Street Journal reporter John Carreyrou, whose \u003ca href=\"http://www.wsj.com/articles/theranos-has-struggled-with-blood-tests-1444881901\" target=\"_blank\">investigative reporting\u003c/a> heralded the beginning of the end for Theranos' status as a golden child of Silicon Valley \"disruption.\" Carreyrou yesterday indulged in a victory tweet:\u003c/p>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "singleTwitterStatus",
"attributes": {
"named": {
"id": "783844650213715968"
},
"numeric": []
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\n\u003cp>\u003cstrong>Litany of Woes\u003c/strong>\u003c/p>\n\u003cp>We won't go into the specifics of the many developments that have led to Theranos in just a year's time becoming -- it's probably fair to say -- a corporate pariah. (See our \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/07/14/the-rise-and-fall-of-theranos-a-cartoon-history/\" target=\"_blank\">cartoon history of the company here\u003c/a> for more.) Theranos made its name by touting what it said was a revolutionary diagnostic technology, which allowed for dozens of blood tests from just a few drops of blood, and for extremely low prices.\u003c/p>\n\u003cp>A high-profile partnership with Walgreens, opening dozens of Theranos blood-testing centers within the pharmacy chain’s stores, gave its technology the imprimatur of a major health care provider.\u003c/p>\n\u003cp>Investors piled on, bestowing the company with a $9 billion valuation, according to Forbes, $4.5 billion of which would accrue to Holmes.\u003c/p>\n\u003cp>But it all came tumbling down -- rapidly. The lab testing community had already been grumbling that Theranos had never published in a a single word of proof in a peer-reviewed journal that its methods worked. Then came \u003ca href=\"https://ww2.kqed.org/futureofyou/2016/01/26/for-theranos-the-bad-news-keeps-coming/\">Wall Street Journal articles alleging\u003c/a>, among other improprieties, that Theranos failed to report tests showing its vaunted tech may not be accurate. CMS soon threatened its sanctions, which were based on an unrelated lab inspection. Scientific studies emerged that showed Theranos' test results deviated from norms; \u003ca href=\"https://ww2.kqed.org/futureofyou/2016/06/12/walgreens-shutting-down-theranos-centers-immediately-as-it-ends-partnership/\">Walgreens bailed\u003c/a>; the company invalidated tens of thousands of patient blood tests; lawsuits proliferated; the SEC and U.S. Attorney's Office for Northern California opened investigations; and an attempted comeback at the annual meeting of the American Association for Clinical Chemistry was a bust: attendees had fully expected, at long last, some hard validating data, but instead got what some characterized as a marketing presentation for a not overly exciting new product.\u003c/p>\n\u003cp>Plus there's the whole \u003ca href=\"http://www.vanityfair.com/hollywood/2016/06/jennifer-lawrence-theranos-elizabeth-holmes\" target=\"_blank\">Jennifer Lawrence thing\u003c/a>. ...\u003c/p>\n\u003cp>More to come, we're sure.\u003c/p>\n\u003cp>Here's yesterday's full \u003ca href=\"https://news.theranos.com/2016/10/05/an-open-letter-elizabeth-holmes/\" target=\"_blank\">open letter \u003c/a>from Holmes on Theranos' website:\u003c/p>\n\u003cblockquote>\u003cp>For our stakeholders,\u003c/p>\n\u003cp>After many months spent assessing our strengths and addressing our weaknesses, we have moved to structure our company around the model best aligned with our core values and mission.\u003c/p>\n\u003cp>We have decided to close our clinical labs and Theranos Wellness Centers, which will impact approximately 340 employees in Arizona, California, and Pennsylvania. We are profoundly grateful to these team members, many of whom have devoted years to Theranos and our mission, for their commitment to our company and our guests.\u003c/p>\n\u003cp>We will return our undivided attention to our miniLab platform. Our ultimate goal is to commercialize miniaturized, automated laboratories capable of small-volume sample testing, with an emphasis on vulnerable patient populations, including oncology, pediatrics, and intensive care.\u003c/p>\n\u003cp>We have a new executive team leading our work toward obtaining FDA clearances, building commercial partnerships, and pursuing publications in scientific journals.\u003c/p>\n\u003cp>We are fortunate to have supporters and investors who believe deeply in our mission of affordable, less invasive lab testing, and to have the runway to realize our vision.\u003c/p>\n\u003cp>I look forward to sharing more with you as we progress along the way.\u003c/p>\n\u003cp>Sincerely,\u003c/p>\n\u003cp>Elizabeth Holmes\u003c/p>\u003c/blockquote>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "floatright"
},
"numeric": [
"floatright"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>\u003cem>This posted has been edited. It originally said that Theranos does not have an in-house spokesperson, which it does. \u003c/em>\u003c/p>\n\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/257644/theranos-shutting-down-blood-testing-centers-and-labs",
"authors": [
"80"
],
"categories": [
"futureofyou_1060",
"futureofyou_452",
"futureofyou_1062",
"futureofyou_1",
"futureofyou_73"
],
"tags": [
"futureofyou_814",
"futureofyou_617"
],
"label": "source_futureofyou_257644"
},
"futureofyou_240541": {
"type": "posts",
"id": "futureofyou_240541",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "240541",
"score": null,
"sort": [
1473275806000
]
},
"parent": 0,
"labelTerm": {
"site": "futureofyou"
},
"blocks": [],
"publishDate": 1473275806,
"format": "aside",
"disqusTitle": "5 Things We Didn't Know From Vanity Fair's Theranos Takedown",
"title": "5 Things We Didn't Know From Vanity Fair's Theranos Takedown",
"headTitle": "KQED Future of You | KQED Science",
"content": "\u003cp>Vanity Fair Tuesday filled in some of the blanks of the Theranos saga, with an article called \"\u003ca href=\"http://www.vanityfair.com/news/2016/09/elizabeth-holmes-theranos-exclusive\" target=\"_blank\">How Elizabeth Holmes' House of Cards Came Tumbling Down\u003c/a>.\" If you don't know the basics yet, it's a little late-- like trying to catch up with the story of the Hindenburg at this particular moment in time:\u003c/p>\n\u003cp>\u003ca href=\"http://ww2.kqed.org/futureofyou/wp-content/uploads/sites/13/2016/09/hindenburg.jpg\">\u003cimg class=\"aligncenter wp-image-240581\" src=\"http://ww2.kqed.org/futureofyou/wp-content/uploads/sites/13/2016/09/hindenburg-654x600.jpg\" alt=\"hindenburg\" width=\"354\" height=\"325\" srcset=\"https://ww2.kqed.org/app/uploads/sites/13/2016/09/hindenburg-654x600.jpg 654w, https://ww2.kqed.org/app/uploads/sites/13/2016/09/hindenburg-400x367.jpg 400w, https://ww2.kqed.org/app/uploads/sites/13/2016/09/hindenburg.jpg 723w\" sizes=\"(max-width: 354px) 100vw, 354px\">\u003c/a>\u003c/p>\n\u003cp>So try our \u003ca href=\"https://ww2.kqed.org/futureofyou/2016/07/14/the-rise-and-fall-of-theranos-a-cartoon-history/\" target=\"_blank\">mini-graphic novel\u003c/a> of the rise and fall of Theranos for a quickish history on the firm and its founder, Elizabeth Holmes. Then, read about some new wrinkles from Vanity Fair reporter Nick Bilton. These stood out:\u003c/p>\n\u003cul>\n\u003cli>When a young Holmes first approached some of her professors at Stanford with the idea that lots of useful data could be gleaned from just a few drops of blood taken from a fingertip, most of them told her it couldn't be done. (See this\u003ca href=\"https://ww2.kqed.org/futureofyou/2016/04/25/analysis-why-medical-lab-experts-were-always-skeptical-of-theranos/\" target=\"_blank\"> post\u003c/a> by Dartmouth medical professor Norman Paradis as to why that's true. \"When you lance a fingertip, you get both blood and tissue fluid, and this means that the concentration of molecules may be different than if the blood sample comes from a vein,\" Paradis wrote.)\u003c/li>\n\u003cli>Google Ventures, a heavy investor in medical technology companies, sent an employee to one of the blood-testing centers Theranos had opened at Walgreens stores. \"As the V.C. sat in a chair and had several large vials of blood drawn from his arm, far more than a pinprick, it became apparent that something was amiss with Theranos’s promise.\" (See this\u003ca href=\"http://www.businessinsider.com/bill-maris-explains-why-gv-didnt-invest-in-theranos-2015-10\" target=\"_blank\"> Business Insider story\u003c/a> for more on why Google Ventures passed on Theranos.)\u003c/li>\n\u003cli>More on Theranos' culture of secrecy. Former Theranos president and COO Sunny Balwani (who left the company in May amid Theranos' manifold regulatory problems) \"ensured that scientists and engineers at Theranos did not talk to one another about their work.\" Job applicants were kept in the dark during hiring interviews as to what the actual position they'd be filling was. \"Employees who spoke publicly about the company were met with legal threats. On LinkedIn, one former employee noted next to his job description, 'I worked here, but every time I say what I did I get a letter from a lawyer. I probably will get a letter from a lawyer for writing this.' If people visited any of Theranos’s offices and refused to sign the company’s lengthy non-disclosure agreement, they were not allowed inside.\"\u003c/li>\n\u003cli>This: \"When I arrived in Palo Alto in July, I wasn’t the only person setting out to interview anyone associated with Theranos and Holmes. .... When I knocked on a door, I was only a day or two behind F.B.I. agents who were trying to put together a time line of what Holmes knew and when she knew it—adding the most unpredictable twist to a story she could no longer control.\"\u003c/li>\n\u003cli>After The Wall Street Journal published reporter John Carreyrou's initial investigative piece, the company called a meeting with employees. Holmes told her staff that the Journal's story was inaccurate. \"Carreyrou, she insisted, with a tinge of fury, was simply picking a fight. She handed the stage to Balwani, who echoed her sentiments. After he wrapped up, the leaders of Theranos stood before their employees and surveyed the room. Then a chant erupted. 'Fuck you . . .,' employees began yelling in unison, “Carreyrou.” It began to grow louder still. 'Fuck you, Carreyrou!' Soon men and women in lab coats, and programmers in T-shirts and jeans, joined in. They were chanting with fervor: 'Fuck you, Carreyrou!,' they cried out. 'Fuck you, Carreyrou! Fuck. You. Carrey-rou!'\u003c/li>\n\u003c/ul>\n\u003cp>Carreyrou so far has only said the following about the article, which called him \"a recalcitrant health-care reporter.\"\u003c/p>\n\u003cp>https://twitter.com/JohnCarreyrou/status/773272569491300352\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\n\u003cp>Though more than one journalist has weighed in that the Theranos employees' \u003ca href=\"https://en.wikipedia.org/wiki/Two_Minutes_Hate\" target=\"_blank\">two-minute hate\u003c/a> was the highest honor he could receive.\u003c/p>\n\u003cp>\u003c/p>\n\u003cp> \u003c/p>\n\n",
"disqusIdentifier": "240541 http://ww2.kqed.org/futureofyou/?p=240541",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/09/07/5-things-we-didnt-know-from-vanity-fairs-theranos-takedown/",
"stats": {
"hasVideo": false,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 671,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 7
},
"modified": 1473276049,
"excerpt": "The magazine fills in the blanks of the blood-testing company's ugly narrative.",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "The magazine fills in the blanks of the blood-testing company's ugly narrative.",
"title": "5 Things We Didn't Know From Vanity Fair's Theranos Takedown | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "5 Things We Didn't Know From Vanity Fair's Theranos Takedown",
"datePublished": "2016-09-07T12:16:46-07:00",
"dateModified": "2016-09-07T12:20:49-07:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "5-things-we-didnt-know-from-vanity-fairs-theranos-takedown",
"status": "publish",
"path": "/futureofyou/240541/5-things-we-didnt-know-from-vanity-fairs-theranos-takedown",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>Vanity Fair Tuesday filled in some of the blanks of the Theranos saga, with an article called \"\u003ca href=\"http://www.vanityfair.com/news/2016/09/elizabeth-holmes-theranos-exclusive\" target=\"_blank\">How Elizabeth Holmes' House of Cards Came Tumbling Down\u003c/a>.\" If you don't know the basics yet, it's a little late-- like trying to catch up with the story of the Hindenburg at this particular moment in time:\u003c/p>\n\u003cp>\u003ca href=\"http://ww2.kqed.org/futureofyou/wp-content/uploads/sites/13/2016/09/hindenburg.jpg\">\u003cimg class=\"aligncenter wp-image-240581\" src=\"http://ww2.kqed.org/futureofyou/wp-content/uploads/sites/13/2016/09/hindenburg-654x600.jpg\" alt=\"hindenburg\" width=\"354\" height=\"325\" srcset=\"https://ww2.kqed.org/app/uploads/sites/13/2016/09/hindenburg-654x600.jpg 654w, https://ww2.kqed.org/app/uploads/sites/13/2016/09/hindenburg-400x367.jpg 400w, https://ww2.kqed.org/app/uploads/sites/13/2016/09/hindenburg.jpg 723w\" sizes=\"(max-width: 354px) 100vw, 354px\">\u003c/a>\u003c/p>\n\u003cp>So try our \u003ca href=\"https://ww2.kqed.org/futureofyou/2016/07/14/the-rise-and-fall-of-theranos-a-cartoon-history/\" target=\"_blank\">mini-graphic novel\u003c/a> of the rise and fall of Theranos for a quickish history on the firm and its founder, Elizabeth Holmes. Then, read about some new wrinkles from Vanity Fair reporter Nick Bilton. These stood out:\u003c/p>\n\u003cul>\n\u003cli>When a young Holmes first approached some of her professors at Stanford with the idea that lots of useful data could be gleaned from just a few drops of blood taken from a fingertip, most of them told her it couldn't be done. (See this\u003ca href=\"https://ww2.kqed.org/futureofyou/2016/04/25/analysis-why-medical-lab-experts-were-always-skeptical-of-theranos/\" target=\"_blank\"> post\u003c/a> by Dartmouth medical professor Norman Paradis as to why that's true. \"When you lance a fingertip, you get both blood and tissue fluid, and this means that the concentration of molecules may be different than if the blood sample comes from a vein,\" Paradis wrote.)\u003c/li>\n\u003cli>Google Ventures, a heavy investor in medical technology companies, sent an employee to one of the blood-testing centers Theranos had opened at Walgreens stores. \"As the V.C. sat in a chair and had several large vials of blood drawn from his arm, far more than a pinprick, it became apparent that something was amiss with Theranos’s promise.\" (See this\u003ca href=\"http://www.businessinsider.com/bill-maris-explains-why-gv-didnt-invest-in-theranos-2015-10\" target=\"_blank\"> Business Insider story\u003c/a> for more on why Google Ventures passed on Theranos.)\u003c/li>\n\u003cli>More on Theranos' culture of secrecy. Former Theranos president and COO Sunny Balwani (who left the company in May amid Theranos' manifold regulatory problems) \"ensured that scientists and engineers at Theranos did not talk to one another about their work.\" Job applicants were kept in the dark during hiring interviews as to what the actual position they'd be filling was. \"Employees who spoke publicly about the company were met with legal threats. On LinkedIn, one former employee noted next to his job description, 'I worked here, but every time I say what I did I get a letter from a lawyer. I probably will get a letter from a lawyer for writing this.' If people visited any of Theranos’s offices and refused to sign the company’s lengthy non-disclosure agreement, they were not allowed inside.\"\u003c/li>\n\u003cli>This: \"When I arrived in Palo Alto in July, I wasn’t the only person setting out to interview anyone associated with Theranos and Holmes. .... When I knocked on a door, I was only a day or two behind F.B.I. agents who were trying to put together a time line of what Holmes knew and when she knew it—adding the most unpredictable twist to a story she could no longer control.\"\u003c/li>\n\u003cli>After The Wall Street Journal published reporter John Carreyrou's initial investigative piece, the company called a meeting with employees. Holmes told her staff that the Journal's story was inaccurate. \"Carreyrou, she insisted, with a tinge of fury, was simply picking a fight. She handed the stage to Balwani, who echoed her sentiments. After he wrapped up, the leaders of Theranos stood before their employees and surveyed the room. Then a chant erupted. 'Fuck you . . .,' employees began yelling in unison, “Carreyrou.” It began to grow louder still. 'Fuck you, Carreyrou!' Soon men and women in lab coats, and programmers in T-shirts and jeans, joined in. They were chanting with fervor: 'Fuck you, Carreyrou!,' they cried out. 'Fuck you, Carreyrou! Fuck. You. Carrey-rou!'\u003c/li>\n\u003c/ul>\n\u003cp>Carreyrou so far has only said the following about the article, which called him \"a recalcitrant health-care reporter.\"\u003c/p>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "singleTwitterStatus",
"attributes": {
"named": {
"id": "773272569491300352"
},
"numeric": []
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>Though more than one journalist has weighed in that the Theranos employees' \u003ca href=\"https://en.wikipedia.org/wiki/Two_Minutes_Hate\" target=\"_blank\">two-minute hate\u003c/a> was the highest honor he could receive.\u003c/p>\n\u003cp>\u003c/p>\n\u003cp> \u003c/p>\n\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/240541/5-things-we-didnt-know-from-vanity-fairs-theranos-takedown",
"authors": [
"80"
],
"categories": [
"futureofyou_1"
],
"tags": [
"futureofyou_814",
"futureofyou_617"
],
"featImg": "futureofyou_203083",
"label": "futureofyou"
},
"futureofyou_234211": {
"type": "posts",
"id": "futureofyou_234211",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "234211",
"score": null,
"sort": [
1472602939000
]
},
"parent": 0,
"labelTerm": {
"site": "futureofyou"
},
"blocks": [],
"publishDate": 1472602939,
"format": "aside",
"disqusTitle": "FDA Finds Lack of Patient Safeguards in Theranos Zika Study: WSJ",
"title": "FDA Finds Lack of Patient Safeguards in Theranos Zika Study: WSJ",
"headTitle": "KQED Future of You | KQED Science",
"content": "\u003cp>Look, we'd \u003cem>really\u003c/em> like to stop posting about Theranos. Honestly we would. But The Wall Street Journal is at it again, so ... here ...\u003c/p>\n\u003cp>http://www.wsj.com/articles/theranos-halts-new-zika-test-after-fda-inspection-1472598332\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\u003cp>\u003c/p>\n",
"disqusIdentifier": "234211 http://ww2.kqed.org/futureofyou/?p=234211",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/08/30/fda-finds-lack-of-patient-safeguards-in-theranos-zika-study-says-wsj/",
"stats": {
"hasVideo": false,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 41,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 3
},
"modified": 1472605358,
"excerpt": "The company withdraws its request for emergency clearance of a Zika blood test cited by Elizabeth Holmes at her scientific presentation earlier this month.",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "The company withdraws its request for emergency clearance of a Zika blood test cited by Elizabeth Holmes at her scientific presentation earlier this month.",
"title": "FDA Finds Lack of Patient Safeguards in Theranos Zika Study: WSJ | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "FDA Finds Lack of Patient Safeguards in Theranos Zika Study: WSJ",
"datePublished": "2016-08-30T17:22:19-07:00",
"dateModified": "2016-08-30T18:02:38-07:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "fda-finds-lack-of-patient-safeguards-in-theranos-zika-study-says-wsj",
"status": "publish",
"customPermalink": "2016/08/30/theranos-zika/",
"path": "/futureofyou/234211/fda-finds-lack-of-patient-safeguards-in-theranos-zika-study-says-wsj",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>Look, we'd \u003cem>really\u003c/em> like to stop posting about Theranos. Honestly we would. But The Wall Street Journal is at it again, so ... here ...\u003c/p>\n\u003cp>http://www.wsj.com/articles/theranos-halts-new-zika-test-after-fda-inspection-1472598332\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\u003cp>\u003c/p>\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/234211/fda-finds-lack-of-patient-safeguards-in-theranos-zika-study-says-wsj",
"authors": [
"80"
],
"categories": [
"futureofyou_1"
],
"tags": [
"futureofyou_814",
"futureofyou_38",
"futureofyou_617",
"futureofyou_1032"
],
"featImg": "futureofyou_152361",
"label": "futureofyou"
},
"futureofyou_231240": {
"type": "posts",
"id": "futureofyou_231240",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "231240",
"score": null,
"sort": [
1472226710000
]
},
"parent": 0,
"labelTerm": {},
"blocks": [],
"publishDate": 1472226710,
"format": "standard",
"disqusTitle": "Theranos to Appeal Severe Government Sanctions",
"title": "Theranos to Appeal Severe Government Sanctions",
"headTitle": "KQED Future of You | KQED Science",
"content": "\u003cp>In a \u003ca href=\"https://news.theranos.com/2016/08/25/theranos-to-appeal-cms-sanctions/\" target=\"_blank\">statement\u003c/a> issued Thursday, the blood-testing company Theranos, which has stretched the adjective \"beleaguered\" to its very limits, said it would appeal the harsh \u003ca href=\"https://ww2.kqed.org/futureofyou/2016/07/08/theranos-lab-license-yanked-elizabeth-holmes-suspended/\" target=\"_blank\">penalties\u003c/a> the Centers for Medicare & Medicaid Services levied on it last month in response to what the agency called life-threatening deficiencies at the company's California lab.\u003c/p>\n\u003cp>Theranos said it has filed an intent to appeal the sanctions with CMS.\u003c/p>\n\u003cp>\"Theranos is not conducting patient testing at its Newark facility,\" the statement said. \"In addition, since CMS originally announced the imposition of sanctions, Theranos has made substantial progress toward correcting the deficiencies CMS identified, including appointing new laboratory leadership; enhancing Theranos’ clinical policies and procedures; and revamping training programs.\u003c/p>\n\u003cp>\"While the appeal is pending, Theranos intends to continue communicating with CMS regarding the possibility of reaching a mutually agreeable resolution to this matter.\"\u003c/p>\n\u003cp>CMS had previously said Theranos could “begin negotiations” with the agency. Any agreement would be based on the ability of Theranos to “remove immediate jeopardy” to patients, the agency said, as well as other factors, such as the severity of the lab's deficiencies and “the overall compliance history of the laboratory.”\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\n\u003cp>The \u003ca href=\"https://www.scribd.com/document/317817195/CMS-Notification-of-Imposition-of-Sanctions-for-Theranos\" target=\"_blank\">penalties\u003c/a> CMS imposed on Theranos include revoking the blood-testing company’s license to operate the Newark, California lab and barring founder and CEO Elizabeth Holmes from owning, operating or directing a lab for at least two years. CMS also canceled the Newark lab’s approval to receive payments from Medicare and Medicaid.\u003c/p>\n\u003cp>When the penalties were announced in July, laboratory medicine experts called them unusually harsh.\u003c/p>\n\u003cp>Dr. Norman Paradis, a professor of medicine at Dartmouth, who has consulted for both diagnostic startups and biomed investors, said the magnitude of the penalties could be one-of-a-kind.\u003c/p>\n\u003cp>“I’ve never heard of a penalty this severe,” he said. “I’m surprised that they could not have avoided this in light of the new involvement of experienced people and renowned attorneys.”\u003c/p>\n\u003cp>In April, Theranos hired a number of experts for its medical advisory board. High-powered lawyer David Boies represents the company and \u003ca href=\"http://www.nytimes.com/2016/02/03/business/dealbook/david-boiess-dual-roles-at-theranos-set-up-conflict.html\" target=\"_blank\">also serves\u003c/a> on its board.\u003c/p>\n\u003cp>Earlier this month, Holmes attempted a fresh start by giving a much-anticipated presentation at the annual meeting of the American Association for Clinical Chemistry. That was a gathering of the very sort of experts who had expressed skepticism about the company's central claim -- that it could perform dozens of tests by collecting just a few drops of the patient's blood from a finger prick. The FDA has approved only one of those assays, for the herpes simplex virus.\u003c/p>\n\u003cp>But rather than using the presentation to produce data verifying its technology, Holmes unveiled a new portable testing device called a miniLab, which was \u003ca href=\"https://ww2.kqed.org/futureofyou/2016/07/29/theranos-elizabeth-holmes-will-face-1000-scientists-monday-can-she-say-anything-to-gain-their-trust/\" target=\"_blank\">underwhelming\u003c/a> to those present.\u003c/p>\n\u003cp>The Wall Street Journal has reported the company is facing at least eight lawsuits related to that original, controversial and mysterious technology, called \"Edison,\" which Theranos\u003cstrong> \u003c/strong>says is now obsolete. In May, the company \u003ca href=\"https://ww2.kqed.org/futureofyou/2016/05/19/theranos-corrects-tens-of-thousands-of-blood-tests/\" target=\"_blank\">voided or corrected\u003c/a> tens of thousands of blood tests from 2014-15.\u003c/p>\n\u003cp>Per \u003ca href=\"https://www.law.cornell.edu/cfr/text/42/493.1844\" target=\"_blank\">federal regulations\u003c/a>, if Theranos loses its appeal, which will go to an administrative law judge, it can file a request for review by an appeals board. If it loses that one, it will have 60 days to request judicial review with the U.S. Court of Appeals.\u003c/p>\n\u003cp>Experts who have commented on the case have said if no settlement can be reached, companies almost never win these things.\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>In the meantime, Theranos is still operating its remaining lab, in Arizona. But how brisk can business be? Walgreens withdrew from its partnership with the company, shutting down dozens of Theranos blood-draw centers in the pharmacy chain's Arizona stores. That leaves just a handful of collection sites for customers to patronize.\u003c/p>\n\n",
"disqusIdentifier": "231240 http://ww2.kqed.org/futureofyou/?p=231240",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/08/26/theranos-to-appeal-severe-government-sanctions/",
"stats": {
"hasVideo": false,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 672,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 18
},
"modified": 1472247793,
"excerpt": "The company said it wants to 'continue communicating' with the Centers for Medicare & Medicaid Services, which levied harsh penalties for problems at Theranos' California lab.",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "The company said it wants to 'continue communicating' with the Centers for Medicare & Medicaid Services, which levied harsh penalties for problems at Theranos' California lab.",
"title": "Theranos to Appeal Severe Government Sanctions | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "Theranos to Appeal Severe Government Sanctions",
"datePublished": "2016-08-26T08:51:50-07:00",
"dateModified": "2016-08-26T14:43:13-07:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "theranos-to-appeal-severe-government-sanctions",
"status": "publish",
"source": "Future of You",
"path": "/futureofyou/231240/theranos-to-appeal-severe-government-sanctions",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>In a \u003ca href=\"https://news.theranos.com/2016/08/25/theranos-to-appeal-cms-sanctions/\" target=\"_blank\">statement\u003c/a> issued Thursday, the blood-testing company Theranos, which has stretched the adjective \"beleaguered\" to its very limits, said it would appeal the harsh \u003ca href=\"https://ww2.kqed.org/futureofyou/2016/07/08/theranos-lab-license-yanked-elizabeth-holmes-suspended/\" target=\"_blank\">penalties\u003c/a> the Centers for Medicare & Medicaid Services levied on it last month in response to what the agency called life-threatening deficiencies at the company's California lab.\u003c/p>\n\u003cp>Theranos said it has filed an intent to appeal the sanctions with CMS.\u003c/p>\n\u003cp>\"Theranos is not conducting patient testing at its Newark facility,\" the statement said. \"In addition, since CMS originally announced the imposition of sanctions, Theranos has made substantial progress toward correcting the deficiencies CMS identified, including appointing new laboratory leadership; enhancing Theranos’ clinical policies and procedures; and revamping training programs.\u003c/p>\n\u003cp>\"While the appeal is pending, Theranos intends to continue communicating with CMS regarding the possibility of reaching a mutually agreeable resolution to this matter.\"\u003c/p>\n\u003cp>CMS had previously said Theranos could “begin negotiations” with the agency. Any agreement would be based on the ability of Theranos to “remove immediate jeopardy” to patients, the agency said, as well as other factors, such as the severity of the lab's deficiencies and “the overall compliance history of the laboratory.”\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>The \u003ca href=\"https://www.scribd.com/document/317817195/CMS-Notification-of-Imposition-of-Sanctions-for-Theranos\" target=\"_blank\">penalties\u003c/a> CMS imposed on Theranos include revoking the blood-testing company’s license to operate the Newark, California lab and barring founder and CEO Elizabeth Holmes from owning, operating or directing a lab for at least two years. CMS also canceled the Newark lab’s approval to receive payments from Medicare and Medicaid.\u003c/p>\n\u003cp>When the penalties were announced in July, laboratory medicine experts called them unusually harsh.\u003c/p>\n\u003cp>Dr. Norman Paradis, a professor of medicine at Dartmouth, who has consulted for both diagnostic startups and biomed investors, said the magnitude of the penalties could be one-of-a-kind.\u003c/p>\n\u003cp>“I’ve never heard of a penalty this severe,” he said. “I’m surprised that they could not have avoided this in light of the new involvement of experienced people and renowned attorneys.”\u003c/p>\n\u003cp>In April, Theranos hired a number of experts for its medical advisory board. High-powered lawyer David Boies represents the company and \u003ca href=\"http://www.nytimes.com/2016/02/03/business/dealbook/david-boiess-dual-roles-at-theranos-set-up-conflict.html\" target=\"_blank\">also serves\u003c/a> on its board.\u003c/p>\n\u003cp>Earlier this month, Holmes attempted a fresh start by giving a much-anticipated presentation at the annual meeting of the American Association for Clinical Chemistry. That was a gathering of the very sort of experts who had expressed skepticism about the company's central claim -- that it could perform dozens of tests by collecting just a few drops of the patient's blood from a finger prick. The FDA has approved only one of those assays, for the herpes simplex virus.\u003c/p>\n\u003cp>But rather than using the presentation to produce data verifying its technology, Holmes unveiled a new portable testing device called a miniLab, which was \u003ca href=\"https://ww2.kqed.org/futureofyou/2016/07/29/theranos-elizabeth-holmes-will-face-1000-scientists-monday-can-she-say-anything-to-gain-their-trust/\" target=\"_blank\">underwhelming\u003c/a> to those present.\u003c/p>\n\u003cp>The Wall Street Journal has reported the company is facing at least eight lawsuits related to that original, controversial and mysterious technology, called \"Edison,\" which Theranos\u003cstrong> \u003c/strong>says is now obsolete. In May, the company \u003ca href=\"https://ww2.kqed.org/futureofyou/2016/05/19/theranos-corrects-tens-of-thousands-of-blood-tests/\" target=\"_blank\">voided or corrected\u003c/a> tens of thousands of blood tests from 2014-15.\u003c/p>\n\u003cp>Per \u003ca href=\"https://www.law.cornell.edu/cfr/text/42/493.1844\" target=\"_blank\">federal regulations\u003c/a>, if Theranos loses its appeal, which will go to an administrative law judge, it can file a request for review by an appeals board. If it loses that one, it will have 60 days to request judicial review with the U.S. Court of Appeals.\u003c/p>\n\u003cp>Experts who have commented on the case have said if no settlement can be reached, companies almost never win these things.\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>In the meantime, Theranos is still operating its remaining lab, in Arizona. But how brisk can business be? Walgreens withdrew from its partnership with the company, shutting down dozens of Theranos blood-draw centers in the pharmacy chain's Arizona stores. That leaves just a handful of collection sites for customers to patronize.\u003c/p>\n\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/231240/theranos-to-appeal-severe-government-sanctions",
"authors": [
"80"
],
"categories": [
"futureofyou_452",
"futureofyou_1",
"futureofyou_73"
],
"tags": [
"futureofyou_971",
"futureofyou_814",
"futureofyou_617"
],
"label": "source_futureofyou_231240"
},
"futureofyou_216744": {
"type": "posts",
"id": "futureofyou_216744",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "216744",
"score": null,
"sort": [
1470355891000
]
},
"parent": 0,
"labelTerm": {
"site": "futureofyou"
},
"blocks": [],
"publishDate": 1470355891,
"format": "standard",
"disqusTitle": "When Female Tech CEOs Stumble",
"title": "When Female Tech CEOs Stumble",
"headTitle": "KQED Future of You | KQED Science",
"content": "\u003cp>Two of the highest profile women in tech have had a tough year. Marissa Mayer, the CEO of Yahoo, saw her company \u003ca href=\"http://www.npr.org/sections/thetwo-way/2016/07/24/486451834/verizon-reportedly-prepares-to-buy-yahoo-for-4-8-billion\">sold to Verizon\u003c/a>. Elizabeth Holmes, the founder of the experimental blood testing company Theranos, \u003ca href=\"http://www.npr.org/sections/thetwo-way/2016/07/09/485355994/theranos-founder-elizabeth-holmes-barred-from-operating-labs-for-two-years\">was banned\u003c/a> from her own labs by regulators for two years.\u003c/p>\n\u003caside class=\"pullquote alignright\">When a Marissa Mayer or Elizabeth Holmes fails, does it feed stereotypes?\u003c/aside>\n\u003cp>Though male founders and CEOs fail all the time, it may have different implications when women mess up, says Marianne Cooper, a sociologist at the Clayman Institute for Gender Research at Stanford University.\u003c/p>\n\u003cp>\"There are so many other male leaders that ... failure doesn't really create expectations about other men's leadership capacities or capabilities,\" she says.\u003c/p>\n\u003cp>When former Enron CEO Kenneth Lay was indicted for securities fraud or Angelo Mozilo, the former chairman of Countrywide Financial, was associated with bringing on the housing crisis nobody suggested it was because they were men.\u003c/p>\n\u003cp>Because there are so few female CEOs, especially in tech, Cooper says when a Marissa Mayer or Elizabeth Holmes fails it can feed stereotypes. \"It not only can damage her career just individually for herself,\" says Cooper, \"but it can actually serve to reconfirm broader cultural beliefs that are out there that women aren't quite the right fit for senior leadership or certain kinds of senior leadership positions.\"\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\n\u003cp>Cooper says there are studies that show that when women and men go to funders with the same idea, women are \u003ca href=\"http://www.pnas.org/content/111/12/4427\">less likely to get backing\u003c/a>.\u003c/p>\n\u003cp>And with the timing of failures by Mayer and Holmes so close, some people do lump them together despite their very different career trajectories. If you read the comments below articles online, both women are the targets of stinging sexism.\u003c/p>\n\u003cp>A recent post on NPR's site said of Mayer's failure — \"simply evidence that \u003ca href=\"http://www.npr.org/sections/alltechconsidered/2016/08/01/488246171/ceo-marissa-mayer-treated-yahoo-like-a-think-tank-not-a-sinking-ship\">women cannot lead\u003c/a>.\" A post on news comment site Reddit — called both women part of the \u003ca href=\"https://www.reddit.com/r/TheRedPill/comments/4rtndp/us_regulator_bans_theranos_ceo_elizabeth_holmes/?st=irfd7ycx&sh=be5928a6\">\"the feminist industrial complex\"\u003c/a> that promotes unqualified women.\u003c/p>\n\u003cp>Despite other successful CEOs in tech, as young, attractive, rising stars Mayer and Holmes became media darlings. Holmes was fashioned as a great female visionary of the tech world. Last year, \u003cem>Time\u003c/em> magazine put her on the list of its \u003ca href=\"http://time.com/3822734/elizabeth-holmes-2015-time-100/\">100 most influential people\u003c/a>. Holmes' penchant for wearing black turtlenecks evoked comparisons to Steve Jobs, who also wore them.\u003c/p>\n\u003cp>Mayer became a symbol of a woman CEO who could juggle her job and \u003ca href=\"http://www.npr.org/2015/09/02/436966682/yahoo-ceo-to-take-limited-leave-after-giving-birth-to-twins\">giving birth to twins\u003c/a>. She appeared on television shows talking about the experience.\u003c/p>\n\u003cp>Many female executives in the tech world still prefer to see Mayer as a role model.\u003c/p>\n\u003cp>\"I think certainly Marissa going in as a CEO who was having a child has shown that you can do both of those things at once. And just having a woman be in that role is normalizing for the rest of us,\" says Natala Menezes, who has been an executive at Amazon, Microsoft and Google and is currently a general manager at the marketing and analytics firm Localytics.\u003c/p>\n\u003cp>Minnie Ingersoll, the chief operating officer and co-founder of Shift, a startup that helps people sell used cars online, likes to see women shoot for the stars. \"One message for young women is that it's OK to take a big risk and to fail,\" she says. \"I think there's something actually for me personally that I find almost inspiring in someone who is willing to take that risk.\"\u003c/p>\n\u003cp>But she doesn't think Mayer and Holmes have much in common. \"Marissa and Elizabeth are both blond women. But other than that, I see what is going on in their careers very differently,\" Ingersoll says.\u003c/p>\n\u003cp>Though being young and blond may have something to do with the media's fascination with these women, there are others succeeding as leaders in tech. Ursula Burns runs Xerox. Meg Whitman now runs HP enterprise — and as the former CEO of eBay she helped turn the company into a giant of online commerce. Ginni Rometty is CEO of IBM.\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>Menezes and Ingersoll hope that their successes will make it easier for women to succeed and dream so big that they can afford to fail as often as men do.\u003c/p>\n\u003cdiv class=\"fullattribution\">Copyright 2016 NPR. To see more, visit http://www.npr.org/.\u003cimg src=\"http://www.google-analytics.com/__utm.gif?utmac=UA-5828686-4&utmdt=Is+There+A+Double+Standard+When+Female+CEOs+In+Tech+Stumble%3F&utme=8(APIKey)9(MDAxOTAwOTE4MDEyMTkxMDAzNjczZDljZA004)\">\u003c/div>\n\n",
"disqusIdentifier": "216744 http://ww2.kqed.org/futureofyou/?p=216744",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/08/04/when-female-tech-ceos-stumble/",
"stats": {
"hasVideo": false,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 709,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 18
},
"modified": 1470356156,
"excerpt": "Male CEOs fail all the time, but when someone like Yahoo's Marissa Mayer or Theranos' Elizabeth Holmes falls short, it can feed stereotypes about women being unfit for leadership.",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "Male CEOs fail all the time, but when someone like Yahoo's Marissa Mayer or Theranos' Elizabeth Holmes falls short, it can feed stereotypes about women being unfit for leadership.",
"title": "When Female Tech CEOs Stumble | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "When Female Tech CEOs Stumble",
"datePublished": "2016-08-04T17:11:31-07:00",
"dateModified": "2016-08-04T17:15:56-07:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "when-female-tech-ceos-stumble",
"status": "publish",
"nprApiLink": "http://api.npr.org/query?id=488569884&apiKey=MDAxOTAwOTE4MDEyMTkxMDAzNjczZDljZA004",
"nprByline": "Laura Sydell\u003cbr />NPR",
"nprStoryDate": "Wed, 03 Aug 2016 18:04:00 -0400",
"nprLastModifiedDate": "Thu, 04 Aug 2016 16:37:26 -0400",
"nprHtmlLink": "http://www.npr.org/sections/alltechconsidered/2016/08/03/488569884/is-there-a-double-standard-when-women-ceos-in-tech-stumble?ft=nprml&f=488569884",
"nprAudio": "http://pd.npr.org/anon.npr-mp3/npr/atc/2016/08/20160803_atc_female_tech_ceo_failures_may_reaffirm_cultural_beliefs_about_women_leaders.mp3?orgId=1&topicId=1019&d=246&p=2&story=488569884&t=progseg&e=488477817&seg=5&ft=nprml&f=488569884",
"nprImageAgency": "Getty Images",
"nprImageCredit": "Stephen Lam",
"nprAudioM3u": "http://api.npr.org/m3u/1488572820-75b020.m3u?orgId=1&topicId=1019&d=246&p=2&story=488569884&t=progseg&e=488477817&seg=5&ft=nprml&f=488569884",
"nprStoryId": "488569884",
"nprRetrievedStory": "1",
"nprPubDate": "Thu, 04 Aug 2016 16:37:00 -0400",
"path": "/futureofyou/216744/when-female-tech-ceos-stumble",
"audioUrl": "http://pd.npr.org/anon.npr-mp3/npr/atc/2016/08/20160803_atc_female_tech_ceo_failures_may_reaffirm_cultural_beliefs_about_women_leaders.mp3?orgId=1&topicId=1019&d=246&p=2&story=488569884&t=progseg&e=488477817&seg=5&ft=nprml&f=488569884",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>Two of the highest profile women in tech have had a tough year. Marissa Mayer, the CEO of Yahoo, saw her company \u003ca href=\"http://www.npr.org/sections/thetwo-way/2016/07/24/486451834/verizon-reportedly-prepares-to-buy-yahoo-for-4-8-billion\">sold to Verizon\u003c/a>. Elizabeth Holmes, the founder of the experimental blood testing company Theranos, \u003ca href=\"http://www.npr.org/sections/thetwo-way/2016/07/09/485355994/theranos-founder-elizabeth-holmes-barred-from-operating-labs-for-two-years\">was banned\u003c/a> from her own labs by regulators for two years.\u003c/p>\n\u003caside class=\"pullquote alignright\">When a Marissa Mayer or Elizabeth Holmes fails, does it feed stereotypes?\u003c/aside>\n\u003cp>Though male founders and CEOs fail all the time, it may have different implications when women mess up, says Marianne Cooper, a sociologist at the Clayman Institute for Gender Research at Stanford University.\u003c/p>\n\u003cp>\"There are so many other male leaders that ... failure doesn't really create expectations about other men's leadership capacities or capabilities,\" she says.\u003c/p>\n\u003cp>When former Enron CEO Kenneth Lay was indicted for securities fraud or Angelo Mozilo, the former chairman of Countrywide Financial, was associated with bringing on the housing crisis nobody suggested it was because they were men.\u003c/p>\n\u003cp>Because there are so few female CEOs, especially in tech, Cooper says when a Marissa Mayer or Elizabeth Holmes fails it can feed stereotypes. \"It not only can damage her career just individually for herself,\" says Cooper, \"but it can actually serve to reconfirm broader cultural beliefs that are out there that women aren't quite the right fit for senior leadership or certain kinds of senior leadership positions.\"\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>Cooper says there are studies that show that when women and men go to funders with the same idea, women are \u003ca href=\"http://www.pnas.org/content/111/12/4427\">less likely to get backing\u003c/a>.\u003c/p>\n\u003cp>And with the timing of failures by Mayer and Holmes so close, some people do lump them together despite their very different career trajectories. If you read the comments below articles online, both women are the targets of stinging sexism.\u003c/p>\n\u003cp>A recent post on NPR's site said of Mayer's failure — \"simply evidence that \u003ca href=\"http://www.npr.org/sections/alltechconsidered/2016/08/01/488246171/ceo-marissa-mayer-treated-yahoo-like-a-think-tank-not-a-sinking-ship\">women cannot lead\u003c/a>.\" A post on news comment site Reddit — called both women part of the \u003ca href=\"https://www.reddit.com/r/TheRedPill/comments/4rtndp/us_regulator_bans_theranos_ceo_elizabeth_holmes/?st=irfd7ycx&sh=be5928a6\">\"the feminist industrial complex\"\u003c/a> that promotes unqualified women.\u003c/p>\n\u003cp>Despite other successful CEOs in tech, as young, attractive, rising stars Mayer and Holmes became media darlings. Holmes was fashioned as a great female visionary of the tech world. Last year, \u003cem>Time\u003c/em> magazine put her on the list of its \u003ca href=\"http://time.com/3822734/elizabeth-holmes-2015-time-100/\">100 most influential people\u003c/a>. Holmes' penchant for wearing black turtlenecks evoked comparisons to Steve Jobs, who also wore them.\u003c/p>\n\u003cp>Mayer became a symbol of a woman CEO who could juggle her job and \u003ca href=\"http://www.npr.org/2015/09/02/436966682/yahoo-ceo-to-take-limited-leave-after-giving-birth-to-twins\">giving birth to twins\u003c/a>. She appeared on television shows talking about the experience.\u003c/p>\n\u003cp>Many female executives in the tech world still prefer to see Mayer as a role model.\u003c/p>\n\u003cp>\"I think certainly Marissa going in as a CEO who was having a child has shown that you can do both of those things at once. And just having a woman be in that role is normalizing for the rest of us,\" says Natala Menezes, who has been an executive at Amazon, Microsoft and Google and is currently a general manager at the marketing and analytics firm Localytics.\u003c/p>\n\u003cp>Minnie Ingersoll, the chief operating officer and co-founder of Shift, a startup that helps people sell used cars online, likes to see women shoot for the stars. \"One message for young women is that it's OK to take a big risk and to fail,\" she says. \"I think there's something actually for me personally that I find almost inspiring in someone who is willing to take that risk.\"\u003c/p>\n\u003cp>But she doesn't think Mayer and Holmes have much in common. \"Marissa and Elizabeth are both blond women. But other than that, I see what is going on in their careers very differently,\" Ingersoll says.\u003c/p>\n\u003cp>Though being young and blond may have something to do with the media's fascination with these women, there are others succeeding as leaders in tech. Ursula Burns runs Xerox. Meg Whitman now runs HP enterprise — and as the former CEO of eBay she helped turn the company into a giant of online commerce. Ginni Rometty is CEO of IBM.\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>Menezes and Ingersoll hope that their successes will make it easier for women to succeed and dream so big that they can afford to fail as often as men do.\u003c/p>\n\u003cdiv class=\"fullattribution\">Copyright 2016 NPR. To see more, visit http://www.npr.org/.\u003cimg src=\"http://www.google-analytics.com/__utm.gif?utmac=UA-5828686-4&utmdt=Is+There+A+Double+Standard+When+Female+CEOs+In+Tech+Stumble%3F&utme=8(APIKey)9(MDAxOTAwOTE4MDEyMTkxMDAzNjczZDljZA004)\">\u003c/div>\n\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/216744/when-female-tech-ceos-stumble",
"authors": [
"byline_futureofyou_216744"
],
"categories": [
"futureofyou_1"
],
"tags": [
"futureofyou_814",
"futureofyou_617"
],
"featImg": "futureofyou_216776",
"label": "futureofyou"
},
"futureofyou_210797": {
"type": "posts",
"id": "futureofyou_210797",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "210797",
"score": null,
"sort": [
1470090334000
]
},
"parent": 0,
"labelTerm": {},
"blocks": [],
"publishDate": 1470090334,
"format": "standard",
"disqusTitle": "Theranos Presentation Mostly a Dud, Say Scientists",
"title": "Theranos Presentation Mostly a Dud, Say Scientists",
"headTitle": "KQED Future of You | KQED Science",
"content": "\u003cp>Forget \"Edison.\" Let's talk \"miniLab.\"\u003c/p>\n\u003cp>That was the message Elizabeth Holmes sent at her highly anticipated presentation Monday at the American Association for Clinical Chemistry's annual meeting in Philadelphia.\u003c/p>\n\u003caside class=\"pullquote alignright\">'In retrospect it was no different from going to a typical talk by a sponsored vendor.'\u003ccite>Dr. Jerry Yeo, University of Chicago\u003c/cite>\u003c/aside>\n\u003cp>Speaking for roughly 55 minutes in front of an estimated 2,650 people -- most of them laboratory scientists -- Holmes introduced a new device that can fit on a desktop. The machine, called a miniLab, integrates several blood-testing methodologies and, using robots and the company's proprietary \"\u003ca href=\"https://www.google.com/search?q=nanotainer\" target=\"_blank\">nanotainer\u003c/a>\" collection tube, will be able to process small volumes of blood remotely and send data back to a centralized location.\u003c/p>\n\u003cp>Holmes presented internal company data that showed the system worked for a range of tests, including a new assay for Zika.\u003c/p>\n\u003cp>Dr. Jerry Yeo, however, director of clinical chemistry laboratories at the University of Chicago, seemed to speak for a number of scientists when he summed up his response this way:\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\n\u003cp>[contextly_sidebar id=\"1op21qHuw941CUAVPi6ZWhtkUjJaSEaz\"]\"There was nothing revolutionary or disruptive behind the technology of the miniLab,\" Yeo said.\u003c/p>\n\u003cp>Yeo said the miniLab uses spectrophotometry and other measurement principles that are \"well known in the field and are existing, current technologies employed by many diagnostic vendors.\"\u003c/p>\n\u003cp>While the internal performance data Holmes showed \"looked impressive,\" he said, \"ultimately the proof will require that these units be tested in independent clinical labs, so for now the jury is out, until we see some peer-reviewed publications from those sources.\"\u003c/p>\n\u003cp>Yeo also said the data Holmes provided were incomplete in terms of fully assessing the machine.\u003c/p>\n\u003cp>\"In retrospect it was no different from going to a typical talk by a sponsored vendor,\" Yeo said.\u003c/p>\n\u003cp>Dr. Stephen R. Master, one of the event's moderators, said the presentation might have gone better had Theranos not previously made so many grandiose claims, most notably that it could perform dozens of tests from just a few drops of blood.\u003c/p>\n\u003cp>\"When push came to shove, what they actually showed was far, far less,\" Master said. \"It wasn’t 'Give me a couple of drops of blood and I’ll do everything. It was 'I'll do a panel of four tests here, or six or eight. Can they do more? They didn't show it.\"\u003c/p>\n\u003cp>Master said that while many of his colleagues thought including different pieces of lab equipment in a box was an interesting feat of engineering, \"It's not as if there's something here we haven't fundamentally seen before.\"\u003c/p>\n\u003cp>He contrasted Theranos' presentation with one he saw the night before, at a plenary session. The presenter \"also had a box with a bunch of different modules, but he had over 200 peer-reviewed papers.\"\u003c/p>\n\u003cp>In response to the criticism, Theranos Scientific and Medical Advisory Board member Susan Evans said Holmes demonstrated that the architecture of Theranos' technologies, as well as the associated science and technology, are sound.\u003c/p>\n\u003cp>\"Innovations like this are very exciting,\" Evans said. \"The Theranos miniLab has the potential to increase access and bring laboratory testing to the patient, whether close to home or in remote locations that are currently underserved.\"\u003c/p>\n\u003cp>(This response, by the way, was sent through public relations colossus Hill+Knowlton Strategies -- now, apparently, working with Theranos.)\u003c/p>\n\u003caside class=\"pullquote alignright\">‘I was not that impressed with the technology, but at least she shared the technology they have.’\u003ccite>Dr. David Koch, former president AACC\u003c/cite>\u003c/aside>\n\u003cp>Many if not most of the audience were expecting Holmes to present data concerning the technology, known as \"Edison,\" behind the problematic consumer blood tests the company ran over the past few years. As part of an attempt to correct problems flagged by the Centers for Medicare and Medicaid Services, Theranos was forced to invalidate tens of thousands of these tests, some of which are now the subject of lawsuits, including one that claims incorrect test results led to a heart attack.\u003c/p>\n\u003cp>But nowhere in her presentation did Holmes present validating data for Edison. Nor did she address problems at the company's California lab that have led to her two-year suspension from owning or operating a lab, and to severe penalties for Theranos.\u003c/p>\n\u003cp>\"We know there’s a lot of questions about the past,” Holmes said, \"and in the appropriate forum, we’ll address those.\"\u003c/p>\n\u003cp>She said the technology known as \"Edison,\" the subject of so much controversy over the past year, is obsolete.\u003c/p>\n\u003cp>After the presentation, Holmes answered questions from the audience for about 35 minutes.\u003c/p>\n\u003cp>Also in the audience was Dr. David Koch, director of clinical chemistry at Grady Memorial Hospital in Atlanta and a past president of the AACC. About the miniLab, he said, \"I was not that impressed with the technology. I think it’s apparently still coming along, but at least she shared the technology they have.”\u003c/p>\n\u003cp>Koch said colleagues noted the absence of any data concerning Theranos' famous claim to be able to perform multiple tests from just a few drops of blood from a fingerprick.\u003c/p>\n\u003cp>But, he said, \"I'm glad she came. It's a start.\"\u003c/p>\n\u003cp>Dr. Greg Miller, professor of pathology at Virginia Commonwealth University, said he thought Holmes did a \"credible job.\"\u003c/p>\n\u003cp>\"She explained the technology they’ve developed. She made it clear it’s the newest version of the technology and that it’s gone through several generations.”\u003c/p>\n\u003cp>While Miller wouldn't call the data presented \"a full validation, of the method or the technology,\" he said \"it showed credibility for the example she showed, and it shows potential for it being a useful piece of technology.\"\u003c/p>\n\u003cp>\u003cstrong>Consensus in the Media: A Failure\u003c/strong>\u003c/p>\n\u003cp>No on has taken a poll of the couple of thousand lab experts in the audience, but the reaction that has made its way through to media covering Theranos, as well as the media's characterization of the presentation itself, mostly ranges from tepid to extremely negative.\u003c/p>\n\u003cp>Nick Stockton of \u003ca href=\"http://www.wired.com/2016/08/theranos-chance-clear-name-instead-tried-pivot/\" target=\"_blank\">Wired\u003c/a> expressed a common theme:\u003c/p>\n\u003cblockquote>\u003cp>The miniLab itself still has to get validated by an independent lab. And even that wouldn’t give Theranos the clean slate it desires. Not from this crowd. Remember, this company got famous claiming faster, cheaper, painless, and above all revolutionary tests. Now it wants that same level of attention to pitch a mini lab that features no radically new technology.\u003c/p>\u003c/blockquote>\n\u003cp>From Jen Christensen, at \u003ca href=\"http://www.cnn.com/2016/08/02/health/theranos-holmes-presentation/index.html\" target=\"_blank\">CNN\u003c/a>:\u003c/p>\n\u003cblockquote>\u003cp>(T)he broader feeling seemed to be that there was not enough there. Some of the crowd lingered after the session to discuss the ideas with their peers.\u003c/p>\n\u003cp>\"There's just not enough data here,\" said Bobby Reddy, who runs a lab-related tech startup in Urbana, Illinois.\u003c/p>\n\u003cp>\"The failing here is to show up without enough data to show that the technology works. It might be enough for a poster session, but not this,\" said Joshua Hayden at Weill Cornell Medicine, who works with one of the moderators at the conference session. \"This industry is hungry for new ideas, we want disruptive technology in this field. But this doesn't seem to be it so far, and most of us don't like all the smoke and mirrors they've used over the years.\"\u003c/p>\u003c/blockquote>\n\u003cp>And Matthew Herper of \u003ca href=\"http://www.forbes.com/sites/matthewherper/2016/08/01/theranos-presents-data-on-new-blood-test-machine-remains-mum-on-previous-technology/#7d5bf7974159\" target=\"_blank\">Forbes\u003c/a>:\u003c/p>\n\u003cblockquote>\u003cp>\"Everything we’re interested in, they’re not talking about,” says Daniel Holmes (no relation), head of clinical chemistry at St. Paul’s Hospital in British Columbia, who reviewed the presentation for FORBES. “This is essentially a prototype instrument. They’re doing initial studies of a prototype.”\u003c/p>\n\u003cp>Geoffrey Baird, an associate professor of medicine at the University of Washington who has been critical of Theranos, went further, calling the presentation “a bait and switch.” He says: “We’re not seeing Theranos technology. We’re seeing an early-stage technology, an idea.”\u003c/p>\n\u003cp>As far as it goes, the data do seem to show a promising prototype. The data do show some agreement between the miniLab and existing devices used by Siemens. The question will be how convincing outside experts find these results.\u003c/p>\u003c/blockquote>\n\u003cp>And Christina Farr at \u003ca href=\"http://www.fastcompany.com/3062433/scientists-wanted-transparency-from-theranos-but-got-a-product-launch-instead\" target=\"_blank\">Fast Company\u003c/a>:\u003c/p>\n\u003cblockquote>\u003cp>\"Clearly, the scientific and medical community was hoping for a data-driven discussion today, and instead got a new product announcement,\" says John Torous, a psychiatrist and clinical informatics fellow at Harvard Medical School. ...\u003c/p>\n\u003cp>(S)cientists are questioning whether the MiniLab technology is a breakthrough. The current market is already fairly saturated: Abbott's iStat system, for instance, is a handheld device for clinicians to test patients for a plethora of common tests. Roche just received FDA clearance for its Cobas device, which can test for ailments like the flu and some strep infections in under 20 minutes. And Theranos competitors Quest and Labcorp already operate versions of this type of equipment in their own labs.\u003c/p>\n\u003cp>\"I can't imagine why they're wasting their time,\" says MIT-trained material scientist and biotech entrepreneur Kaveh Milaninia by phone. \"It's a tough market.\"\u003c/p>\u003c/blockquote>\n\u003cp>And (Theranos' Public Enemy No. 1) \u003ca href=\"http://www.wsj.com/articles/theranos-founder-elizabeth-holmes-introduces-new-blood-testing-device-1470089582\" target=\"_blank\">John Carreyrou of \u003c/a>\u003ca href=\"http://www.wsj.com/articles/theranos-founder-elizabeth-holmes-introduces-new-blood-testing-device-1470089582\" target=\"_blank\">The Wall Street Journal\u003c/a>\u003ca href=\"http://www.wsj.com/articles/theranos-founder-elizabeth-holmes-introduces-new-blood-testing-device-1470089582\" target=\"_blank\">:\u003c/a>\u003c/p>\n\u003cblockquote>\u003cp>The data covered 11 blood tests, but the miniLab can’t perform all of those tests on a single 160-microliter blood sample, according to a person familiar with the matter. At most, the miniLab can perform only three or four tests on a sample of that size, so a patient ordering all 11 tests would need to have his finger pricked three to four times, the person said….\u003c/p>\n\u003cp>Some lab experts at the conference said the underlying lab techniques relied on by Theranos’s new device, such as spectrophotometry, have been in use for years. The length of time needed to process samples and produce results, ranging from 20 minutes to two hours, also doesn’t improve on what is commercially available, some lab experts said.\u003c/p>\u003c/blockquote>\n\u003cp>And Beth Mole of \u003ca href=\"http://arstechnica.com/science/2016/08/with-chance-to-soothe-theranos-critics-with-data-holmes-gives-sales-pitch/\" target=\"_blank\">Ars Technica\u003c/a>:\u003c/p>\n\u003cblockquote>\u003cp>Yesterday’s presentation could have been the data-driven turning point Holmes has been promising. And the conference attendees—experts in clinical testing—gathered anxiously to hear the results.\u003c/p>\n\u003cp>But instead of validation studies of its existing technology, they got, essentially, a sales pitch for future technology.\u003c/p>\n\u003cp>Holmes spent her entire 45-minute time slot talking about a new blood testing device called the miniLab. Any questions about the company's old, disastrous blood testing device (the Edison) were flatly refused—even including questions about the differences between the Edison and miniLab.\u003c/p>\u003c/blockquote>\n\u003cp>Some in the audience, or those who were following online, expressed their dissatisfaction with the presentation on Twitter:\u003c/p>\n\u003cp>https://twitter.com/AAdamsonMD/status/760243720981716992\u003c/p>\n\u003cp> \u003c/p>\n\u003cp>https://twitter.com/CherylRofer/status/760235711106654210\u003c/p>\n\u003cp> \u003c/p>\n\u003cp>https://twitter.com/rvaughanw/status/760233452574765056\u003c/p>\n\u003cp> \u003c/p>\n\u003cp>https://twitter.com/NVTolan/status/760231507512463360\u003c/p>\n\u003cp> \u003c/p>\n\u003cp>https://twitter.com/clayew/status/760231816796200960\u003c/p>\n\u003cp> \u003c/p>\n\u003cp>https://twitter.com/Rachakonda_V/status/760231187772153856\u003c/p>\n\u003cp> \u003c/p>\n\u003cp>https://twitter.com/JohnTorousMD/status/760220182740697090\u003c/p>\n\u003cp> \u003c/p>\n\u003cp>https://twitter.com/fishbyte/status/760229430484733952\u003c/p>\n\u003cp>\u003cstrong>Previous post\u003c/strong>\u003c/p>\n\u003cp>Hey, try this archetypal nightmare out for size ...\u003c/p>\n\u003cp>\u003cem>Youʼre in a room. Speaking. There are people there -- hundreds and hundreds of people. They are not particularly friendly. Actually, they are hostile. You have displeased them. You had made certain unsubstantiated claims about something they know a great deal about. Yes, they are experts. They know exactly how to determine what is truth. And what is ... \u003c/em>\u003c/p>\n\u003cp>Then you wake up. Covered in sweat ...\u003c/p>\n\u003cp>This is pretty much the scenario Theranos CEO and founder Elizabeth Holmes is going to face on Monday in Philadelphia, at the American Association for Clinical Chemistry's 68th Annual Scientific Meeting & Clinical Lab Expo.\u003c/p>\n\u003cp>Holmes will \u003ca href=\"https://www.aacc.org/meetings-and-events/2016-annual-meeting-and-expo/conference-program/theranos-science-and-technology\" target=\"_blank\">present\u003c/a>, for the first time and in front of hundreds of lab experts, “reproducibility and correlation data” for the blood-testing technology her company claims to have developed but has never proven to the satisfaction of the scientific community. Holmes will also “share data to demonstrate the precision and accuracy” of its tests.\u003c/p>\n\u003caside class=\"pullquote alignright\">'If she presents us with scientific data ... she could feasibly convince people in the room that she has what she has been saying she has, all along.'\u003ccite>Dr. Patti Jones,\u003cbr>\nAmerican Association for Clinical Chemists\u003c/cite>\u003c/aside>\n\u003cp>Those tests can ostensibly be performed using only a small amount of capillary blood from a patient's finger, instead of the traditional tubes-full taken from a vein.\u003c/p>\n\u003cp>But a \u003ca href=\"http://www.wsj.com/articles/theranos-has-struggled-with-blood-tests-1444881901\" target=\"_blank\">Wall Street Journal investigation\u003c/a> characterized those claims as dubious. Later, a Theranos lab in California was found by its regulator to be so deficient as to represent a threat to patients' lives. And this month, regulators suspended the lab’s license and banned Holmes from owning, operating or directing a blood-testing lab for two years. (The company has until early September to appeal the government’s decision, and the suspensions don’t take place for the appeal period.)\u003c/p>\n\u003cp>Both the U.S. Attorneyʼs Office for the Northern District of California and the SEC are \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/04/18/elizabeth-holmes-says-theranos-will-absolutely-survive-video/\" target=\"_blank\">investigating\u003c/a>, and \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/07/19/lawsuit-faulty-theranos-test-results-contributed-to-heart-attack/\" target=\"_blank\">lawsuits aplenty\u003c/a> have been filed.\u003c/p>\n\u003cp>[contextly_sidebar id=\"Oo2Y0iji0udKw2zJpUVJaUL2HOf28w6T\"]Now Theranos is typically described with adjectives ranging from “troubled” to “beleaguered” to “disgraced.” And the company, once valued at $9 billion, is in serious danger of becoming permanent \u003ca href=\"https://www.youtube.com/watch?v=CU94GPs-LQw&ab_channel=texasjoehotdoggy\" target=\"_blank\">shorthand\u003c/a> for greed-driven Silicon Valley hubris.\u003c/p>\n\u003cp>If Holmes has any chance of rebuilding her shattered reputation, and if Theranos is to have any chance of clawing its way back to respectability, it will start in Philadelphia, on Monday. The company has appointed a \u003ca href=\"https://www.theranos.com/news/posts/theranos-announces-leading-medical-and-laboratory-experts-join-scientific-and-medical-advisory-board\" target=\"_blank\">scientific and medical advisory board\u003c/a>, in part to help with \"publication and presentation in scientific journals and at scientific meetings.\" The board includes several former AACC officials, so one would assume Holmes will, as they say, come correct.\u003c/p>\n\u003cp>\u003cstrong>90 Minutes\u003c/strong>\u003c/p>\n\u003cp>Still, whatever she presents may or may not be enough to convert hardcore skeptics. The presentation will last 45 minutes, followed by a 45-minute question-and-answer period, according to AACC members helping with the session. Anywhere from 800 to 1,500 people are expected to be in attendance, and the presentation is open to anyone who registers for the conference, including the media, though no questions from reporters will be taken.\u003c/p>\n\u003cp>Three moderators will ask their own questions as well as questions from the audience, which will be forwarded to the moderators after three other experts come to a consensus as what is most scientifically relevant to the discussion.\u003c/p>\n\u003caside class=\"pullquote alignright\">'The reason why a lot of us are skeptical, and perhaps even disgusted with the whole thing, is that they had a very cavalier attitude about the data that they were producing.' \u003ccite>Dr. David Koch, Grady Memorial Hospital\u003c/cite>\u003c/aside>\n\u003cp>The AACC had extended an invitation to Holmes for several years before she agreed to come speak. The announcement of this year's talk came soon after the Centers for Medicare & Medicaid Services threatened unprecedented sanctions against Theranos, as well as news of the U.S. Attorneyʼs and SEC's investigations.I asked Dr. Patti Jones, who made the decision to invite Holmes this year, if she had any reservations after all that news shook out.\u003c/p>\n\u003cp>“Of course,” said Jones, who is the clinical director of the chemistry and metabolic disease labs at Children’s Medical Center in Dallas. “I reconsidered every step along the way. But the bottom line is, I really think there is an opportunity to really see data here, to see the science. AACCʼs members have the expertise to interpret what she tells us. To be able to look at that data and say, 'Okay,' or 'Not okay.' \"\u003c/p>\n\u003cp>Jones said she had heard from members both opposed and in support of the invitation, and that the opposition was “much more\u003cbr>\nvocal.” She said no one from the AACC leadership will see Holmesʼ presentation in advance.\u003c/p>\n\u003cp>\"Weʼre not endorsing her in any way,\" Jones said. \"Weʼre just providing a room to show us what she has.”\u003c/p>\n\u003cp>I asked her if Holmes had any chance, given recent history, of convincing her colleagues she's legit.\u003c/p>\n\u003cp>“I think she can,” Jones said. “I think if she presents us with scientific data that shows not only that her system -- both the collection and the analysis work -- but how well they work in comparison to other methods, then she could feasibly convince people in the room that she has what she has been saying she has all along.”\u003c/p>\n\u003cfigure id=\"attachment_156559\" class=\"wp-caption aligncenter\" style=\"max-width: 640px\">\u003ca href=\"http://ww2.kqed.org/futureofyou/wp-content/uploads/sites/13/2016/05/ap_458918420528_wide-7b077d6d2c055cd84422729660306a155c7c88a8-e1469754321977.jpg\">\u003cimg class=\"wp-image-156559 size-large\" src=\"http://ww2.kqed.org/futureofyou/wp-content/uploads/sites/13/2016/05/ap_458918420528_wide-7b077d6d2c055cd84422729660306a155c7c88a8-1180x664.jpg\" alt=\"Elizabeth Holmes, founder and CEO of Theranos, speaks at the Fortune Global Forum in San Francisco, Nov. 2, 2015.\" width=\"640\" height=\"360\">\u003c/a>\u003cfigcaption class=\"wp-caption-text\">Elizabeth Holmes speaks at the Fortune Global Forum in San Francisco, Nov. 2, 2015.\u003c/figcaption>\u003c/figure>\n\u003cp>I asked five other experts in laboratory medicine, most of whom will be in attendance Monday, what Holmes has to do to turn things around. Here are edited excerpts from those conversations:\u003c/p>\n\u003cp>\u003cstrong>\u003cem>Dr. David Koch, director of clinical chemistry, Grady Memorial Hospital, Atlanta; former president AACC\u003c/em>\u003c/strong>\u003c/p>\n\u003cp>\"She really needs to talk about how she and Theranos didn't understand clinical laboratories and how best to practice laboratory medicine. She needs to acknowledge that they've made mistakes and that she has, in fact, made a turn from past practices and behaviors. She needs to say one of those mistakes was not sharing data, not having it vetted by professionals in the field, and not coming to meetings such as the AACC Annual Meeting.\u003c/p>\n\u003caside class=\"pullquote alignright\">'Their technology is still a black box, which nobody knows what the details are. Anything that she presents would not be peer-reviewed.\u003ccite>Dr. Eleftherios Diamandis,\u003cbr>\nMount Sinai Hospital, Toronto\u003c/cite>\u003c/aside>\n\u003cp>The reason why a lot of us are skeptical, and perhaps even disgusted with the whole thing, is that they had a very cavalier attitude about the data they were producing, much of which turns out to apparently not be correct.\u003c/p>\n\u003cp>The laboratory has advanced year by year for the whole history of our profession, and if this is one more advancement, fine. But we want to see the data and even evaluate the instrument or device in our laboratories. Or in physicians offices, drugstores, or even in patients' homes.\u003c/p>\n\u003cp>I expect some hard questions, especially if her presentation is a little lacking, weak on substance.\u003c/p>\n\u003cp>\u003cstrong>\u003cem>Dr. Eleftherios Diamandis, division head of clinical biochemistry, Mount Sinai Hospital, Toronto; \u003ca href=\"https://www.ghdonline.org/uploads/Diamandis_-_2015_-%20_Theranos_phenomenon_promises_and_fallacies.pdf\" target=\"_blank\">\"Theranos phenomenon: Promises and fallacies\"\u003c/a>\u003c/em>\u003c/strong>\u003c/p>\n\u003cp>I think the AACC is in a very odd situation, to have a lecture by somebody who was caught manipulating quality assurance, delivering results that some people believe have endangered patients.\u003c/p>\n\u003caside class=\"pullquote alignright\">'Their situation is so unique that they really just need to turn this machine over to a completely independent person.'\u003ccite>Dr. Norman Paradis, Dartmouth College\u003c/cite>\u003c/aside>\n\u003cp>I think her reputation is in big question here. Irrespective of the opinion of people like me, that she shouldn't be invited in the first place, apparently she's going to show up and give the lecture, although I will wait until I see her before I believe that.\u003c/p>\n\u003cp>Their technology is still a black box, which nobody knows what the details are. They still haven't published a single word. Anything that she presents would not be peer-reviewed. It will be something that experts in the field have not seen or had a chance to really criticize.\u003c/p>\n\u003cp>That will be a major hurdle, because she can come and tell us anything she wants. She's got the magic black box. You put in one little drop of blood and you get 1,000 analyses with impossible accuracy,\u003c/p>\n\u003cp>But how am I going to be able to verify that the claims are actually correct? I will only believe it if experts evaluate this technology and find it to be robust.\u003c/p>\n\u003cp>\u003cstrong>\u003cem>Dr. Fred Apple, medical director of clinical laboratories, Hennepin County Medical Center, Minnesota\u003c/em>\u003c/strong>\u003c/p>\n\u003cp>Iʼm hoping we're going to see, ʻHereʼs my technology, hereʼs my process, how we generate data, and here is the R&D weʼve done that proves our technology works.'\u003c/p>\n\u003cp>We want to look at clinical sensitivity, limits of detection, reproducibility, analytical correlation against another assay, turnaround time, stability of samples, as well as how it compares to whatʼs already out there in the literature.\u003c/p>\n\u003cp>Show me some data and a statistically relevant number of patients, so we can do some comparisons.\u003c/p>\n\u003cp>\u003cstrong>\u003cem>Dr. Jerry Yeo, director, clinical chemistry laboratories, Department of Pathology, University of Chicago\u003c/em>\u003c/strong>\u003c/p>\n\u003cp>At this point, Holmes has a very high bar to clear to gain\u003cbr>\ncredibility, given her history of secrecy, lack of peer-reviewed publications and most damaging, the abject failures with compliance with basic requirements of the CLIA (Clinical Labroatory Improvement Amendments) guidelines leading to CMS banning her for 2 years.\u003c/p>\n\u003cp>Even if she suddenly revealed “revolutionary performance data” of her mysterious Edison invention, she still has to explain how that system managed to put out two years of bad data that had to be\u003ca href=\"http://ww2.kqed.org/futureofyou/2016/05/19/theranos-corrects-tens-of-thousands-of-blood-tests/\" target=\"_blank\"> voided, corrected\u003c/a>. Or how the system failed to comply with CLIA\u003cbr>\nregulations.\u003c/p>\n\u003cp>I seriously doubt she can do all that at this AACC venue. If it turns out to be a highly staged presentation with sanitized, prescreened questions, it might produce an opposite effect of loss of credibility to\u003cbr>\nboth Holmes and AACC leadership.\u003c/p>\n\u003cp>\u003cstrong>\u003cem>Dr. Norman Paradis, professor of medicine, Dartmouth; \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/04/25/analysis-why-medical-lab-experts-were-always-skeptical-of-theranos/\" target=\"_blank\">\"Why Medical Lab Experts Were Always Skeptical of Theranos\"\u003c/a>\u003c/em>\u003c/strong>\u003c/p>\n\u003cp>If she puts up real data, there's got to be some credibility associated with that. But this has never really happened before.\u003c/p>\n\u003cp>Big pharma gets in trouble every so often in big ways, but this just doesn't tend to happen in diagnostics: People know how to validate assays. That's not a new thing. You could take your tech and just go to a completely independent university-based group to validate it. You can do it internally, by bringing in what's called a clinical research organization.\u003c/p>\n\u003cp>The FDA has published a voluminous document on good clinical practices. Why it's taken so long is just not clear.\u003c/p>\n\u003cp>So I do think if they show real data, that will be something. If she's managed to get data in a stealth manner, get data that is independent, then that obviously would be a much more reassuring thing.\u003c/p>\n\u003cp>But they still need to get FDA approval. And this won't move them along at all on that front.\u003c/p>\n\u003cp>Their situation is so unique that they really just need to turn this machine over to a completely independent person.\u003c/p>\n\u003cp>[ad floatright]\u003c/p>\n\u003cp>This is absolutely an amazing story. I've never seen anything like it.\u003c/p>\n\n",
"disqusIdentifier": "210797 http://ww2.kqed.org/futureofyou/?p=210797",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/08/01/theranos-elizabeth-holmes-will-face-1000-scientists-monday-can-she-say-anything-to-gain-their-trust/",
"stats": {
"hasVideo": false,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 3858,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 102
},
"modified": 1475781103,
"excerpt": "The founder of the beleaguered company sought to turn the page on deficiencies in its blood-testing technology by unveiling a new device.",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "The founder of the beleaguered company sought to turn the page on deficiencies in its blood-testing technology by unveiling a new device.",
"title": "Theranos Presentation Mostly a Dud, Say Scientists | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "Theranos Presentation Mostly a Dud, Say Scientists",
"datePublished": "2016-08-01T15:25:34-07:00",
"dateModified": "2016-10-06T12:11:43-07:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "theranos-elizabeth-holmes-will-face-1000-scientists-monday-can-she-say-anything-to-gain-their-trust",
"status": "publish",
"customPermalink": "2016/07/29/theranos-elizabeth-holmes-will-face-1000-scientists-monday-can-she-say-anything-to-gain-their-trust/",
"source": "Future of You",
"path": "/futureofyou/210797/theranos-elizabeth-holmes-will-face-1000-scientists-monday-can-she-say-anything-to-gain-their-trust",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>Forget \"Edison.\" Let's talk \"miniLab.\"\u003c/p>\n\u003cp>That was the message Elizabeth Holmes sent at her highly anticipated presentation Monday at the American Association for Clinical Chemistry's annual meeting in Philadelphia.\u003c/p>\n\u003caside class=\"pullquote alignright\">'In retrospect it was no different from going to a typical talk by a sponsored vendor.'\u003ccite>Dr. Jerry Yeo, University of Chicago\u003c/cite>\u003c/aside>\n\u003cp>Speaking for roughly 55 minutes in front of an estimated 2,650 people -- most of them laboratory scientists -- Holmes introduced a new device that can fit on a desktop. The machine, called a miniLab, integrates several blood-testing methodologies and, using robots and the company's proprietary \"\u003ca href=\"https://www.google.com/search?q=nanotainer\" target=\"_blank\">nanotainer\u003c/a>\" collection tube, will be able to process small volumes of blood remotely and send data back to a centralized location.\u003c/p>\n\u003cp>Holmes presented internal company data that showed the system worked for a range of tests, including a new assay for Zika.\u003c/p>\n\u003cp>Dr. Jerry Yeo, however, director of clinical chemistry laboratories at the University of Chicago, seemed to speak for a number of scientists when he summed up his response this way:\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>\u003c/p>\u003cp>\u003c/p>\u003cp>\"There was nothing revolutionary or disruptive behind the technology of the miniLab,\" Yeo said.\u003c/p>\n\u003cp>Yeo said the miniLab uses spectrophotometry and other measurement principles that are \"well known in the field and are existing, current technologies employed by many diagnostic vendors.\"\u003c/p>\n\u003cp>While the internal performance data Holmes showed \"looked impressive,\" he said, \"ultimately the proof will require that these units be tested in independent clinical labs, so for now the jury is out, until we see some peer-reviewed publications from those sources.\"\u003c/p>\n\u003cp>Yeo also said the data Holmes provided were incomplete in terms of fully assessing the machine.\u003c/p>\n\u003cp>\"In retrospect it was no different from going to a typical talk by a sponsored vendor,\" Yeo said.\u003c/p>\n\u003cp>Dr. Stephen R. Master, one of the event's moderators, said the presentation might have gone better had Theranos not previously made so many grandiose claims, most notably that it could perform dozens of tests from just a few drops of blood.\u003c/p>\n\u003cp>\"When push came to shove, what they actually showed was far, far less,\" Master said. \"It wasn’t 'Give me a couple of drops of blood and I’ll do everything. It was 'I'll do a panel of four tests here, or six or eight. Can they do more? They didn't show it.\"\u003c/p>\n\u003cp>Master said that while many of his colleagues thought including different pieces of lab equipment in a box was an interesting feat of engineering, \"It's not as if there's something here we haven't fundamentally seen before.\"\u003c/p>\n\u003cp>He contrasted Theranos' presentation with one he saw the night before, at a plenary session. The presenter \"also had a box with a bunch of different modules, but he had over 200 peer-reviewed papers.\"\u003c/p>\n\u003cp>In response to the criticism, Theranos Scientific and Medical Advisory Board member Susan Evans said Holmes demonstrated that the architecture of Theranos' technologies, as well as the associated science and technology, are sound.\u003c/p>\n\u003cp>\"Innovations like this are very exciting,\" Evans said. \"The Theranos miniLab has the potential to increase access and bring laboratory testing to the patient, whether close to home or in remote locations that are currently underserved.\"\u003c/p>\n\u003cp>(This response, by the way, was sent through public relations colossus Hill+Knowlton Strategies -- now, apparently, working with Theranos.)\u003c/p>\n\u003caside class=\"pullquote alignright\">‘I was not that impressed with the technology, but at least she shared the technology they have.’\u003ccite>Dr. David Koch, former president AACC\u003c/cite>\u003c/aside>\n\u003cp>Many if not most of the audience were expecting Holmes to present data concerning the technology, known as \"Edison,\" behind the problematic consumer blood tests the company ran over the past few years. As part of an attempt to correct problems flagged by the Centers for Medicare and Medicaid Services, Theranos was forced to invalidate tens of thousands of these tests, some of which are now the subject of lawsuits, including one that claims incorrect test results led to a heart attack.\u003c/p>\n\u003cp>But nowhere in her presentation did Holmes present validating data for Edison. Nor did she address problems at the company's California lab that have led to her two-year suspension from owning or operating a lab, and to severe penalties for Theranos.\u003c/p>\n\u003cp>\"We know there’s a lot of questions about the past,” Holmes said, \"and in the appropriate forum, we’ll address those.\"\u003c/p>\n\u003cp>She said the technology known as \"Edison,\" the subject of so much controversy over the past year, is obsolete.\u003c/p>\n\u003cp>After the presentation, Holmes answered questions from the audience for about 35 minutes.\u003c/p>\n\u003cp>Also in the audience was Dr. David Koch, director of clinical chemistry at Grady Memorial Hospital in Atlanta and a past president of the AACC. About the miniLab, he said, \"I was not that impressed with the technology. I think it’s apparently still coming along, but at least she shared the technology they have.”\u003c/p>\n\u003cp>Koch said colleagues noted the absence of any data concerning Theranos' famous claim to be able to perform multiple tests from just a few drops of blood from a fingerprick.\u003c/p>\n\u003cp>But, he said, \"I'm glad she came. It's a start.\"\u003c/p>\n\u003cp>Dr. Greg Miller, professor of pathology at Virginia Commonwealth University, said he thought Holmes did a \"credible job.\"\u003c/p>\n\u003cp>\"She explained the technology they’ve developed. She made it clear it’s the newest version of the technology and that it’s gone through several generations.”\u003c/p>\n\u003cp>While Miller wouldn't call the data presented \"a full validation, of the method or the technology,\" he said \"it showed credibility for the example she showed, and it shows potential for it being a useful piece of technology.\"\u003c/p>\n\u003cp>\u003cstrong>Consensus in the Media: A Failure\u003c/strong>\u003c/p>\n\u003cp>No on has taken a poll of the couple of thousand lab experts in the audience, but the reaction that has made its way through to media covering Theranos, as well as the media's characterization of the presentation itself, mostly ranges from tepid to extremely negative.\u003c/p>\n\u003cp>Nick Stockton of \u003ca href=\"http://www.wired.com/2016/08/theranos-chance-clear-name-instead-tried-pivot/\" target=\"_blank\">Wired\u003c/a> expressed a common theme:\u003c/p>\n\u003cblockquote>\u003cp>The miniLab itself still has to get validated by an independent lab. And even that wouldn’t give Theranos the clean slate it desires. Not from this crowd. Remember, this company got famous claiming faster, cheaper, painless, and above all revolutionary tests. Now it wants that same level of attention to pitch a mini lab that features no radically new technology.\u003c/p>\u003c/blockquote>\n\u003cp>From Jen Christensen, at \u003ca href=\"http://www.cnn.com/2016/08/02/health/theranos-holmes-presentation/index.html\" target=\"_blank\">CNN\u003c/a>:\u003c/p>\n\u003cblockquote>\u003cp>(T)he broader feeling seemed to be that there was not enough there. Some of the crowd lingered after the session to discuss the ideas with their peers.\u003c/p>\n\u003cp>\"There's just not enough data here,\" said Bobby Reddy, who runs a lab-related tech startup in Urbana, Illinois.\u003c/p>\n\u003cp>\"The failing here is to show up without enough data to show that the technology works. It might be enough for a poster session, but not this,\" said Joshua Hayden at Weill Cornell Medicine, who works with one of the moderators at the conference session. \"This industry is hungry for new ideas, we want disruptive technology in this field. But this doesn't seem to be it so far, and most of us don't like all the smoke and mirrors they've used over the years.\"\u003c/p>\u003c/blockquote>\n\u003cp>And Matthew Herper of \u003ca href=\"http://www.forbes.com/sites/matthewherper/2016/08/01/theranos-presents-data-on-new-blood-test-machine-remains-mum-on-previous-technology/#7d5bf7974159\" target=\"_blank\">Forbes\u003c/a>:\u003c/p>\n\u003cblockquote>\u003cp>\"Everything we’re interested in, they’re not talking about,” says Daniel Holmes (no relation), head of clinical chemistry at St. Paul’s Hospital in British Columbia, who reviewed the presentation for FORBES. “This is essentially a prototype instrument. They’re doing initial studies of a prototype.”\u003c/p>\n\u003cp>Geoffrey Baird, an associate professor of medicine at the University of Washington who has been critical of Theranos, went further, calling the presentation “a bait and switch.” He says: “We’re not seeing Theranos technology. We’re seeing an early-stage technology, an idea.”\u003c/p>\n\u003cp>As far as it goes, the data do seem to show a promising prototype. The data do show some agreement between the miniLab and existing devices used by Siemens. The question will be how convincing outside experts find these results.\u003c/p>\u003c/blockquote>\n\u003cp>And Christina Farr at \u003ca href=\"http://www.fastcompany.com/3062433/scientists-wanted-transparency-from-theranos-but-got-a-product-launch-instead\" target=\"_blank\">Fast Company\u003c/a>:\u003c/p>\n\u003cblockquote>\u003cp>\"Clearly, the scientific and medical community was hoping for a data-driven discussion today, and instead got a new product announcement,\" says John Torous, a psychiatrist and clinical informatics fellow at Harvard Medical School. ...\u003c/p>\n\u003cp>(S)cientists are questioning whether the MiniLab technology is a breakthrough. The current market is already fairly saturated: Abbott's iStat system, for instance, is a handheld device for clinicians to test patients for a plethora of common tests. Roche just received FDA clearance for its Cobas device, which can test for ailments like the flu and some strep infections in under 20 minutes. And Theranos competitors Quest and Labcorp already operate versions of this type of equipment in their own labs.\u003c/p>\n\u003cp>\"I can't imagine why they're wasting their time,\" says MIT-trained material scientist and biotech entrepreneur Kaveh Milaninia by phone. \"It's a tough market.\"\u003c/p>\u003c/blockquote>\n\u003cp>And (Theranos' Public Enemy No. 1) \u003ca href=\"http://www.wsj.com/articles/theranos-founder-elizabeth-holmes-introduces-new-blood-testing-device-1470089582\" target=\"_blank\">John Carreyrou of \u003c/a>\u003ca href=\"http://www.wsj.com/articles/theranos-founder-elizabeth-holmes-introduces-new-blood-testing-device-1470089582\" target=\"_blank\">The Wall Street Journal\u003c/a>\u003ca href=\"http://www.wsj.com/articles/theranos-founder-elizabeth-holmes-introduces-new-blood-testing-device-1470089582\" target=\"_blank\">:\u003c/a>\u003c/p>\n\u003cblockquote>\u003cp>The data covered 11 blood tests, but the miniLab can’t perform all of those tests on a single 160-microliter blood sample, according to a person familiar with the matter. At most, the miniLab can perform only three or four tests on a sample of that size, so a patient ordering all 11 tests would need to have his finger pricked three to four times, the person said….\u003c/p>\n\u003cp>Some lab experts at the conference said the underlying lab techniques relied on by Theranos’s new device, such as spectrophotometry, have been in use for years. The length of time needed to process samples and produce results, ranging from 20 minutes to two hours, also doesn’t improve on what is commercially available, some lab experts said.\u003c/p>\u003c/blockquote>\n\u003cp>And Beth Mole of \u003ca href=\"http://arstechnica.com/science/2016/08/with-chance-to-soothe-theranos-critics-with-data-holmes-gives-sales-pitch/\" target=\"_blank\">Ars Technica\u003c/a>:\u003c/p>\n\u003cblockquote>\u003cp>Yesterday’s presentation could have been the data-driven turning point Holmes has been promising. And the conference attendees—experts in clinical testing—gathered anxiously to hear the results.\u003c/p>\n\u003cp>But instead of validation studies of its existing technology, they got, essentially, a sales pitch for future technology.\u003c/p>\n\u003cp>Holmes spent her entire 45-minute time slot talking about a new blood testing device called the miniLab. Any questions about the company's old, disastrous blood testing device (the Edison) were flatly refused—even including questions about the differences between the Edison and miniLab.\u003c/p>\u003c/blockquote>\n\u003cp>Some in the audience, or those who were following online, expressed their dissatisfaction with the presentation on Twitter:\u003c/p>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "singleTwitterStatus",
"attributes": {
"named": {
"id": "760243720981716992"
},
"numeric": []
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\n\u003cp> \u003c/p>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "singleTwitterStatus",
"attributes": {
"named": {
"id": "760235711106654210"
},
"numeric": []
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\n\u003cp> \u003c/p>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "singleTwitterStatus",
"attributes": {
"named": {
"id": "760233452574765056"
},
"numeric": []
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\n\u003cp> \u003c/p>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "singleTwitterStatus",
"attributes": {
"named": {
"id": "760231507512463360"
},
"numeric": []
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\n\u003cp> \u003c/p>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "singleTwitterStatus",
"attributes": {
"named": {
"id": "760231816796200960"
},
"numeric": []
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\n\u003cp> \u003c/p>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "singleTwitterStatus",
"attributes": {
"named": {
"id": "760231187772153856"
},
"numeric": []
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\n\u003cp> \u003c/p>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "singleTwitterStatus",
"attributes": {
"named": {
"id": "760220182740697090"
},
"numeric": []
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\n\u003cp> \u003c/p>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "singleTwitterStatus",
"attributes": {
"named": {
"id": "760229430484733952"
},
"numeric": []
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\n\u003cp>\u003cstrong>Previous post\u003c/strong>\u003c/p>\n\u003cp>Hey, try this archetypal nightmare out for size ...\u003c/p>\n\u003cp>\u003cem>Youʼre in a room. Speaking. There are people there -- hundreds and hundreds of people. They are not particularly friendly. Actually, they are hostile. You have displeased them. You had made certain unsubstantiated claims about something they know a great deal about. Yes, they are experts. They know exactly how to determine what is truth. And what is ... \u003c/em>\u003c/p>\n\u003cp>Then you wake up. Covered in sweat ...\u003c/p>\n\u003cp>This is pretty much the scenario Theranos CEO and founder Elizabeth Holmes is going to face on Monday in Philadelphia, at the American Association for Clinical Chemistry's 68th Annual Scientific Meeting & Clinical Lab Expo.\u003c/p>\n\u003cp>Holmes will \u003ca href=\"https://www.aacc.org/meetings-and-events/2016-annual-meeting-and-expo/conference-program/theranos-science-and-technology\" target=\"_blank\">present\u003c/a>, for the first time and in front of hundreds of lab experts, “reproducibility and correlation data” for the blood-testing technology her company claims to have developed but has never proven to the satisfaction of the scientific community. Holmes will also “share data to demonstrate the precision and accuracy” of its tests.\u003c/p>\n\u003caside class=\"pullquote alignright\">'If she presents us with scientific data ... she could feasibly convince people in the room that she has what she has been saying she has, all along.'\u003ccite>Dr. Patti Jones,\u003cbr>\nAmerican Association for Clinical Chemists\u003c/cite>\u003c/aside>\n\u003cp>Those tests can ostensibly be performed using only a small amount of capillary blood from a patient's finger, instead of the traditional tubes-full taken from a vein.\u003c/p>\n\u003cp>But a \u003ca href=\"http://www.wsj.com/articles/theranos-has-struggled-with-blood-tests-1444881901\" target=\"_blank\">Wall Street Journal investigation\u003c/a> characterized those claims as dubious. Later, a Theranos lab in California was found by its regulator to be so deficient as to represent a threat to patients' lives. And this month, regulators suspended the lab’s license and banned Holmes from owning, operating or directing a blood-testing lab for two years. (The company has until early September to appeal the government’s decision, and the suspensions don’t take place for the appeal period.)\u003c/p>\n\u003cp>Both the U.S. Attorneyʼs Office for the Northern District of California and the SEC are \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/04/18/elizabeth-holmes-says-theranos-will-absolutely-survive-video/\" target=\"_blank\">investigating\u003c/a>, and \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/07/19/lawsuit-faulty-theranos-test-results-contributed-to-heart-attack/\" target=\"_blank\">lawsuits aplenty\u003c/a> have been filed.\u003c/p>\n\u003cp>\u003c/p>\u003cp>\u003c/p>\u003cp>Now Theranos is typically described with adjectives ranging from “troubled” to “beleaguered” to “disgraced.” And the company, once valued at $9 billion, is in serious danger of becoming permanent \u003ca href=\"https://www.youtube.com/watch?v=CU94GPs-LQw&ab_channel=texasjoehotdoggy\" target=\"_blank\">shorthand\u003c/a> for greed-driven Silicon Valley hubris.\u003c/p>\n\u003cp>If Holmes has any chance of rebuilding her shattered reputation, and if Theranos is to have any chance of clawing its way back to respectability, it will start in Philadelphia, on Monday. The company has appointed a \u003ca href=\"https://www.theranos.com/news/posts/theranos-announces-leading-medical-and-laboratory-experts-join-scientific-and-medical-advisory-board\" target=\"_blank\">scientific and medical advisory board\u003c/a>, in part to help with \"publication and presentation in scientific journals and at scientific meetings.\" The board includes several former AACC officials, so one would assume Holmes will, as they say, come correct.\u003c/p>\n\u003cp>\u003cstrong>90 Minutes\u003c/strong>\u003c/p>\n\u003cp>Still, whatever she presents may or may not be enough to convert hardcore skeptics. The presentation will last 45 minutes, followed by a 45-minute question-and-answer period, according to AACC members helping with the session. Anywhere from 800 to 1,500 people are expected to be in attendance, and the presentation is open to anyone who registers for the conference, including the media, though no questions from reporters will be taken.\u003c/p>\n\u003cp>Three moderators will ask their own questions as well as questions from the audience, which will be forwarded to the moderators after three other experts come to a consensus as what is most scientifically relevant to the discussion.\u003c/p>\n\u003caside class=\"pullquote alignright\">'The reason why a lot of us are skeptical, and perhaps even disgusted with the whole thing, is that they had a very cavalier attitude about the data that they were producing.' \u003ccite>Dr. David Koch, Grady Memorial Hospital\u003c/cite>\u003c/aside>\n\u003cp>The AACC had extended an invitation to Holmes for several years before she agreed to come speak. The announcement of this year's talk came soon after the Centers for Medicare & Medicaid Services threatened unprecedented sanctions against Theranos, as well as news of the U.S. Attorneyʼs and SEC's investigations.I asked Dr. Patti Jones, who made the decision to invite Holmes this year, if she had any reservations after all that news shook out.\u003c/p>\n\u003cp>“Of course,” said Jones, who is the clinical director of the chemistry and metabolic disease labs at Children’s Medical Center in Dallas. “I reconsidered every step along the way. But the bottom line is, I really think there is an opportunity to really see data here, to see the science. AACCʼs members have the expertise to interpret what she tells us. To be able to look at that data and say, 'Okay,' or 'Not okay.' \"\u003c/p>\n\u003cp>Jones said she had heard from members both opposed and in support of the invitation, and that the opposition was “much more\u003cbr>\nvocal.” She said no one from the AACC leadership will see Holmesʼ presentation in advance.\u003c/p>\n\u003cp>\"Weʼre not endorsing her in any way,\" Jones said. \"Weʼre just providing a room to show us what she has.”\u003c/p>\n\u003cp>I asked her if Holmes had any chance, given recent history, of convincing her colleagues she's legit.\u003c/p>\n\u003cp>“I think she can,” Jones said. “I think if she presents us with scientific data that shows not only that her system -- both the collection and the analysis work -- but how well they work in comparison to other methods, then she could feasibly convince people in the room that she has what she has been saying she has all along.”\u003c/p>\n\u003cfigure id=\"attachment_156559\" class=\"wp-caption aligncenter\" style=\"max-width: 640px\">\u003ca href=\"http://ww2.kqed.org/futureofyou/wp-content/uploads/sites/13/2016/05/ap_458918420528_wide-7b077d6d2c055cd84422729660306a155c7c88a8-e1469754321977.jpg\">\u003cimg class=\"wp-image-156559 size-large\" src=\"http://ww2.kqed.org/futureofyou/wp-content/uploads/sites/13/2016/05/ap_458918420528_wide-7b077d6d2c055cd84422729660306a155c7c88a8-1180x664.jpg\" alt=\"Elizabeth Holmes, founder and CEO of Theranos, speaks at the Fortune Global Forum in San Francisco, Nov. 2, 2015.\" width=\"640\" height=\"360\">\u003c/a>\u003cfigcaption class=\"wp-caption-text\">Elizabeth Holmes speaks at the Fortune Global Forum in San Francisco, Nov. 2, 2015.\u003c/figcaption>\u003c/figure>\n\u003cp>I asked five other experts in laboratory medicine, most of whom will be in attendance Monday, what Holmes has to do to turn things around. Here are edited excerpts from those conversations:\u003c/p>\n\u003cp>\u003cstrong>\u003cem>Dr. David Koch, director of clinical chemistry, Grady Memorial Hospital, Atlanta; former president AACC\u003c/em>\u003c/strong>\u003c/p>\n\u003cp>\"She really needs to talk about how she and Theranos didn't understand clinical laboratories and how best to practice laboratory medicine. She needs to acknowledge that they've made mistakes and that she has, in fact, made a turn from past practices and behaviors. She needs to say one of those mistakes was not sharing data, not having it vetted by professionals in the field, and not coming to meetings such as the AACC Annual Meeting.\u003c/p>\n\u003caside class=\"pullquote alignright\">'Their technology is still a black box, which nobody knows what the details are. Anything that she presents would not be peer-reviewed.\u003ccite>Dr. Eleftherios Diamandis,\u003cbr>\nMount Sinai Hospital, Toronto\u003c/cite>\u003c/aside>\n\u003cp>The reason why a lot of us are skeptical, and perhaps even disgusted with the whole thing, is that they had a very cavalier attitude about the data they were producing, much of which turns out to apparently not be correct.\u003c/p>\n\u003cp>The laboratory has advanced year by year for the whole history of our profession, and if this is one more advancement, fine. But we want to see the data and even evaluate the instrument or device in our laboratories. Or in physicians offices, drugstores, or even in patients' homes.\u003c/p>\n\u003cp>I expect some hard questions, especially if her presentation is a little lacking, weak on substance.\u003c/p>\n\u003cp>\u003cstrong>\u003cem>Dr. Eleftherios Diamandis, division head of clinical biochemistry, Mount Sinai Hospital, Toronto; \u003ca href=\"https://www.ghdonline.org/uploads/Diamandis_-_2015_-%20_Theranos_phenomenon_promises_and_fallacies.pdf\" target=\"_blank\">\"Theranos phenomenon: Promises and fallacies\"\u003c/a>\u003c/em>\u003c/strong>\u003c/p>\n\u003cp>I think the AACC is in a very odd situation, to have a lecture by somebody who was caught manipulating quality assurance, delivering results that some people believe have endangered patients.\u003c/p>\n\u003caside class=\"pullquote alignright\">'Their situation is so unique that they really just need to turn this machine over to a completely independent person.'\u003ccite>Dr. Norman Paradis, Dartmouth College\u003c/cite>\u003c/aside>\n\u003cp>I think her reputation is in big question here. Irrespective of the opinion of people like me, that she shouldn't be invited in the first place, apparently she's going to show up and give the lecture, although I will wait until I see her before I believe that.\u003c/p>\n\u003cp>Their technology is still a black box, which nobody knows what the details are. They still haven't published a single word. Anything that she presents would not be peer-reviewed. It will be something that experts in the field have not seen or had a chance to really criticize.\u003c/p>\n\u003cp>That will be a major hurdle, because she can come and tell us anything she wants. She's got the magic black box. You put in one little drop of blood and you get 1,000 analyses with impossible accuracy,\u003c/p>\n\u003cp>But how am I going to be able to verify that the claims are actually correct? I will only believe it if experts evaluate this technology and find it to be robust.\u003c/p>\n\u003cp>\u003cstrong>\u003cem>Dr. Fred Apple, medical director of clinical laboratories, Hennepin County Medical Center, Minnesota\u003c/em>\u003c/strong>\u003c/p>\n\u003cp>Iʼm hoping we're going to see, ʻHereʼs my technology, hereʼs my process, how we generate data, and here is the R&D weʼve done that proves our technology works.'\u003c/p>\n\u003cp>We want to look at clinical sensitivity, limits of detection, reproducibility, analytical correlation against another assay, turnaround time, stability of samples, as well as how it compares to whatʼs already out there in the literature.\u003c/p>\n\u003cp>Show me some data and a statistically relevant number of patients, so we can do some comparisons.\u003c/p>\n\u003cp>\u003cstrong>\u003cem>Dr. Jerry Yeo, director, clinical chemistry laboratories, Department of Pathology, University of Chicago\u003c/em>\u003c/strong>\u003c/p>\n\u003cp>At this point, Holmes has a very high bar to clear to gain\u003cbr>\ncredibility, given her history of secrecy, lack of peer-reviewed publications and most damaging, the abject failures with compliance with basic requirements of the CLIA (Clinical Labroatory Improvement Amendments) guidelines leading to CMS banning her for 2 years.\u003c/p>\n\u003cp>Even if she suddenly revealed “revolutionary performance data” of her mysterious Edison invention, she still has to explain how that system managed to put out two years of bad data that had to be\u003ca href=\"http://ww2.kqed.org/futureofyou/2016/05/19/theranos-corrects-tens-of-thousands-of-blood-tests/\" target=\"_blank\"> voided, corrected\u003c/a>. Or how the system failed to comply with CLIA\u003cbr>\nregulations.\u003c/p>\n\u003cp>I seriously doubt she can do all that at this AACC venue. If it turns out to be a highly staged presentation with sanitized, prescreened questions, it might produce an opposite effect of loss of credibility to\u003cbr>\nboth Holmes and AACC leadership.\u003c/p>\n\u003cp>\u003cstrong>\u003cem>Dr. Norman Paradis, professor of medicine, Dartmouth; \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/04/25/analysis-why-medical-lab-experts-were-always-skeptical-of-theranos/\" target=\"_blank\">\"Why Medical Lab Experts Were Always Skeptical of Theranos\"\u003c/a>\u003c/em>\u003c/strong>\u003c/p>\n\u003cp>If she puts up real data, there's got to be some credibility associated with that. But this has never really happened before.\u003c/p>\n\u003cp>Big pharma gets in trouble every so often in big ways, but this just doesn't tend to happen in diagnostics: People know how to validate assays. That's not a new thing. You could take your tech and just go to a completely independent university-based group to validate it. You can do it internally, by bringing in what's called a clinical research organization.\u003c/p>\n\u003cp>The FDA has published a voluminous document on good clinical practices. Why it's taken so long is just not clear.\u003c/p>\n\u003cp>So I do think if they show real data, that will be something. If she's managed to get data in a stealth manner, get data that is independent, then that obviously would be a much more reassuring thing.\u003c/p>\n\u003cp>But they still need to get FDA approval. And this won't move them along at all on that front.\u003c/p>\n\u003cp>Their situation is so unique that they really just need to turn this machine over to a completely independent person.\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "floatright"
},
"numeric": [
"floatright"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>This is absolutely an amazing story. I've never seen anything like it.\u003c/p>\n\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/210797/theranos-elizabeth-holmes-will-face-1000-scientists-monday-can-she-say-anything-to-gain-their-trust",
"authors": [
"80"
],
"categories": [
"futureofyou_452",
"futureofyou_1",
"futureofyou_73"
],
"tags": [
"futureofyou_865",
"futureofyou_814",
"futureofyou_617"
],
"featImg": "futureofyou_203083",
"label": "source_futureofyou_210797"
},
"futureofyou_206905": {
"type": "posts",
"id": "futureofyou_206905",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "206905",
"score": null,
"sort": [
1468970843000
]
},
"parent": 0,
"labelTerm": {
"site": "futureofyou"
},
"blocks": [],
"publishDate": 1468970843,
"format": "standard",
"disqusTitle": "Lawsuit: Faulty Theranos Test Results Contributed to Heart Attack",
"title": "Lawsuit: Faulty Theranos Test Results Contributed to Heart Attack",
"headTitle": "KQED Future of You | KQED Science",
"content": "\u003cp>A lawsuit filed in Arizona federal court Friday claims that faulty Theranos blood test results contributed to a patient's heart attack.\u003c/p>\n\u003cp>The \u003ca href=\"http://arstechnica.com/wp-content/uploads/2016/07/7-15-RCvsTheranos.pdf\" target=\"_blank\">suit\u003c/a>, which seeks class-action status, accuses the blood-testing company and/or its partner, Walgreens Boots Alliance, of consumer fraud, negligence, breach of contract and civil conspiracy, among other causes of action.\u003c/p>\n\u003cp>According to the suit, the plaintiff, identified only by the initials R.C., had blood drawn at a \"Theranos Wellness Center\" in a Walgreens pharmacy in Sun City West, Arizona, in February 2015. The patient had been sent there for a routine test of cholesterol and blood sugar, to \"monitor R.C.'s annual heart health.\"\u003c/p>\n\u003cp>\"Based on the normal blood test results, R.C.'s doctor recommended R.C. maintain his current medication regime and to return in one year for repeat testing,\" the suit asserts. Less than a month later, according to the suit, the plaintiff suffered a heart attack, requiring two stents.\u003c/p>\n\u003cp>The suit then suggests that the normal test results were incorrect, alleviating any concern the doctor may have had, so that the doctor failed to intervene when it might have been necessary:\u003c/p>\n\u003cblockquote>\u003cp>R.C. and his cardiologist were concerned that R.C. had even suffered an attack given that his blood panels came back clear less than a month prior. Additional blood work performed during his hospitalization strongly suggested that the near-contemporaneous Theranos blood test was inaccurate and that R.C. and his cardiologist’s reliance on the Theranos’ test results was potentially inaccurate or even harmful.\u003c/p>\u003c/blockquote>\n\u003cp>The plaintiff alleges that Theranos later voided the blood test, a nullification that would have been one of \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/05/19/theranos-corrects-tens-of-thousands-of-blood-tests/\" target=\"_blank\">tens of thousands\u003c/a> of changes to test results the company made as part of a failed attempt to assuage the ire of the Centers for Medicare & Medicaid Services. The federal regulator was threatening Theranos with unprecedented sanctions for running tests at its California lab that failed quality control assessments, among other deficiencies. CMS \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/07/08/theranos-lab-license-yanked-elizabeth-holmes-suspended/\" target=\"_blank\">imposed\u003c/a> those sanctions earlier this month.\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\n\u003cp>The voiding of his test \"strengthened [R.C's] concern that the Theranos test results were in fact inaccurate,\" the suit says.\u003c/p>\n\u003cp>In response to the lawsuit, a Theranos spokesperson sent this statement:\u003c/p>\n\u003cblockquote>\u003cp>“Patient safety and clinical quality are our top priorities. This matter involves ongoing litigation which will resolve itself in due course. In the meantime, we remain committed to the highest standards across all our labs and look forward to continuing to bring access to high-integrity, affordable health information to every person.”\u003c/p>\u003c/blockquote>\n\u003cp>Walgreens said it doesn't normally comment on litigation and would not do so in this case. In June, the pharmacy chain shuttered every one of the dozens of Theranos centers in its stores.\u003c/p>\n\u003cp>The Wall Street Journal last week \u003ca href=\"http://www.wsj.com/articles/under-fire-theranos-ceo-stifled-bad-news-1468195377\">reported\u003c/a> that at least eight consumer lawsuits seeking class-action status have been filed against Theranos.\u003c/p>\n\u003cp>But this latest filing could represent the most serious accusation of harm to come out of the Theranos debacle, which has seen the company go from a $9 billion Silicon Valley phenom to, basically, a pariah in the biomed tech world. On July 8, in a lengthy \u003ca href=\"https://www.theranos.com/news/posts/theranos-statement-on-cms-findings\" target=\"_blank\">response\u003c/a> to the CMS ruling on imposing sanctions, Theranos wrote a sort of FAQ about the case that included its answer to the question, \"Was anyone injured because of the issues found at the Newark, Calif. lab?\"\u003c/p>\n\u003cp>\"As of now, we have not been made aware -- by CMS, physicians or patients -- of any harm to patient health resulting from our tests,\" Theranos wrote.\u003c/p>\n\u003cp>Meanwhile, Dr. William H. Foege, a member of the company's scientific and medical advisory board and its board of directors, wrote \u003ca href=\"http://thehill.com/blogs/congress-blog/healthcare/288134-theranos-looking-ahead\" target=\"_blank\">in an op-ed\u003c/a> in The Hill today that Theranos is preparing \"for the publication of its data in peer-reviewed scientific journals and presentations at public meetings.\"\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>\"Theranos has a strong and exciting future ahead,\" he wrote.\u003c/p>\n\n",
"disqusIdentifier": "206905 http://ww2.kqed.org/futureofyou/?p=206905",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/07/19/lawsuit-faulty-theranos-test-results-contributed-to-heart-attack/",
"stats": {
"hasVideo": false,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 680,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 18
},
"modified": 1469031967,
"excerpt": "The suit, filed last Friday, may represent the most serious accusation of harm against the company. ",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "The suit, filed last Friday, may represent the most serious accusation of harm against the company. ",
"title": "Lawsuit: Faulty Theranos Test Results Contributed to Heart Attack | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "Lawsuit: Faulty Theranos Test Results Contributed to Heart Attack",
"datePublished": "2016-07-19T16:27:23-07:00",
"dateModified": "2016-07-20T09:26:07-07:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "lawsuit-faulty-theranos-test-results-contributed-to-heart-attack",
"status": "publish",
"path": "/futureofyou/206905/lawsuit-faulty-theranos-test-results-contributed-to-heart-attack",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>A lawsuit filed in Arizona federal court Friday claims that faulty Theranos blood test results contributed to a patient's heart attack.\u003c/p>\n\u003cp>The \u003ca href=\"http://arstechnica.com/wp-content/uploads/2016/07/7-15-RCvsTheranos.pdf\" target=\"_blank\">suit\u003c/a>, which seeks class-action status, accuses the blood-testing company and/or its partner, Walgreens Boots Alliance, of consumer fraud, negligence, breach of contract and civil conspiracy, among other causes of action.\u003c/p>\n\u003cp>According to the suit, the plaintiff, identified only by the initials R.C., had blood drawn at a \"Theranos Wellness Center\" in a Walgreens pharmacy in Sun City West, Arizona, in February 2015. The patient had been sent there for a routine test of cholesterol and blood sugar, to \"monitor R.C.'s annual heart health.\"\u003c/p>\n\u003cp>\"Based on the normal blood test results, R.C.'s doctor recommended R.C. maintain his current medication regime and to return in one year for repeat testing,\" the suit asserts. Less than a month later, according to the suit, the plaintiff suffered a heart attack, requiring two stents.\u003c/p>\n\u003cp>The suit then suggests that the normal test results were incorrect, alleviating any concern the doctor may have had, so that the doctor failed to intervene when it might have been necessary:\u003c/p>\n\u003cblockquote>\u003cp>R.C. and his cardiologist were concerned that R.C. had even suffered an attack given that his blood panels came back clear less than a month prior. Additional blood work performed during his hospitalization strongly suggested that the near-contemporaneous Theranos blood test was inaccurate and that R.C. and his cardiologist’s reliance on the Theranos’ test results was potentially inaccurate or even harmful.\u003c/p>\u003c/blockquote>\n\u003cp>The plaintiff alleges that Theranos later voided the blood test, a nullification that would have been one of \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/05/19/theranos-corrects-tens-of-thousands-of-blood-tests/\" target=\"_blank\">tens of thousands\u003c/a> of changes to test results the company made as part of a failed attempt to assuage the ire of the Centers for Medicare & Medicaid Services. The federal regulator was threatening Theranos with unprecedented sanctions for running tests at its California lab that failed quality control assessments, among other deficiencies. CMS \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/07/08/theranos-lab-license-yanked-elizabeth-holmes-suspended/\" target=\"_blank\">imposed\u003c/a> those sanctions earlier this month.\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>The voiding of his test \"strengthened [R.C's] concern that the Theranos test results were in fact inaccurate,\" the suit says.\u003c/p>\n\u003cp>In response to the lawsuit, a Theranos spokesperson sent this statement:\u003c/p>\n\u003cblockquote>\u003cp>“Patient safety and clinical quality are our top priorities. This matter involves ongoing litigation which will resolve itself in due course. In the meantime, we remain committed to the highest standards across all our labs and look forward to continuing to bring access to high-integrity, affordable health information to every person.”\u003c/p>\u003c/blockquote>\n\u003cp>Walgreens said it doesn't normally comment on litigation and would not do so in this case. In June, the pharmacy chain shuttered every one of the dozens of Theranos centers in its stores.\u003c/p>\n\u003cp>The Wall Street Journal last week \u003ca href=\"http://www.wsj.com/articles/under-fire-theranos-ceo-stifled-bad-news-1468195377\">reported\u003c/a> that at least eight consumer lawsuits seeking class-action status have been filed against Theranos.\u003c/p>\n\u003cp>But this latest filing could represent the most serious accusation of harm to come out of the Theranos debacle, which has seen the company go from a $9 billion Silicon Valley phenom to, basically, a pariah in the biomed tech world. On July 8, in a lengthy \u003ca href=\"https://www.theranos.com/news/posts/theranos-statement-on-cms-findings\" target=\"_blank\">response\u003c/a> to the CMS ruling on imposing sanctions, Theranos wrote a sort of FAQ about the case that included its answer to the question, \"Was anyone injured because of the issues found at the Newark, Calif. lab?\"\u003c/p>\n\u003cp>\"As of now, we have not been made aware -- by CMS, physicians or patients -- of any harm to patient health resulting from our tests,\" Theranos wrote.\u003c/p>\n\u003cp>Meanwhile, Dr. William H. Foege, a member of the company's scientific and medical advisory board and its board of directors, wrote \u003ca href=\"http://thehill.com/blogs/congress-blog/healthcare/288134-theranos-looking-ahead\" target=\"_blank\">in an op-ed\u003c/a> in The Hill today that Theranos is preparing \"for the publication of its data in peer-reviewed scientific journals and presentations at public meetings.\"\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>\"Theranos has a strong and exciting future ahead,\" he wrote.\u003c/p>\n\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/206905/lawsuit-faulty-theranos-test-results-contributed-to-heart-attack",
"authors": [
"80"
],
"categories": [
"futureofyou_1"
],
"tags": [
"futureofyou_617"
],
"featImg": "futureofyou_152361",
"label": "futureofyou"
},
"futureofyou_199691": {
"type": "posts",
"id": "futureofyou_199691",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "199691",
"score": null,
"sort": [
1467987796000
]
},
"parent": 0,
"labelTerm": {},
"blocks": [],
"publishDate": 1467987796,
"format": "standard",
"disqusTitle": "Theranos Lab License Yanked, Elizabeth Holmes Suspended",
"title": "Theranos Lab License Yanked, Elizabeth Holmes Suspended",
"headTitle": "KQED Future of You | KQED Science",
"content": "\u003cp>The feds finally lowered the boom on Theranos.\u003c/p>\n\u003cp>The Centers for Medicare & Medicaid Services \u003ca href=\"https://www.scribd.com/document/317817195/CMS-Notification-of-Imposition-of-Sanctions-for-Theranos\" target=\"_blank\">has revoked\u003c/a> the blood-testing company's license to operate its Newark, California lab and barred founder and CEO Elizabeth Holmes from owning, operating or directing a lab for at least two years. CMS also cancelled the Newark lab's approval to receive payments from Medicare and Medicaid. (The news first broke when Theranos released a statement last night \u003ca href=\"https://www.theranos.com/news/posts/theranos-receives-notice-of-sanctions-from-the-centers-for-medicare-medicaid-services\" target=\"_blank\">announcing\u003c/a> the sanctions.)\u003c/p>\n\u003cp>The harsh, even crippling federal sanctions resulted from an inspection of the lab last November. That inspection found numerous deficiencies in the lab's operations, including problems with a blood-clotting test that were potentially life-threatening.\u003c/p>\n\u003cp>CMS had threatened the penalties in April but gave Theranos a chance to respond. In the interim, Theranos voided or corrected \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/05/19/theranos-corrects-tens-of-thousands-of-blood-tests/\" target=\"_blank\">tens of thousands of blood tests\u003c/a>, sending notices to doctors and patients in May.\u003c/p>\n\u003cp>“We accept full responsibility for the issues at our laboratory in Newark, California, and have already worked to undertake comprehensive remedial actions,\" said Holmes in a statement. \"Those actions include shutting down and subsequently rebuilding the Newark lab from the ground up, rebuilding quality systems, adding highly experienced leadership, personnel and experts, and implementing enhanced quality and training procedures.\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\n\u003cp>\"While we are disappointed by CMS’ decision, we take these matters very seriously and are committed to fully resolving all outstanding issues with CMS and to demonstrating our dedication to the highest standards of quality and compliance.”\u003c/p>\n\u003cp>The tone of \u003ca href=\"https://www.scribd.com/document/317817195/CMS-Notification-of-Imposition-of-Sanctions-for-Theranos\">CMS' 33-page missive\u003c/a> detailing Theranos' failure to mitigate the inadequacies of its lab reads like a school administrator's report to the parents of a kid about to get kicked out of school. Despite five separate submissions containing what Theranos said were proof of corrections, CMS asserted that response was \"not credible.\" Among the problems CMS found with Theranos' filings was a lack of proof of the company's claims that patients were unaffected by tests not meeting quality control standards. CMS also dinged the firm for not finding the cause of quality control failures and for making \"contradictory statements in the submissions (that) call into question the reliability of the information contained in the submission.\"\u003c/p>\n\u003cp>CMS spokesman Aaron Albright said in an email that Theranos could \"begin negotiations\" with the agency. Any agreement would be based on the ability of Theranos to \"remove immediate jeopardy,\" he said, as well as other factors like the severity of the stipulated deficiencies and \"the overall compliance history of the laboratory.\"\u003c/p>\n\u003cp>That does not sound particularly hopeful for Theranos, but it does have two rounds of administrative appeals available to it, which could delay some of the penalties, including the revocation of the Newark lab's license. The company has 60 days before the revocation takes effect, to decide whether to appeal.\u003c/p>\n\u003cp>Theranos has ceased operations at the problematic Newark lab but still operates a testing facility in Arizona. However, that may also be in jeopardy, according to the Journal, which reported Theranos could potentially be barred from operating \u003cem>any\u003c/em> labs. If and when sanctions are imposed, the Journal said, \"Holmes could no longer own shares of any private company operating laboratories. ... . If she remains with the company, Theranos could be forced to shut down the Arizona lab, lawyers say. \"\u003c/p>\n\u003cp>Speaking to the paper, Geoffrey Baird, associate professor in the University of Washington's department of laboratory medicine, said CMS' action is especially harsh.\u003c/p>\n\u003cp>\"I can't think of anything this severe ever happening to a clinical laboratory of this size and scale,\" Baird said. \"I think the company will have to show [Holmes] the door somehow, which might not be possible under the current governance. This is so rare, and essentially unprecedented in a company of this size, that it is hard to know exactly how they will proceed. Personally, I believe she is obligated to step down immediately.”\u003c/p>\n\u003cp>Dr. Norman Paradis, a professor of medicine at Dartmouth, who has consulted for both diagnostic startups and biomed investors, agreed that the magnitude of the penalty could be one-of-a-kind.\u003c/p>\n\u003cp>\"I've never heard of a penalty this severe,\" he said in an email. \"I'm surprised that they could not have avoided this in light of the new involvement of experienced people and renowned attorneys.\"\u003c/p>\n\u003cp>In April, Theranos hired a number of experts for its medical advisory board. High-powered lawyer David Boies represents the company and \u003ca href=\"http://www.nytimes.com/2016/02/03/business/dealbook/david-boiess-dual-roles-at-theranos-set-up-conflict.html\" target=\"_blank\">also serves\u003c/a> on its board.\u003c/p>\n\u003cp>\u003cstrong>Rapid Fall\u003c/strong>\u003c/p>\n\u003cp>It's hard to believe that, at this time last year, Theranos was riding high, having \u003ca href=\"http://fortune.com/2015/10/28/theranos-is-seeking-to-raise-200-million-in-new-funding/\">raised as much as $750 million\u003c/a>, with its latest round of funding valuing the company at around $9 billion. Holmes herself was estimated to be worth $4.5 billion, putting her at the very top of Forbes' \u003ca href=\"http://www.forbes.com/self-made-women/#3ad19b014177\">list\u003c/a> of \"richest self-made women.\" (Besting even Oprah.)\u003c/p>\n\u003cp>Holmes and the company she founded in 2003 had risen to prominence on its claim of having devised groundbreaking technology that required only a finger-prick's worth of blood to test for an array of diseases and conditions, all at an extremely low cost. Holmes frequently used the language of patient self-empowerment to portray her company as a disruptor of the highly profitable diagnostic-testing industry.\u003c/p>\n\u003cp>But in late October, The Wall Street Journal published a pair of \u003ca href=\"http://www.wsj.com/articles/theranos-has-struggled-with-blood-tests-1444881901\" target=\"_blank\">investigative articles\u003c/a> citing anonymous former employees who claimed Theranos' technology, which the company dubbed \"Edison,\" did not work as advertised, and that Theranos may have cheated on required proficiency testing. That was followed in January by the partial release of the CMS report, which stated the situation at the Newark lab could cause \"serious injury or harm, or death, to individuals served by the laboratory or to the health and safety of the general public.”\u003c/p>\n\u003cp>That assessment seemed to buttress the opinion of some scientists who had complained about Theranos' failure to publish evidence that its technology actually worked, which is the \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/05/02/theranos-debacle-shows-differences-between-silicon-valley-and-biomed/\" target=\"_blank\">usual route\u003c/a> to acceptance by the scientific community. And the bad news just kept coming:\u003c/p>\n\u003cul>\n\u003cli>Negative reaction caused Hillary Clinton to \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/03/16/elizabeth-holmes-fundraiser-for-hillary-clinton-at-theranos-raises-eyebrows/\" target=\"_blank\">move a scheduled fundraiser\u003c/a> hosted by Holmes at Theranos headquarters.\u003c/li>\n\u003cli>A published \u003ca href=\"http://www.forbes.com/sites/matthewherper/2016/03/28/theranos-tests-have-flaws-but-may-be-fixable-independent-researchers-say/#4a83e2a9560b\" target=\"_blank\">study said\u003c/a> some of Theranos' test results were significantly off.\u003c/li>\n\u003cli>Federal prosecutors and the SEC launched \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/04/18/elizabeth-holmes-says-theranos-will-absolutely-survive-video/\" target=\"_blank\">investigations\u003c/a> into the company.\u003c/li>\n\u003cli>A flurry of consumer \u003ca href=\"http://arstechnica.com/science/2016/05/walgreens-failed-to-vet-theranos-tests-that-patients-are-now-suing-over/\" target=\"_blank\">lawsuits\u003c/a> were filed.\u003c/li>\n\u003cli>Spokeswoman Brooke Buchanan, who had helmed press relations for John McCain's 2008 presidential campaign, \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/06/24/report-theranos-spokesperson-brooke-buchanan-leaving-company/\" target=\"_blank\">left the firm\u003c/a>.\u003c/li>\n\u003cli>Walgreens \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/06/12/walgreens-shutting-down-theranos-centers-immediately-as-it-ends-partnership/\" target=\"_blank\">shut down\u003c/a> all Theranos centers within its stores.\u003c/li>\n\u003cli>Forbes said Holmes' net worth had \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/06/01/theranos-from-all-angles/\" target=\"_blank\">dropped to zero\u003c/a>.\u003c/li>\n\u003c/ul>\n\u003cp>Coming up next: a scheduled appearance by Holmes at the American Association for Clinical Chemistry's annual meeting, Aug. 1 in Philadelphia. There, Holmes is slated to present \"Reproducibility and correlation data for various tests comparing Theranos’ capillary collection and storage device with traditional venipuncture methods.\" In attendance will be hundreds of laboratory medicine experts and academics, well-qualified to endorse or debunk whatever Holmes presents. From Kimberly Weiseul of \u003ca href=\"http://www.inc.com/kimberly-weisul/theranos-promises-to-share-research-in-august.html\" target=\"_blank\">Inc.\u003c/a> last month:\u003c/p>\n\u003cblockquote>\u003cp>[Holmes] may actually face a somewhat sympathetic audience, says Dr. Patricia Jones, the president of the AACC and the clinical director of chemistry for the Children's Medical Center in Dallas.\u003c/p>\n\u003cp>\"I've talked to all sorts of members of our organization since we announced that she's speaking,\" says Jones. \"There's some real excitement that we're going to get to see what she's doing, and there are some who say it's all smoke and mirrors, and she's not going to show us anything.\"\u003c/p>\n\u003cp>While \"everyone is concerned,\" Jones also says, \"I think for the most part people are willing to give her the benefit of the doubt, even at this point.\"\u003c/p>\u003c/blockquote>\n\u003cp>Well that was last month's \"this point.\" Next month's \"this point\" may be a whole other story.\u003c/p>\n\u003cp>[ad floatright]\u003c/p>\n\u003cp>[scribd id=317817195 key=key-189WxKQFu0HGaDjm0Ze2 mode=scroll]\u003c/p>\n\n",
"disqusIdentifier": "199691 http://ww2.kqed.org/futureofyou/?p=199691",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/07/08/theranos-lab-license-yanked-elizabeth-holmes-suspended/",
"stats": {
"hasVideo": false,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 1343,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 28
},
"modified": 1468254424,
"excerpt": "The Centers for Medicare & Medicaid Services follows through on the sanctions it threatened in April.",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "The Centers for Medicare & Medicaid Services follows through on the sanctions it threatened in April.",
"title": "Theranos Lab License Yanked, Elizabeth Holmes Suspended | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "Theranos Lab License Yanked, Elizabeth Holmes Suspended",
"datePublished": "2016-07-08T07:23:16-07:00",
"dateModified": "2016-07-11T09:27:04-07:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "theranos-lab-license-yanked-elizabeth-holmes-suspended",
"status": "publish",
"source": "Future of You",
"path": "/futureofyou/199691/theranos-lab-license-yanked-elizabeth-holmes-suspended",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>The feds finally lowered the boom on Theranos.\u003c/p>\n\u003cp>The Centers for Medicare & Medicaid Services \u003ca href=\"https://www.scribd.com/document/317817195/CMS-Notification-of-Imposition-of-Sanctions-for-Theranos\" target=\"_blank\">has revoked\u003c/a> the blood-testing company's license to operate its Newark, California lab and barred founder and CEO Elizabeth Holmes from owning, operating or directing a lab for at least two years. CMS also cancelled the Newark lab's approval to receive payments from Medicare and Medicaid. (The news first broke when Theranos released a statement last night \u003ca href=\"https://www.theranos.com/news/posts/theranos-receives-notice-of-sanctions-from-the-centers-for-medicare-medicaid-services\" target=\"_blank\">announcing\u003c/a> the sanctions.)\u003c/p>\n\u003cp>The harsh, even crippling federal sanctions resulted from an inspection of the lab last November. That inspection found numerous deficiencies in the lab's operations, including problems with a blood-clotting test that were potentially life-threatening.\u003c/p>\n\u003cp>CMS had threatened the penalties in April but gave Theranos a chance to respond. In the interim, Theranos voided or corrected \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/05/19/theranos-corrects-tens-of-thousands-of-blood-tests/\" target=\"_blank\">tens of thousands of blood tests\u003c/a>, sending notices to doctors and patients in May.\u003c/p>\n\u003cp>“We accept full responsibility for the issues at our laboratory in Newark, California, and have already worked to undertake comprehensive remedial actions,\" said Holmes in a statement. \"Those actions include shutting down and subsequently rebuilding the Newark lab from the ground up, rebuilding quality systems, adding highly experienced leadership, personnel and experts, and implementing enhanced quality and training procedures.\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>\"While we are disappointed by CMS’ decision, we take these matters very seriously and are committed to fully resolving all outstanding issues with CMS and to demonstrating our dedication to the highest standards of quality and compliance.”\u003c/p>\n\u003cp>The tone of \u003ca href=\"https://www.scribd.com/document/317817195/CMS-Notification-of-Imposition-of-Sanctions-for-Theranos\">CMS' 33-page missive\u003c/a> detailing Theranos' failure to mitigate the inadequacies of its lab reads like a school administrator's report to the parents of a kid about to get kicked out of school. Despite five separate submissions containing what Theranos said were proof of corrections, CMS asserted that response was \"not credible.\" Among the problems CMS found with Theranos' filings was a lack of proof of the company's claims that patients were unaffected by tests not meeting quality control standards. CMS also dinged the firm for not finding the cause of quality control failures and for making \"contradictory statements in the submissions (that) call into question the reliability of the information contained in the submission.\"\u003c/p>\n\u003cp>CMS spokesman Aaron Albright said in an email that Theranos could \"begin negotiations\" with the agency. Any agreement would be based on the ability of Theranos to \"remove immediate jeopardy,\" he said, as well as other factors like the severity of the stipulated deficiencies and \"the overall compliance history of the laboratory.\"\u003c/p>\n\u003cp>That does not sound particularly hopeful for Theranos, but it does have two rounds of administrative appeals available to it, which could delay some of the penalties, including the revocation of the Newark lab's license. The company has 60 days before the revocation takes effect, to decide whether to appeal.\u003c/p>\n\u003cp>Theranos has ceased operations at the problematic Newark lab but still operates a testing facility in Arizona. However, that may also be in jeopardy, according to the Journal, which reported Theranos could potentially be barred from operating \u003cem>any\u003c/em> labs. If and when sanctions are imposed, the Journal said, \"Holmes could no longer own shares of any private company operating laboratories. ... . If she remains with the company, Theranos could be forced to shut down the Arizona lab, lawyers say. \"\u003c/p>\n\u003cp>Speaking to the paper, Geoffrey Baird, associate professor in the University of Washington's department of laboratory medicine, said CMS' action is especially harsh.\u003c/p>\n\u003cp>\"I can't think of anything this severe ever happening to a clinical laboratory of this size and scale,\" Baird said. \"I think the company will have to show [Holmes] the door somehow, which might not be possible under the current governance. This is so rare, and essentially unprecedented in a company of this size, that it is hard to know exactly how they will proceed. Personally, I believe she is obligated to step down immediately.”\u003c/p>\n\u003cp>Dr. Norman Paradis, a professor of medicine at Dartmouth, who has consulted for both diagnostic startups and biomed investors, agreed that the magnitude of the penalty could be one-of-a-kind.\u003c/p>\n\u003cp>\"I've never heard of a penalty this severe,\" he said in an email. \"I'm surprised that they could not have avoided this in light of the new involvement of experienced people and renowned attorneys.\"\u003c/p>\n\u003cp>In April, Theranos hired a number of experts for its medical advisory board. High-powered lawyer David Boies represents the company and \u003ca href=\"http://www.nytimes.com/2016/02/03/business/dealbook/david-boiess-dual-roles-at-theranos-set-up-conflict.html\" target=\"_blank\">also serves\u003c/a> on its board.\u003c/p>\n\u003cp>\u003cstrong>Rapid Fall\u003c/strong>\u003c/p>\n\u003cp>It's hard to believe that, at this time last year, Theranos was riding high, having \u003ca href=\"http://fortune.com/2015/10/28/theranos-is-seeking-to-raise-200-million-in-new-funding/\">raised as much as $750 million\u003c/a>, with its latest round of funding valuing the company at around $9 billion. Holmes herself was estimated to be worth $4.5 billion, putting her at the very top of Forbes' \u003ca href=\"http://www.forbes.com/self-made-women/#3ad19b014177\">list\u003c/a> of \"richest self-made women.\" (Besting even Oprah.)\u003c/p>\n\u003cp>Holmes and the company she founded in 2003 had risen to prominence on its claim of having devised groundbreaking technology that required only a finger-prick's worth of blood to test for an array of diseases and conditions, all at an extremely low cost. Holmes frequently used the language of patient self-empowerment to portray her company as a disruptor of the highly profitable diagnostic-testing industry.\u003c/p>\n\u003cp>But in late October, The Wall Street Journal published a pair of \u003ca href=\"http://www.wsj.com/articles/theranos-has-struggled-with-blood-tests-1444881901\" target=\"_blank\">investigative articles\u003c/a> citing anonymous former employees who claimed Theranos' technology, which the company dubbed \"Edison,\" did not work as advertised, and that Theranos may have cheated on required proficiency testing. That was followed in January by the partial release of the CMS report, which stated the situation at the Newark lab could cause \"serious injury or harm, or death, to individuals served by the laboratory or to the health and safety of the general public.”\u003c/p>\n\u003cp>That assessment seemed to buttress the opinion of some scientists who had complained about Theranos' failure to publish evidence that its technology actually worked, which is the \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/05/02/theranos-debacle-shows-differences-between-silicon-valley-and-biomed/\" target=\"_blank\">usual route\u003c/a> to acceptance by the scientific community. And the bad news just kept coming:\u003c/p>\n\u003cul>\n\u003cli>Negative reaction caused Hillary Clinton to \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/03/16/elizabeth-holmes-fundraiser-for-hillary-clinton-at-theranos-raises-eyebrows/\" target=\"_blank\">move a scheduled fundraiser\u003c/a> hosted by Holmes at Theranos headquarters.\u003c/li>\n\u003cli>A published \u003ca href=\"http://www.forbes.com/sites/matthewherper/2016/03/28/theranos-tests-have-flaws-but-may-be-fixable-independent-researchers-say/#4a83e2a9560b\" target=\"_blank\">study said\u003c/a> some of Theranos' test results were significantly off.\u003c/li>\n\u003cli>Federal prosecutors and the SEC launched \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/04/18/elizabeth-holmes-says-theranos-will-absolutely-survive-video/\" target=\"_blank\">investigations\u003c/a> into the company.\u003c/li>\n\u003cli>A flurry of consumer \u003ca href=\"http://arstechnica.com/science/2016/05/walgreens-failed-to-vet-theranos-tests-that-patients-are-now-suing-over/\" target=\"_blank\">lawsuits\u003c/a> were filed.\u003c/li>\n\u003cli>Spokeswoman Brooke Buchanan, who had helmed press relations for John McCain's 2008 presidential campaign, \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/06/24/report-theranos-spokesperson-brooke-buchanan-leaving-company/\" target=\"_blank\">left the firm\u003c/a>.\u003c/li>\n\u003cli>Walgreens \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/06/12/walgreens-shutting-down-theranos-centers-immediately-as-it-ends-partnership/\" target=\"_blank\">shut down\u003c/a> all Theranos centers within its stores.\u003c/li>\n\u003cli>Forbes said Holmes' net worth had \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/06/01/theranos-from-all-angles/\" target=\"_blank\">dropped to zero\u003c/a>.\u003c/li>\n\u003c/ul>\n\u003cp>Coming up next: a scheduled appearance by Holmes at the American Association for Clinical Chemistry's annual meeting, Aug. 1 in Philadelphia. There, Holmes is slated to present \"Reproducibility and correlation data for various tests comparing Theranos’ capillary collection and storage device with traditional venipuncture methods.\" In attendance will be hundreds of laboratory medicine experts and academics, well-qualified to endorse or debunk whatever Holmes presents. From Kimberly Weiseul of \u003ca href=\"http://www.inc.com/kimberly-weisul/theranos-promises-to-share-research-in-august.html\" target=\"_blank\">Inc.\u003c/a> last month:\u003c/p>\n\u003cblockquote>\u003cp>[Holmes] may actually face a somewhat sympathetic audience, says Dr. Patricia Jones, the president of the AACC and the clinical director of chemistry for the Children's Medical Center in Dallas.\u003c/p>\n\u003cp>\"I've talked to all sorts of members of our organization since we announced that she's speaking,\" says Jones. \"There's some real excitement that we're going to get to see what she's doing, and there are some who say it's all smoke and mirrors, and she's not going to show us anything.\"\u003c/p>\n\u003cp>While \"everyone is concerned,\" Jones also says, \"I think for the most part people are willing to give her the benefit of the doubt, even at this point.\"\u003c/p>\u003c/blockquote>\n\u003cp>Well that was last month's \"this point.\" Next month's \"this point\" may be a whole other story.\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "floatright"
},
"numeric": [
"floatright"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>\u003c/p>\u003cp>\u003ciframe\n class=\"scribd_iframe_embed\"\n src=\"//www.scribd.com/embeds/317817195/content?start_page=1&view_mode=&access_key=key-189WxKQFu0HGaDjm0Ze2\"\n title=\"http://www.scribd.com/doc/317817195\"\n data-auto-height=\"true\" scrolling=\"no\" id=\"scribd_317817195\"\n width=\"100%\" height=\"500\" frameborder=\"0\">\u003c/iframe>\n \u003ca class=\"utils-parseShortcode-shortcodes-__scribdShortcode__scribd_footer\"\n href=\"http://www.scribd.com/doc/317817195\"\n target=\"_blank\" rel=\"noopener noreferrer\">View this document on Scribd\u003c/a>\u003c/p>\u003cp>\u003c/p>\n\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/199691/theranos-lab-license-yanked-elizabeth-holmes-suspended",
"authors": [
"80"
],
"categories": [
"futureofyou_452",
"futureofyou_1",
"futureofyou_73"
],
"tags": [
"futureofyou_971",
"futureofyou_814",
"futureofyou_80",
"futureofyou_617"
],
"featImg": "futureofyou_145322",
"label": "source_futureofyou_199691"
},
"futureofyou_190748": {
"type": "posts",
"id": "futureofyou_190748",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "190748",
"score": null,
"sort": [
1466802902000
]
},
"parent": 0,
"labelTerm": {},
"blocks": [],
"publishDate": 1466802902,
"format": "standard",
"disqusTitle": "Theranos Spokesperson Brooke Buchanan Leaving Company",
"title": "Theranos Spokesperson Brooke Buchanan Leaving Company",
"headTitle": "KQED Future of You | KQED Science",
"content": "\u003cp>San Francisco Chronicle tech columnist Thomas Lee says Theranos's top spokesperson, Brooke Buchanan, is \u003ca href=\"http://www.sfchronicle.com/business/article/Theranos-spokeswoman-Brooke-Buchanan-to-exit-8323546.php\" target=\"_blank\">leaving the company\u003c/a>.\u003c/p>\n\u003cp>Buchanan did not return a call and text to her cellphone, but the Chronicle says she confirmed her departure, without offering further comment.\u003c/p>\n\u003cp>Lee writes ...\u003c/p>\n\u003cblockquote>\u003cp>(I)t was not clear whether [Theranos founder Elizabeth] Holmes was listening to [Buchanan's] advice. For example, Theranos \u003ca href=\"http://www.sfchronicle.com/business/article/Theranos-CEO-Elizabeth-Holmes-takes-big-gamble-at-8003887.php\">recently agreed to present the company’s blood-testing technology at a major medical conference Aug. 1\u003c/a>. Holmes also plans to hold a major press conference after the event with 200 members of the national media, a \u003ca href=\"http://www.sfchronicle.com/business/article/Theranos-CEO-Elizabeth-Holmes-takes-big-gamble-at-8003887.php\">decision that public-relations experts\u003c/a> I spoke to earlier this \u003ca href=\"https://ly.linkedin.com/in/brooke-buchanan-56218021?trk=pub-pbmap\">month\u003c/a> strongly questioned. Why would Holmes agree to speak to reporters when Theranos is facing a criminal investigation from federal prosecutors and inquiries from regulatory agencies?\u003c/p>\u003c/blockquote>\n\u003cp>Buchanan, whose title is vice president of communications, joined Theranos last November, not long after The Wall Street Journal had published two devastating \u003ca href=\"http://www.wsj.com/articles/theranos-has-struggled-with-blood-tests-1444881901\" target=\"_blank\">investigative reports\u003c/a> about the company. It was all downhill from there. One of Buchananan's skills listed on \u003ca href=\"https://ly.linkedin.com/in/brooke-buchanan-56218021?trk=pub-pbmap\">Linkedin\u003c/a> is \"crisis communications,\" something that must have come in handy as she was forced to \u003ca href=\"https://www.theranos.com/news/press-releases\">respond\u003c/a> to a drumbeat of bad news about the company, including a failed government inspection, the resulting threat of crippling sanctions, and the severing of its partnership with Walgreens, which unceremoniously announced it would immediately stop offering Theranos services in its stores. We could go into more detail, but suffice it to say the whole saga is dramatic enough to inspire a \u003ca href=\"http://www.vanityfair.com/hollywood/2016/06/jennifer-lawrence-theranos-elizabeth-holmes\" target=\"_blank\">coming movie\u003c/a> with Jennifer Lawrence.\u003c/p>\n\u003cp>Buchanan came to Theranos after \u003ca href=\"https://www.linkedin.com/in/brooke-buchanan-56218021\" target=\"_blank\">stints\u003c/a> at Williams-Sonoma and Walmart. But she is best known as the press secretary for GOP presidential candidate John McCain during his 2008 election campaign against Barack Obama. (\u003ca href=\"https://www.youtube.com/watch?v=J-z6Of25r8k\" target=\"_blank\">Here she i\u003c/a>s in 2007, saying she \"will quit smoking when we win the nomination.\")\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>Buchananan's departure would be yet another blow for Theranos, and will open up another job at the company. Among the\u003ca href=\"https://www.theranos.com/careers/corporate\" target=\"_blank\"> positions\u003c/a> listed on the Theranos website: both an executive assistant and a personal assistant for founder and CEO Elizabeth Holmes.\u003c/p>\n\n",
"disqusIdentifier": "190748 http://ww2.kqed.org/futureofyou/?p=190748",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/06/24/report-theranos-spokesperson-brooke-buchanan-leaving-company/",
"stats": {
"hasVideo": false,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 366,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 9
},
"modified": 1466870533,
"excerpt": "The San Francisco Chronicle says the former press aide to John McCain is leaving the troubled company.",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "The San Francisco Chronicle says the former press aide to John McCain is leaving the troubled company.",
"title": "Theranos Spokesperson Brooke Buchanan Leaving Company | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "Theranos Spokesperson Brooke Buchanan Leaving Company",
"datePublished": "2016-06-24T14:15:02-07:00",
"dateModified": "2016-06-25T09:02:13-07:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "report-theranos-spokesperson-brooke-buchanan-leaving-company",
"status": "publish",
"source": "Future of You",
"path": "/futureofyou/190748/report-theranos-spokesperson-brooke-buchanan-leaving-company",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>San Francisco Chronicle tech columnist Thomas Lee says Theranos's top spokesperson, Brooke Buchanan, is \u003ca href=\"http://www.sfchronicle.com/business/article/Theranos-spokeswoman-Brooke-Buchanan-to-exit-8323546.php\" target=\"_blank\">leaving the company\u003c/a>.\u003c/p>\n\u003cp>Buchanan did not return a call and text to her cellphone, but the Chronicle says she confirmed her departure, without offering further comment.\u003c/p>\n\u003cp>Lee writes ...\u003c/p>\n\u003cblockquote>\u003cp>(I)t was not clear whether [Theranos founder Elizabeth] Holmes was listening to [Buchanan's] advice. For example, Theranos \u003ca href=\"http://www.sfchronicle.com/business/article/Theranos-CEO-Elizabeth-Holmes-takes-big-gamble-at-8003887.php\">recently agreed to present the company’s blood-testing technology at a major medical conference Aug. 1\u003c/a>. Holmes also plans to hold a major press conference after the event with 200 members of the national media, a \u003ca href=\"http://www.sfchronicle.com/business/article/Theranos-CEO-Elizabeth-Holmes-takes-big-gamble-at-8003887.php\">decision that public-relations experts\u003c/a> I spoke to earlier this \u003ca href=\"https://ly.linkedin.com/in/brooke-buchanan-56218021?trk=pub-pbmap\">month\u003c/a> strongly questioned. Why would Holmes agree to speak to reporters when Theranos is facing a criminal investigation from federal prosecutors and inquiries from regulatory agencies?\u003c/p>\u003c/blockquote>\n\u003cp>Buchanan, whose title is vice president of communications, joined Theranos last November, not long after The Wall Street Journal had published two devastating \u003ca href=\"http://www.wsj.com/articles/theranos-has-struggled-with-blood-tests-1444881901\" target=\"_blank\">investigative reports\u003c/a> about the company. It was all downhill from there. One of Buchananan's skills listed on \u003ca href=\"https://ly.linkedin.com/in/brooke-buchanan-56218021?trk=pub-pbmap\">Linkedin\u003c/a> is \"crisis communications,\" something that must have come in handy as she was forced to \u003ca href=\"https://www.theranos.com/news/press-releases\">respond\u003c/a> to a drumbeat of bad news about the company, including a failed government inspection, the resulting threat of crippling sanctions, and the severing of its partnership with Walgreens, which unceremoniously announced it would immediately stop offering Theranos services in its stores. We could go into more detail, but suffice it to say the whole saga is dramatic enough to inspire a \u003ca href=\"http://www.vanityfair.com/hollywood/2016/06/jennifer-lawrence-theranos-elizabeth-holmes\" target=\"_blank\">coming movie\u003c/a> with Jennifer Lawrence.\u003c/p>\n\u003cp>Buchanan came to Theranos after \u003ca href=\"https://www.linkedin.com/in/brooke-buchanan-56218021\" target=\"_blank\">stints\u003c/a> at Williams-Sonoma and Walmart. But she is best known as the press secretary for GOP presidential candidate John McCain during his 2008 election campaign against Barack Obama. (\u003ca href=\"https://www.youtube.com/watch?v=J-z6Of25r8k\" target=\"_blank\">Here she i\u003c/a>s in 2007, saying she \"will quit smoking when we win the nomination.\")\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>Buchananan's departure would be yet another blow for Theranos, and will open up another job at the company. Among the\u003ca href=\"https://www.theranos.com/careers/corporate\" target=\"_blank\"> positions\u003c/a> listed on the Theranos website: both an executive assistant and a personal assistant for founder and CEO Elizabeth Holmes.\u003c/p>\n\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/190748/report-theranos-spokesperson-brooke-buchanan-leaving-company",
"authors": [
"80"
],
"categories": [
"futureofyou_1",
"futureofyou_73"
],
"tags": [
"futureofyou_964",
"futureofyou_814",
"futureofyou_617"
],
"featImg": "futureofyou_190769",
"label": "source_futureofyou_190748"
},
"futureofyou_182744": {
"type": "posts",
"id": "futureofyou_182744",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "182744",
"score": null,
"sort": [
1465792023000
]
},
"parent": 0,
"labelTerm": {
"site": "futureofyou"
},
"blocks": [],
"publishDate": 1465792023,
"format": "standard",
"disqusTitle": "Walgreens Shutting Down Theranos Centers 'Immediately'",
"title": "Walgreens Shutting Down Theranos Centers 'Immediately'",
"headTitle": "KQED Future of You | KQED Science",
"content": "\u003cp>Walgreens has had enough of Theranos, the beleaguered blood-testing company.\u003c/p>\n\u003cp>In a \u003ca href=\"http://news.walgreens.com/press-releases/general-news/walgreens-terminates-relationship-with-theranos-will-be-closing-operations-at-all-40-theranos-wellness-centers-in-arizona.htm\" target=\"_blank\">press release\u003c/a> Sunday, the drugstore chain announced \"it will be terminating its relationship and closing operations at all 40 Theranos Wellness Centers at its stores in Arizona, effective immediately.\"\u003c/p>\n\u003cp>“In light of the voiding of a number of test results,\" said Walgreens Senior Vice President Brad Fluegel, in the statement, \"and as the Centers for Medicare and Medicaid Services (CMS) has rejected Theranos’ plan of correction and considers sanctions, we have carefully considered our relationship with Theranos and believe it is in our customers’ best interests to terminate our partnership.”\u003c/p>\n\u003cp>The announcement ends a relationship that began in 2013, with the \u003ca href=\"http://www.businesswire.com/news/home/20131113005513/en/Theranos-Walgreens-Expand-Diagnostic-Lab-Testing-Phoenix\">opening\u003c/a> of Theranos centers at Walgreens in Phoenix and Scottsdale, putting a previously furtive Theranos on the map.\u003c/p>\n\u003cp>Brooke Buchanan, Theranos' vice president of communications (one can think of cushier jobs at this point), issued \u003ca href=\"https://www.theranos.com/news/posts/statement-from-theranos-7\">this statement\u003c/a> in response to Walgreens' announcement:\u003c/p>\n\u003cblockquote>\u003cp>Quality and safety are our top priorities and we are working closely with government officials to ensure that we not only comply with all federal regulations but exceed them. We are disappointed that Walgreens has chosen to terminate our relationship and remain fully committed to our mission to provide patients access to affordable health information and look forward to continuing to serve customers in Arizona and California through our independent retail locations.\u003c/p>\u003c/blockquote>\n\u003cp>The \u003ca href=\"http://www.wsj.com/articles/walgreen-terminates-partnership-with-blood-testing-firm-theranos-1465777062\">Wall Street Journal\u003c/a> is reporting that Walgreens executives decided to sever the relationship with Theranos in January, after the Centers for Medicare & Medicaid Services, which regulates the nation's blood labs, found serious, even life-threatening, deficiencies at Theranos' facility in Newark, Calif. The federal agency later rejected Theranos' submission of proof that it had corrected those problems, threatening to pull the lab's license and ban founder and CEO Elizabeth Holmes from operating a lab for two years.\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\n\u003cp>Theranos has since submitted a further plan of correction and is awaiting a final decision from CMS. Theranos also voided or corrected tens of thousands of blood tests, sending notices to doctors and patients in May.\u003c/p>\n\u003cp>The Journal, citing \"people familiar with the matter,\" said Walgreens waited until now to terminate the Theranos deal out of fear it would be sued.\u003c/p>\n\u003cp>Theranos helped \u003ca href=\"http://www.usatoday.com/story/tech/2015/07/02/new-arizona-law-and-fda-approval-gives-theranos-something-to-celebrate/29634373/\">push through an Arizona law\u003c/a> in 2015 that gave consumers the right to order their own blood tests.\u003c/p>\n\u003cp>Theranos still lists five locations where consumers can get their blood tested, four in Arizona and one in California. The Walgreens web page that used to list the locations of Theranos centers now redirects to the drugstore chain's home page.\u003c/p>\n\u003cp>So what effect will this have on Theranos' business? From \u003ca href=\"http://www.nytimes.com/2016/06/13/business/walgreens-cuts-ties-to-blood-testing-company-theranos.html\">The New York Times\u003c/a>:\u003c/p>\n\u003cblockquote>\u003cp>While Theranos might struggle along with its own retail units, clearly most of its customers came from the testing centers in Walgreens. Having easily accessible locations in corner drugstores was part of Theranos’s grand plan to upend the laboratory testing business, and it had at one time said it eventually envisioned being in Walgreens drugstores nationwide.\u003c/p>\u003c/blockquote>\n\u003cp>And from \u003ca href=\"http://www.wsj.com/articles/walgreen-terminates-partnership-with-blood-testing-firm-theranos-1465777062\">The Wall Street Journal\u003c/a>:\u003c/p>\n\u003cblockquote>\u003cp>Without Walgreens, Theranos would no longer be competing with major labs. To regain its access to consumers, it would have to forge a new retail partnership, offer its blood-testing services directly to more doctors’ offices or open its own blood-draw sites, among other options. It already has moved to open a blood-testing center in Arizona. Recently, the company has been exploring a tie-up with another pharmacy or supermarket, according to a person familiar with the matter.\u003c/p>\u003c/blockquote>\n\u003cp>\u003c/p>\n\u003cp>And don't forget, \u003ca href=\"http://www.beckershospitalreview.com/legal-regulatory-issues/third-theranos-lawsuit-brings-walgreens-into-the-mix.html\" target=\"_blank\">several lawsuits\u003c/a> are pending, as well.\u003c/p>\n\n",
"disqusIdentifier": "182744 http://ww2.kqed.org/futureofyou/?p=182744",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/06/12/walgreens-shutting-down-theranos-centers-immediately-as-it-ends-partnership/",
"stats": {
"hasVideo": false,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 625,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 18
},
"modified": 1465843316,
"excerpt": "The drugstore chain says it's closing all 40 Theranos Wellness Centers in its Arizona stores.",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "The drugstore chain says it's closing all 40 Theranos Wellness Centers in its Arizona stores.",
"title": "Walgreens Shutting Down Theranos Centers 'Immediately' | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "Walgreens Shutting Down Theranos Centers 'Immediately'",
"datePublished": "2016-06-12T21:27:03-07:00",
"dateModified": "2016-06-13T11:41:56-07:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "walgreens-shutting-down-theranos-centers-immediately-as-it-ends-partnership",
"status": "publish",
"path": "/futureofyou/182744/walgreens-shutting-down-theranos-centers-immediately-as-it-ends-partnership",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>Walgreens has had enough of Theranos, the beleaguered blood-testing company.\u003c/p>\n\u003cp>In a \u003ca href=\"http://news.walgreens.com/press-releases/general-news/walgreens-terminates-relationship-with-theranos-will-be-closing-operations-at-all-40-theranos-wellness-centers-in-arizona.htm\" target=\"_blank\">press release\u003c/a> Sunday, the drugstore chain announced \"it will be terminating its relationship and closing operations at all 40 Theranos Wellness Centers at its stores in Arizona, effective immediately.\"\u003c/p>\n\u003cp>“In light of the voiding of a number of test results,\" said Walgreens Senior Vice President Brad Fluegel, in the statement, \"and as the Centers for Medicare and Medicaid Services (CMS) has rejected Theranos’ plan of correction and considers sanctions, we have carefully considered our relationship with Theranos and believe it is in our customers’ best interests to terminate our partnership.”\u003c/p>\n\u003cp>The announcement ends a relationship that began in 2013, with the \u003ca href=\"http://www.businesswire.com/news/home/20131113005513/en/Theranos-Walgreens-Expand-Diagnostic-Lab-Testing-Phoenix\">opening\u003c/a> of Theranos centers at Walgreens in Phoenix and Scottsdale, putting a previously furtive Theranos on the map.\u003c/p>\n\u003cp>Brooke Buchanan, Theranos' vice president of communications (one can think of cushier jobs at this point), issued \u003ca href=\"https://www.theranos.com/news/posts/statement-from-theranos-7\">this statement\u003c/a> in response to Walgreens' announcement:\u003c/p>\n\u003cblockquote>\u003cp>Quality and safety are our top priorities and we are working closely with government officials to ensure that we not only comply with all federal regulations but exceed them. We are disappointed that Walgreens has chosen to terminate our relationship and remain fully committed to our mission to provide patients access to affordable health information and look forward to continuing to serve customers in Arizona and California through our independent retail locations.\u003c/p>\u003c/blockquote>\n\u003cp>The \u003ca href=\"http://www.wsj.com/articles/walgreen-terminates-partnership-with-blood-testing-firm-theranos-1465777062\">Wall Street Journal\u003c/a> is reporting that Walgreens executives decided to sever the relationship with Theranos in January, after the Centers for Medicare & Medicaid Services, which regulates the nation's blood labs, found serious, even life-threatening, deficiencies at Theranos' facility in Newark, Calif. The federal agency later rejected Theranos' submission of proof that it had corrected those problems, threatening to pull the lab's license and ban founder and CEO Elizabeth Holmes from operating a lab for two years.\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>Theranos has since submitted a further plan of correction and is awaiting a final decision from CMS. Theranos also voided or corrected tens of thousands of blood tests, sending notices to doctors and patients in May.\u003c/p>\n\u003cp>The Journal, citing \"people familiar with the matter,\" said Walgreens waited until now to terminate the Theranos deal out of fear it would be sued.\u003c/p>\n\u003cp>Theranos helped \u003ca href=\"http://www.usatoday.com/story/tech/2015/07/02/new-arizona-law-and-fda-approval-gives-theranos-something-to-celebrate/29634373/\">push through an Arizona law\u003c/a> in 2015 that gave consumers the right to order their own blood tests.\u003c/p>\n\u003cp>Theranos still lists five locations where consumers can get their blood tested, four in Arizona and one in California. The Walgreens web page that used to list the locations of Theranos centers now redirects to the drugstore chain's home page.\u003c/p>\n\u003cp>So what effect will this have on Theranos' business? From \u003ca href=\"http://www.nytimes.com/2016/06/13/business/walgreens-cuts-ties-to-blood-testing-company-theranos.html\">The New York Times\u003c/a>:\u003c/p>\n\u003cblockquote>\u003cp>While Theranos might struggle along with its own retail units, clearly most of its customers came from the testing centers in Walgreens. Having easily accessible locations in corner drugstores was part of Theranos’s grand plan to upend the laboratory testing business, and it had at one time said it eventually envisioned being in Walgreens drugstores nationwide.\u003c/p>\u003c/blockquote>\n\u003cp>And from \u003ca href=\"http://www.wsj.com/articles/walgreen-terminates-partnership-with-blood-testing-firm-theranos-1465777062\">The Wall Street Journal\u003c/a>:\u003c/p>\n\u003cblockquote>\u003cp>Without Walgreens, Theranos would no longer be competing with major labs. To regain its access to consumers, it would have to forge a new retail partnership, offer its blood-testing services directly to more doctors’ offices or open its own blood-draw sites, among other options. It already has moved to open a blood-testing center in Arizona. Recently, the company has been exploring a tie-up with another pharmacy or supermarket, according to a person familiar with the matter.\u003c/p>\u003c/blockquote>\n\u003cp>\u003c/p>\n\u003cp>And don't forget, \u003ca href=\"http://www.beckershospitalreview.com/legal-regulatory-issues/third-theranos-lawsuit-brings-walgreens-into-the-mix.html\" target=\"_blank\">several lawsuits\u003c/a> are pending, as well.\u003c/p>\n\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/182744/walgreens-shutting-down-theranos-centers-immediately-as-it-ends-partnership",
"authors": [
"80"
],
"categories": [
"futureofyou_452",
"futureofyou_1",
"futureofyou_73"
],
"tags": [
"futureofyou_617",
"futureofyou_245"
],
"featImg": "futureofyou_152361",
"label": "futureofyou"
},
"futureofyou_157362": {
"type": "posts",
"id": "futureofyou_157362",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "157362",
"score": null,
"sort": [
1464800229000
]
},
"parent": 0,
"labelTerm": {
"site": "futureofyou"
},
"blocks": [],
"publishDate": 1464800229,
"format": "standard",
"disqusTitle": "Theranos CEO Holmes' Net Worth Is Now Zero, Says Forbes",
"title": "Theranos CEO Holmes' Net Worth Is Now Zero, Says Forbes",
"headTitle": "KQED Future of You | KQED Science",
"content": "\u003cp>\u003cstrong>Update Wednesday, June 1:\u003c/strong> Forbes Slashes Estimates of Elizabeth Holmes' Net Worth\u003c/p>\n\u003cp>Forbes \u003ca href=\"http://www.forbes.com/sites/matthewherper/2016/06/01/from-4-5-billion-to-nothing-forbes-revises-estimated-net-worth-of-theranos-founder-elizabeth-holmes/#610806f12f29\" target=\"_blank\">announced today\u003c/a> it has revised its estimate of the net worth of Theranos founder Elizabeth Holmes, from last year's $4.5 billion to: absolutely nothing. Analysts cut the estimate of the company's net worth to $800 million, a fraction of its previous estimated value of $9 billion. The magazine reports Theranos had no comment. From the Forbes story:\u003c/p>\n\u003cblockquote>\u003cp>Our estimate of Holmes’ wealth is based entirely on her 50% stake in Theranos, the blood-testing company she founded in 2003 with plans of revolutionizing the diagnostic test market. Theranos shares are not traded on any stock market; private investors purchased stakes in 2014 at a price that implied a $9 billion valuation for the company.\u003c/p>\n\u003cp>Since then, Theranos has been hit with allegations that its tests are inaccurate and is being investigated by an alphabet soup of federal agencies. That, plus new information indicating Theranos’ annual revenues are less than $100 million, has led FORBES to come up with a new, lower estimate of Theranos’ value.\u003c/p>\n\u003cp>FORBES spoke to a dozen venture capitalists, analysts and industry experts and concluded that a more realistic value for Theranos is $800 million, rather than $9 billion.\u003c/p>\u003c/blockquote>\n\u003cp>\u003cstrong>Update Thursday, May 26: \u003c/strong> And now, the lawsuits.\u003c/p>\n\u003cp>On the heels of Theranos \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/05/19/theranos-corrects-tens-of-thousands-of-blood-tests/\">voiding or correcting\u003c/a> tens of thousands of blood tests it performed at its California lab, two suits seeking class action status have been filed in Northern California. The \u003ca href=\"http://fortune.com/2016/05/26/theranos-class-action-lawsuit/\">first suit\u003c/a> was filed Wednesday on behalf of an unidentified Arizona man. The suit accuses the blood-testing company of fraud.\u003c/p>\n\u003cp>Today, a \u003ca href=\"https://cdn2.vox-cdn.com/uploads/chorus_asset/file/6552851/jones-theranos.0.pdf\">second class-action suit\u003c/a> was filed on behalf of a man named Casey Jones. Jones visited a Theranos Wellness Center inside a Phoenix Walgreens in September 2015 to obtain a routine blood panel as well as a test marked \"reproductive health,\" as he was concerned about his ability to impregnate his wife, the suit says. His doctor had spoken highly of Theranos' finger-prick test as being minimally invasive, and Jones was also influenced by heavy media coverage.\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\n\u003cp>\"Upon arriving at Walgreens, Mr. Jones' experience differed greatly from what was promoted,\" the lawsuit claims. \"He had several large vials of blood drawn ... the same as what he would have had drawn at any other lab. There was no disclaimer made to Mr. Jones about this apparent change in the blood draw procedure.\"\u003c/p>\n\u003cp>The suit claims Theranos breached its contract with the plaintiff by not drawing blood in the advertised, minimally invasive way. It also recaps the history of Theranos' disastrous government inspection of its lab and claims Theranos failed to maintain its equipment to industry or government standards. The suit also accuses Theranos of deceptive advertising and fraudulent business practices.\u003c/p>\n\u003cp>\"Because of the reported issues with Theranos, Mr. Jones has serious concerns about the lab results he received, including concerns regarding the reliability and accuracy of the tests,\" the suit says.\u003c/p>\n\u003cp>\u003ca href=\"http://www.vanityfair.com/news/2016/05/elizabeth-holmes-theranos-class-action-lawsuit\">The Verge\u003c/a> says Theranos spokeswoman Brooke Buchanan issued the same response to today's lawsuit as she did to yesterday's: “The lawsuit filed today against Theranos is without merit. The company will vigorously defend itself against these claims.”\u003c/p>\n\u003cp>Whether any patients have been truly harmed by decisions they or their doctors made based on inaccurate Theranos results is not yet known. The Wall Street Journal has\u003ca href=\"http://www.wsj.com/articles/theranos-voids-two-years-of-edison-blood-test-results-1463616976\"> reported\u003c/a> that one physician who received a corrected report said she'd unnecessarily sent a patient to the ER based on abnormally high test results.\u003c/p>\n\u003cp>Also of note for Theranos watchers: The Wall Street Journal Wednesday \u003ca href=\"http://www.wsj.com/articles/craving-growth-walgreens-dismissed-its-doubts-about-theranos-1464207285\">recounted the history\u003c/a> of the company's partnership with Walgreens, which allowed for the opening of dozens of Theranos centers inside the drugstore chain's Arizona stores. The story suggests Walgreens, in its eagerness to expand into next-wave health care, did less than due diligence in vetting Theranos.\u003c/p>\n\u003cp>\u003cstrong>Original post: Theranos, From All Angles\u003c/strong>\u003c/p>\n\u003cp>Think fast:\u003c/p>\n\u003cp>Charlize Theron or Scarlett Johannson as Elizabeth Holmes in \"Theranos: The Movie\"?\u003c/p>\n\u003cp>There's a lot of drama here, as business stories go. Is the company going to be definitively exposed as the Enron of biotech startups? Or will it be vindicated as a misunderstood and unfairly persecuted innovator that, well, made a few mistakes.\u003c/p>\n\u003cp>If the former, you get the sense only a talent on a par with \u003ca href=\"http://www.theatlantic.com/magazine/archive/2008/01/the-angriest-man-in-television/306581/\">David Simon's\u003c/a> could coherently dramatize the shortcomings of the multiple institutions implicated in this mess. The story is compelling even without the appearance to date of the most important characters -- real-life patients who may have been harmed by Theranos' \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/05/19/theranos-corrects-tens-of-thousands-of-blood-tests/\">faulty blood tests\u003c/a>.\u003c/p>\n\u003caside class=\"pullquote alignright\">\u003ca href=\"#articles\">\u003cstrong>See below for Theranos analysis from around the Web.\u003c/strong>\u003c/a>\u003c/aside>\n\u003cp>That may not be the case much longer. Last week, we saw the first report of an actual patient impacted by erroneous results issued by Theranos' California lab. The Wall Street Journal, in a \u003ca href=\"http://www.wsj.com/articles/theranos-voids-two-years-of-edison-blood-test-results-1463616976\">story\u003c/a> about thousands of blood tests Theranos now says were incorrect, reported that a physician in the Phoenix area recently received a revised report for a Theranos patient whom the doctor unnecessarily sent to the ER based on abnormally high results.\u003c/p>\n\u003cp>Nick Stockton, who in \u003ca href=\"http://www.wired.com/2016/05/theranos-inching-towards-legal-bull-issh/\">Wired\u003c/a>, Friday, wrote that Theranos \"is really testing the old adage that all press is good press,\" reported the company has left itself vulnerable to all manner of lawsuits:\u003c/p>\n\u003cblockquote>\u003cp>Many people probably made medical decisions based on those two years of voided tests. Or perhaps they wrongfully decided to forgo medical treatment for a misdiagnosed condition. “If Theranos negligently did blood tests, then someone has a right to sue,” says [UC Berkeley law professor Steven] Davidoff-Soloman. “And it looks like it might be a good case.” But so far, he says he has not seen any examples where a person has popped up and said they were adversely affected by the results from a Theranos test. So again, wait and see.\u003c/p>\n\u003cp>As an accredited lab, Theranos was available to patients through Medicare and Medicaid. “Here you have a situation where they were not just deceiving patients, but also the federal government, who is paying for those tests,” says [University of Michigan law professor Adam] Pritchard. “That is something the Department of Justice is going to be very interested in.” The DOJ itself could bring suit. And depending on what that suit entails, class action lawyers could come calling with cases of mass consumer fraud. Nightmare.\u003c/p>\u003c/blockquote>\n\u003cp>\u003cstrong>'Whatever They're Up To, I Can't Figure It Out'\u003c/strong>\u003c/p>\n\u003cp>Dr. Norman Paradis, a professor of medicine at Dartmouth who has consulted for both diagnostic startups and biomed investors, told me recently that several years ago he looked into Theranos at the request of some potential investors. He found nothing that could be assessed.\u003c/p>\n\u003caside class=\"pullquote alignright\">'Their patents — there’s nothing there. There’s nothing you look at and say, ‘Oh, I can build that.''\u003ccite>Dr. Norman Paradis, Geisel School of Medicine, Dartmouth College\u003c/cite>\u003c/aside>\n\u003cp>\"I said whatever they're up to, I can't figure it out. I didn't see it in their patents or regulatory filings. Their patents -- there's nothing there. There's nothing you look at and say, 'Oh I can build that.'\"\u003c/p>\n\u003cp>Paradis says the molecular diagnostics space is not exactly fertile ground for startups to begin with, because of the royalties due companies that have developed the antibodies indicating a particular illness or condition. Because of this, he says, it is unlikely the low-cost tests Theranos offers are breaking even.\u003c/p>\n\u003cp>\"I have seen smart business types look at this model, and they’ve said I can’t see how you make money here.\"\u003c/p>\n\u003cp>Christina Farr, in \u003ca href=\"http://www.fastcompany.com/3059230/the-theranos-scandal-is-just-the-beginning\">Fast Company\u003c/a>, writes that whatever the company's business plan, it seemed to be a nonstarter with the most prestigious biotech investing firms. \"None of the top biotech investors invested in Theranos,\" Farr wrote. \"Five of the best-regarded biotech firms—Venrock, Third Rock Ventures, Polaris, Deerfield, Versant—either didn't meet with Theranos at all or passed on the pitch. The Silicon Valley firms with health care practices, like Google Ventures and Bessemer Venture Partners, weren't swayed, either.\"\u003c/p>\n\u003cp>Dartmouth's Paradis does give the company credit for submitting over 100 tests for FDA approval, even though a \u003ca href=\"http://www.theverge.com/2015/11/17/9750048/ldt-loophole-fda-hearing-theranos-lab-tests\">legal loophole\u003c/a> regarding \"\u003ca href=\"http://www.fda.gov/medicaldevices/productsandmedicalprocedures/invitrodiagnostics/ucm407296.htm\">Laboratory Developed Tests\u003c/a>\" allows it and \u003ca href=\"http://www.theverge.com/science/2015/11/11/9706356/fda-theranos-health-diagnostics-cancer-tests-regulation-loophole-ldt\">other diagnostic startups\u003c/a> to bring these tests to market without doing so. (The FDA plans on issuing its final version of a \u003ca href=\"http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm416685.pdf\">draft plan\u003c/a> to phase in \u003ca href=\"https://www.genomeweb.com/molecular-diagnostics/fda-finalize-ldt-guidance-amid-uncertainty-number-genetic-tests-impacted\">oversight of LDTS\u003c/a> sometime this year.)\u003c/p>\n\u003cp>\"For Theranos to decide to go the FDA route does show considerable rigor on Theranos’ part,\" Paradis says. \"When they made that decision, people were not doing it that way.\"\u003c/p>\n\u003cp>Soon, we may get another key development in the story, courtesy of the U.S. government. The Centers for Medicare & Medicaid Services is still mulling whether to revoke the license of Theranos' California lab, and whether to suspend Elizabeth Holmes from involvement in the blood-testing industry for two years. If things go that way, the company still has a couple of administrative appeals available to it. And beyond that, there's always the courts.\u003c/p>\n\u003cp>Meanwhile, Theranos is \u003ca href=\"https://www.statnews.com/2016/05/19/theranos-expansion-plans/\">still hiring\u003c/a>, and Holmes is scheduled to give a presentation at a plenary session of the American Association for Clinical Chemistry's annual meeting in Philadelphia on Aug. 1. \"For the first time, Holmes will present data at a scientific conference that describes Theranos’ technologies, including small sample volume testing and finger-stick collection,\" said the press release.\u003c/p>\n\u003cp>That one should be put on pay-per-view.\u003c/p>\n\u003chr>\n\u003cp>[ad floatright]\u003c/p>\n\u003cp>\u003ca id=\"articles\">\u003c/a>Below are some of the most interesting recent takes on the Theranos saga:\u003c/p>\n\u003cul>\n\u003cli>\u003ca href=\"http://www.vanityfair.com/news/2016/05/theranos-silicon-valley-media\">The Secret Culprit in the Theranos Mess\u003c/a> (Nick Bilton, Vanity Fair)\u003cbr>\n\u003cblockquote>\u003cp>(I)f you peel back all of the layers of this tale, at the center you will find one of the more insidious culprits: the Silicon Valley tech press. They embraced Holmes and her start-up with a surprising paucity of questions about the technology she had supposedly developed. They praised her as “the next Steve Jobs,” over and over (the black turtleneck didn’t hurt), until it was no longer a question, but seemingly a fact. At TechCrunch Disrupt, blogger Jon Shieber had his blood drawn onstage as he interviewed her. There were no tough questions about whether Theranos’s technology actually worked; just praise. When it seemed that the tech press had vetted Holmes, she subsequently went mainstream. She got her New Yorker profile, and her face appeared on the cover of T: The New York Times Style Magazine, among others.\u003c/p>\u003c/blockquote>\n\u003c/li>\n\u003cli>\u003ca href=\"http://www.businessinsider.com/why-investor-tim-draper-still-loves-theranos-2016-5\">Blood-testing 'vampires' want to take down Theranos, says investor Tim Draper\u003c/a> (Julie Bort, Business Insider)\u003cbr>\n\u003cblockquote>\u003cp>Troubled blood-testing startup Theranos still has one big, vocal fan: the guy that invested the seed money to get the company started, famed investor Tim Draper. Draper tells Business Insider that of all the startups out there, Theranos is among those he's most excited about. ... Although Draper is not listed as a board member, his take is that all of the questions about Theranos is smoke and mirrors from the established blood-testing industry that doesn't want to see itself overthrown by a one-drop-of-blood-alternative. He says he's seen this struggle many times in his investing career, how telecom companies fought Skype, taxis fought Uber, car companies fought Tesla and so on.\u003c/p>\u003c/blockquote>\n\u003c/li>\n\u003cli>\u003ca href=\"http://www.fastcompany.com/3059230/the-theranos-scandal-is-just-the-beginning\">The Theranos Scandal Is Just The Beginning\u003c/a> (Christina Farr, Fast Company)\u003cbr>\n\u003cblockquote>\u003cp>(A)fter we find our scapegoats, the problem will not be solved. Until we address all the factors that led to Theranos' rise and its downfall, this will happen again. Launch, hype-cycle, demise. Launch, hype-cycle, demise. Again and again. One the biggest catalysts for this cycle? Dumb money. ...The biotech funding process might be flawed, but it works well enough to smell a very large rat.\u003c/p>\u003c/blockquote>\n\u003c/li>\n\u003cli>\u003ca href=\"http://time.com/4299943/the-theranos-downfall-was-inevitable/\">The Theranos Downfall Was Inevitable\u003c/a> (Alice Park, Time)\u003cbr>\n\u003cblockquote>\u003cp>At issue is the secrecy with which Theranos developed and brought to market the technology and its proprietary blood-testing process from day one. Theranos did not share with outside scientists which machines the company used to perform its tests, and they wouldn’t then reveal how its technology differed from the microfluidics that other companies were using to perform similar—though less extensive—assays as Theranos’. Nor did they publish in any peer-reviewed journal any research that proved the effectiveness of their product. To do so, Holmes said, would make them lose their competitive advantage of being the first to offer such tests. When Dr. Eric Topol, director of the Scripps Translational Science Institute, had his blood drawn and tested using the system, he says, “I wasn’t allowed to see the equipment, wasn’t allowed to go near it.”\u003c/p>\u003c/blockquote>\n\u003c/li>\n\u003cli>\u003ca href=\"http://www.wsj.com/articles/from-lending-club-to-theranos-the-limits-of-disruption-1463161745\">From LendingClub to Theranos, the Limits of Disruption\u003c/a> (Justin Lahart, The Wall Street Journal)\u003cbr>\n\u003cblockquote>\u003cp>(E)arly critics of Theranos complained the company had published little data in peer-reviewed journals that would have helped provide insight into the quality of its tests. But innovators often see ignoring criticism as a feature, says University of Toronto economist Joshua Gans, author of a recent book on disruption. That is particularly true when the criticism comes from incumbents who, as ousted Zenefits chief Parker Conrad once complained, often cry foul and look to regulators for protection. The problem is that while critics may be protecting turf, there also may be some truth to what they say. Indeed, the norms incumbents adhere to, and the rules they play by, are often there for reasons that go beyond protecting their moats. That’s particularly true of many old-line industries, such as banking, insurance brokers and medicine, that seem ripe for new entrants.\u003c/p>\u003c/blockquote>\n\u003c/li>\n\u003cli>\u003ca href=\"http://ww2.kqed.org/futureofyou/2016/04/25/analysis-why-medical-lab-experts-were-always-skeptical-of-theranos/\">Analysis: Why Medical Lab Experts Were Always Skeptical of Theranos\u003c/a> (Norman A. Paradis, The Conversation)\u003cbr>\n\u003cblockquote>\u003cp>The vast majority of FDA-approved medically important laboratory tests are based on blood taken from a vein, not from the finger. ... To understand why that matters, let’s start with some simple physiology. The human body can be considered a series of compartments; the concentration of any given molecule in blood or tissue fluid may vary from one compartment to the next. A small molecule, such as glucose, can move easily between these compartments, and any bodily fluid can generally be used to test its concentration. This is why testing blood sugar with a finger prick works. But large, medically important molecules like proteins and lipids are not always found in uniform concentrations throughout the body. The composition of blood from finger pricks from the same person can vary, a problem that doesn’t happen in blood taken from a vein. When you lance a fingertip, you get both blood and tissue fluid, and this means that the concentration of molecules may be different than if the blood sample comes from a vein.\u003c/p>\u003c/blockquote>\n\u003c/li>\n\u003cli>\u003ca href=\"http://fivethirtyeight.com/features/theranos-is-wrong-we-dont-need-more-blood-tests/\">Theranos is Wrong: We Don't Need More Blood Tests\u003c/a> (Katherine Hobson, FiveThirtyEight)\u003cbr>\n\u003cblockquote>\u003cp>Much of the debate over the last few months has been about whether Theranos’s technology can actually do what the company has said it can. But there’s a dubious assumption at the heart of Theranos, arguably just as damning as the questions about its technology. Theranos wants us to believe that ostensibly healthy people can get healthier by having more tests. But the science suggests that is far from true.\u003c/p>\u003c/blockquote>\n\u003c/li>\n\u003cli>\u003ca href=\"http://www.natlawreview.com/article/theranos-sec-s-pursuit-unicorns-and-taking-reins-internal-controls\">Theranos, the SEC’s Pursuit of Unicorns, and Taking the Reins of Internal Controls\u003c/a> (The National Law Review)\u003cbr>\n\u003cblockquote>\u003cp>Even beyond potential misrepresentation issues, we believe the SEC may also be focused on the adequacy of internal controls at privately-held companies, potentially viewing governance and control problems as contributing factors to other issues. ...(I)n a recent speech addressing issues relating to pre-IPO companies, SEC Chair Mary Jo White noted that the SEC was looking closely at privately-held “unicorns”, even where the investors appeared to be venture capital and private equity funds. She stated that control issues were a major risk factor that could lead to opportunities to misstate financial results: “The risk of distortion and inaccuracy is amplified because start-up companies, even quite mature ones, often have far less robust internal controls and governance procedures than most public companies.”\u003c/p>\u003c/blockquote>\n\u003c/li>\n\u003c/ul>\n\n",
"disqusIdentifier": "157362 http://ww2.kqed.org/futureofyou/?p=157362",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/06/01/theranos-from-all-angles/",
"stats": {
"hasVideo": false,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 2836,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 45
},
"modified": 1464806234,
"excerpt": "The Theranos saga is about as dramatic as it gets when it comes to Silicon Valley stories.",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "The Theranos saga is about as dramatic as it gets when it comes to Silicon Valley stories.",
"title": "Theranos CEO Holmes' Net Worth Is Now Zero, Says Forbes | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "Theranos CEO Holmes' Net Worth Is Now Zero, Says Forbes",
"datePublished": "2016-06-01T09:57:09-07:00",
"dateModified": "2016-06-01T11:37:14-07:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "theranos-from-all-angles",
"status": "publish",
"path": "/futureofyou/157362/theranos-from-all-angles",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>\u003cstrong>Update Wednesday, June 1:\u003c/strong> Forbes Slashes Estimates of Elizabeth Holmes' Net Worth\u003c/p>\n\u003cp>Forbes \u003ca href=\"http://www.forbes.com/sites/matthewherper/2016/06/01/from-4-5-billion-to-nothing-forbes-revises-estimated-net-worth-of-theranos-founder-elizabeth-holmes/#610806f12f29\" target=\"_blank\">announced today\u003c/a> it has revised its estimate of the net worth of Theranos founder Elizabeth Holmes, from last year's $4.5 billion to: absolutely nothing. Analysts cut the estimate of the company's net worth to $800 million, a fraction of its previous estimated value of $9 billion. The magazine reports Theranos had no comment. From the Forbes story:\u003c/p>\n\u003cblockquote>\u003cp>Our estimate of Holmes’ wealth is based entirely on her 50% stake in Theranos, the blood-testing company she founded in 2003 with plans of revolutionizing the diagnostic test market. Theranos shares are not traded on any stock market; private investors purchased stakes in 2014 at a price that implied a $9 billion valuation for the company.\u003c/p>\n\u003cp>Since then, Theranos has been hit with allegations that its tests are inaccurate and is being investigated by an alphabet soup of federal agencies. That, plus new information indicating Theranos’ annual revenues are less than $100 million, has led FORBES to come up with a new, lower estimate of Theranos’ value.\u003c/p>\n\u003cp>FORBES spoke to a dozen venture capitalists, analysts and industry experts and concluded that a more realistic value for Theranos is $800 million, rather than $9 billion.\u003c/p>\u003c/blockquote>\n\u003cp>\u003cstrong>Update Thursday, May 26: \u003c/strong> And now, the lawsuits.\u003c/p>\n\u003cp>On the heels of Theranos \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/05/19/theranos-corrects-tens-of-thousands-of-blood-tests/\">voiding or correcting\u003c/a> tens of thousands of blood tests it performed at its California lab, two suits seeking class action status have been filed in Northern California. The \u003ca href=\"http://fortune.com/2016/05/26/theranos-class-action-lawsuit/\">first suit\u003c/a> was filed Wednesday on behalf of an unidentified Arizona man. The suit accuses the blood-testing company of fraud.\u003c/p>\n\u003cp>Today, a \u003ca href=\"https://cdn2.vox-cdn.com/uploads/chorus_asset/file/6552851/jones-theranos.0.pdf\">second class-action suit\u003c/a> was filed on behalf of a man named Casey Jones. Jones visited a Theranos Wellness Center inside a Phoenix Walgreens in September 2015 to obtain a routine blood panel as well as a test marked \"reproductive health,\" as he was concerned about his ability to impregnate his wife, the suit says. His doctor had spoken highly of Theranos' finger-prick test as being minimally invasive, and Jones was also influenced by heavy media coverage.\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>\"Upon arriving at Walgreens, Mr. Jones' experience differed greatly from what was promoted,\" the lawsuit claims. \"He had several large vials of blood drawn ... the same as what he would have had drawn at any other lab. There was no disclaimer made to Mr. Jones about this apparent change in the blood draw procedure.\"\u003c/p>\n\u003cp>The suit claims Theranos breached its contract with the plaintiff by not drawing blood in the advertised, minimally invasive way. It also recaps the history of Theranos' disastrous government inspection of its lab and claims Theranos failed to maintain its equipment to industry or government standards. The suit also accuses Theranos of deceptive advertising and fraudulent business practices.\u003c/p>\n\u003cp>\"Because of the reported issues with Theranos, Mr. Jones has serious concerns about the lab results he received, including concerns regarding the reliability and accuracy of the tests,\" the suit says.\u003c/p>\n\u003cp>\u003ca href=\"http://www.vanityfair.com/news/2016/05/elizabeth-holmes-theranos-class-action-lawsuit\">The Verge\u003c/a> says Theranos spokeswoman Brooke Buchanan issued the same response to today's lawsuit as she did to yesterday's: “The lawsuit filed today against Theranos is without merit. The company will vigorously defend itself against these claims.”\u003c/p>\n\u003cp>Whether any patients have been truly harmed by decisions they or their doctors made based on inaccurate Theranos results is not yet known. The Wall Street Journal has\u003ca href=\"http://www.wsj.com/articles/theranos-voids-two-years-of-edison-blood-test-results-1463616976\"> reported\u003c/a> that one physician who received a corrected report said she'd unnecessarily sent a patient to the ER based on abnormally high test results.\u003c/p>\n\u003cp>Also of note for Theranos watchers: The Wall Street Journal Wednesday \u003ca href=\"http://www.wsj.com/articles/craving-growth-walgreens-dismissed-its-doubts-about-theranos-1464207285\">recounted the history\u003c/a> of the company's partnership with Walgreens, which allowed for the opening of dozens of Theranos centers inside the drugstore chain's Arizona stores. The story suggests Walgreens, in its eagerness to expand into next-wave health care, did less than due diligence in vetting Theranos.\u003c/p>\n\u003cp>\u003cstrong>Original post: Theranos, From All Angles\u003c/strong>\u003c/p>\n\u003cp>Think fast:\u003c/p>\n\u003cp>Charlize Theron or Scarlett Johannson as Elizabeth Holmes in \"Theranos: The Movie\"?\u003c/p>\n\u003cp>There's a lot of drama here, as business stories go. Is the company going to be definitively exposed as the Enron of biotech startups? Or will it be vindicated as a misunderstood and unfairly persecuted innovator that, well, made a few mistakes.\u003c/p>\n\u003cp>If the former, you get the sense only a talent on a par with \u003ca href=\"http://www.theatlantic.com/magazine/archive/2008/01/the-angriest-man-in-television/306581/\">David Simon's\u003c/a> could coherently dramatize the shortcomings of the multiple institutions implicated in this mess. The story is compelling even without the appearance to date of the most important characters -- real-life patients who may have been harmed by Theranos' \u003ca href=\"http://ww2.kqed.org/futureofyou/2016/05/19/theranos-corrects-tens-of-thousands-of-blood-tests/\">faulty blood tests\u003c/a>.\u003c/p>\n\u003caside class=\"pullquote alignright\">\u003ca href=\"#articles\">\u003cstrong>See below for Theranos analysis from around the Web.\u003c/strong>\u003c/a>\u003c/aside>\n\u003cp>That may not be the case much longer. Last week, we saw the first report of an actual patient impacted by erroneous results issued by Theranos' California lab. The Wall Street Journal, in a \u003ca href=\"http://www.wsj.com/articles/theranos-voids-two-years-of-edison-blood-test-results-1463616976\">story\u003c/a> about thousands of blood tests Theranos now says were incorrect, reported that a physician in the Phoenix area recently received a revised report for a Theranos patient whom the doctor unnecessarily sent to the ER based on abnormally high results.\u003c/p>\n\u003cp>Nick Stockton, who in \u003ca href=\"http://www.wired.com/2016/05/theranos-inching-towards-legal-bull-issh/\">Wired\u003c/a>, Friday, wrote that Theranos \"is really testing the old adage that all press is good press,\" reported the company has left itself vulnerable to all manner of lawsuits:\u003c/p>\n\u003cblockquote>\u003cp>Many people probably made medical decisions based on those two years of voided tests. Or perhaps they wrongfully decided to forgo medical treatment for a misdiagnosed condition. “If Theranos negligently did blood tests, then someone has a right to sue,” says [UC Berkeley law professor Steven] Davidoff-Soloman. “And it looks like it might be a good case.” But so far, he says he has not seen any examples where a person has popped up and said they were adversely affected by the results from a Theranos test. So again, wait and see.\u003c/p>\n\u003cp>As an accredited lab, Theranos was available to patients through Medicare and Medicaid. “Here you have a situation where they were not just deceiving patients, but also the federal government, who is paying for those tests,” says [University of Michigan law professor Adam] Pritchard. “That is something the Department of Justice is going to be very interested in.” The DOJ itself could bring suit. And depending on what that suit entails, class action lawyers could come calling with cases of mass consumer fraud. Nightmare.\u003c/p>\u003c/blockquote>\n\u003cp>\u003cstrong>'Whatever They're Up To, I Can't Figure It Out'\u003c/strong>\u003c/p>\n\u003cp>Dr. Norman Paradis, a professor of medicine at Dartmouth who has consulted for both diagnostic startups and biomed investors, told me recently that several years ago he looked into Theranos at the request of some potential investors. He found nothing that could be assessed.\u003c/p>\n\u003caside class=\"pullquote alignright\">'Their patents — there’s nothing there. There’s nothing you look at and say, ‘Oh, I can build that.''\u003ccite>Dr. Norman Paradis, Geisel School of Medicine, Dartmouth College\u003c/cite>\u003c/aside>\n\u003cp>\"I said whatever they're up to, I can't figure it out. I didn't see it in their patents or regulatory filings. Their patents -- there's nothing there. There's nothing you look at and say, 'Oh I can build that.'\"\u003c/p>\n\u003cp>Paradis says the molecular diagnostics space is not exactly fertile ground for startups to begin with, because of the royalties due companies that have developed the antibodies indicating a particular illness or condition. Because of this, he says, it is unlikely the low-cost tests Theranos offers are breaking even.\u003c/p>\n\u003cp>\"I have seen smart business types look at this model, and they’ve said I can’t see how you make money here.\"\u003c/p>\n\u003cp>Christina Farr, in \u003ca href=\"http://www.fastcompany.com/3059230/the-theranos-scandal-is-just-the-beginning\">Fast Company\u003c/a>, writes that whatever the company's business plan, it seemed to be a nonstarter with the most prestigious biotech investing firms. \"None of the top biotech investors invested in Theranos,\" Farr wrote. \"Five of the best-regarded biotech firms—Venrock, Third Rock Ventures, Polaris, Deerfield, Versant—either didn't meet with Theranos at all or passed on the pitch. The Silicon Valley firms with health care practices, like Google Ventures and Bessemer Venture Partners, weren't swayed, either.\"\u003c/p>\n\u003cp>Dartmouth's Paradis does give the company credit for submitting over 100 tests for FDA approval, even though a \u003ca href=\"http://www.theverge.com/2015/11/17/9750048/ldt-loophole-fda-hearing-theranos-lab-tests\">legal loophole\u003c/a> regarding \"\u003ca href=\"http://www.fda.gov/medicaldevices/productsandmedicalprocedures/invitrodiagnostics/ucm407296.htm\">Laboratory Developed Tests\u003c/a>\" allows it and \u003ca href=\"http://www.theverge.com/science/2015/11/11/9706356/fda-theranos-health-diagnostics-cancer-tests-regulation-loophole-ldt\">other diagnostic startups\u003c/a> to bring these tests to market without doing so. (The FDA plans on issuing its final version of a \u003ca href=\"http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm416685.pdf\">draft plan\u003c/a> to phase in \u003ca href=\"https://www.genomeweb.com/molecular-diagnostics/fda-finalize-ldt-guidance-amid-uncertainty-number-genetic-tests-impacted\">oversight of LDTS\u003c/a> sometime this year.)\u003c/p>\n\u003cp>\"For Theranos to decide to go the FDA route does show considerable rigor on Theranos’ part,\" Paradis says. \"When they made that decision, people were not doing it that way.\"\u003c/p>\n\u003cp>Soon, we may get another key development in the story, courtesy of the U.S. government. The Centers for Medicare & Medicaid Services is still mulling whether to revoke the license of Theranos' California lab, and whether to suspend Elizabeth Holmes from involvement in the blood-testing industry for two years. If things go that way, the company still has a couple of administrative appeals available to it. And beyond that, there's always the courts.\u003c/p>\n\u003cp>Meanwhile, Theranos is \u003ca href=\"https://www.statnews.com/2016/05/19/theranos-expansion-plans/\">still hiring\u003c/a>, and Holmes is scheduled to give a presentation at a plenary session of the American Association for Clinical Chemistry's annual meeting in Philadelphia on Aug. 1. \"For the first time, Holmes will present data at a scientific conference that describes Theranos’ technologies, including small sample volume testing and finger-stick collection,\" said the press release.\u003c/p>\n\u003cp>That one should be put on pay-per-view.\u003c/p>\n\u003chr>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "floatright"
},
"numeric": [
"floatright"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>\u003ca id=\"articles\">\u003c/a>Below are some of the most interesting recent takes on the Theranos saga:\u003c/p>\n\u003cul>\n\u003cli>\u003ca href=\"http://www.vanityfair.com/news/2016/05/theranos-silicon-valley-media\">The Secret Culprit in the Theranos Mess\u003c/a> (Nick Bilton, Vanity Fair)\u003cbr>\n\u003cblockquote>\u003cp>(I)f you peel back all of the layers of this tale, at the center you will find one of the more insidious culprits: the Silicon Valley tech press. They embraced Holmes and her start-up with a surprising paucity of questions about the technology she had supposedly developed. They praised her as “the next Steve Jobs,” over and over (the black turtleneck didn’t hurt), until it was no longer a question, but seemingly a fact. At TechCrunch Disrupt, blogger Jon Shieber had his blood drawn onstage as he interviewed her. There were no tough questions about whether Theranos’s technology actually worked; just praise. When it seemed that the tech press had vetted Holmes, she subsequently went mainstream. She got her New Yorker profile, and her face appeared on the cover of T: The New York Times Style Magazine, among others.\u003c/p>\u003c/blockquote>\n\u003c/li>\n\u003cli>\u003ca href=\"http://www.businessinsider.com/why-investor-tim-draper-still-loves-theranos-2016-5\">Blood-testing 'vampires' want to take down Theranos, says investor Tim Draper\u003c/a> (Julie Bort, Business Insider)\u003cbr>\n\u003cblockquote>\u003cp>Troubled blood-testing startup Theranos still has one big, vocal fan: the guy that invested the seed money to get the company started, famed investor Tim Draper. Draper tells Business Insider that of all the startups out there, Theranos is among those he's most excited about. ... Although Draper is not listed as a board member, his take is that all of the questions about Theranos is smoke and mirrors from the established blood-testing industry that doesn't want to see itself overthrown by a one-drop-of-blood-alternative. He says he's seen this struggle many times in his investing career, how telecom companies fought Skype, taxis fought Uber, car companies fought Tesla and so on.\u003c/p>\u003c/blockquote>\n\u003c/li>\n\u003cli>\u003ca href=\"http://www.fastcompany.com/3059230/the-theranos-scandal-is-just-the-beginning\">The Theranos Scandal Is Just The Beginning\u003c/a> (Christina Farr, Fast Company)\u003cbr>\n\u003cblockquote>\u003cp>(A)fter we find our scapegoats, the problem will not be solved. Until we address all the factors that led to Theranos' rise and its downfall, this will happen again. Launch, hype-cycle, demise. Launch, hype-cycle, demise. Again and again. One the biggest catalysts for this cycle? Dumb money. ...The biotech funding process might be flawed, but it works well enough to smell a very large rat.\u003c/p>\u003c/blockquote>\n\u003c/li>\n\u003cli>\u003ca href=\"http://time.com/4299943/the-theranos-downfall-was-inevitable/\">The Theranos Downfall Was Inevitable\u003c/a> (Alice Park, Time)\u003cbr>\n\u003cblockquote>\u003cp>At issue is the secrecy with which Theranos developed and brought to market the technology and its proprietary blood-testing process from day one. Theranos did not share with outside scientists which machines the company used to perform its tests, and they wouldn’t then reveal how its technology differed from the microfluidics that other companies were using to perform similar—though less extensive—assays as Theranos’. Nor did they publish in any peer-reviewed journal any research that proved the effectiveness of their product. To do so, Holmes said, would make them lose their competitive advantage of being the first to offer such tests. When Dr. Eric Topol, director of the Scripps Translational Science Institute, had his blood drawn and tested using the system, he says, “I wasn’t allowed to see the equipment, wasn’t allowed to go near it.”\u003c/p>\u003c/blockquote>\n\u003c/li>\n\u003cli>\u003ca href=\"http://www.wsj.com/articles/from-lending-club-to-theranos-the-limits-of-disruption-1463161745\">From LendingClub to Theranos, the Limits of Disruption\u003c/a> (Justin Lahart, The Wall Street Journal)\u003cbr>\n\u003cblockquote>\u003cp>(E)arly critics of Theranos complained the company had published little data in peer-reviewed journals that would have helped provide insight into the quality of its tests. But innovators often see ignoring criticism as a feature, says University of Toronto economist Joshua Gans, author of a recent book on disruption. That is particularly true when the criticism comes from incumbents who, as ousted Zenefits chief Parker Conrad once complained, often cry foul and look to regulators for protection. The problem is that while critics may be protecting turf, there also may be some truth to what they say. Indeed, the norms incumbents adhere to, and the rules they play by, are often there for reasons that go beyond protecting their moats. That’s particularly true of many old-line industries, such as banking, insurance brokers and medicine, that seem ripe for new entrants.\u003c/p>\u003c/blockquote>\n\u003c/li>\n\u003cli>\u003ca href=\"http://ww2.kqed.org/futureofyou/2016/04/25/analysis-why-medical-lab-experts-were-always-skeptical-of-theranos/\">Analysis: Why Medical Lab Experts Were Always Skeptical of Theranos\u003c/a> (Norman A. Paradis, The Conversation)\u003cbr>\n\u003cblockquote>\u003cp>The vast majority of FDA-approved medically important laboratory tests are based on blood taken from a vein, not from the finger. ... To understand why that matters, let’s start with some simple physiology. The human body can be considered a series of compartments; the concentration of any given molecule in blood or tissue fluid may vary from one compartment to the next. A small molecule, such as glucose, can move easily between these compartments, and any bodily fluid can generally be used to test its concentration. This is why testing blood sugar with a finger prick works. But large, medically important molecules like proteins and lipids are not always found in uniform concentrations throughout the body. The composition of blood from finger pricks from the same person can vary, a problem that doesn’t happen in blood taken from a vein. When you lance a fingertip, you get both blood and tissue fluid, and this means that the concentration of molecules may be different than if the blood sample comes from a vein.\u003c/p>\u003c/blockquote>\n\u003c/li>\n\u003cli>\u003ca href=\"http://fivethirtyeight.com/features/theranos-is-wrong-we-dont-need-more-blood-tests/\">Theranos is Wrong: We Don't Need More Blood Tests\u003c/a> (Katherine Hobson, FiveThirtyEight)\u003cbr>\n\u003cblockquote>\u003cp>Much of the debate over the last few months has been about whether Theranos’s technology can actually do what the company has said it can. But there’s a dubious assumption at the heart of Theranos, arguably just as damning as the questions about its technology. Theranos wants us to believe that ostensibly healthy people can get healthier by having more tests. But the science suggests that is far from true.\u003c/p>\u003c/blockquote>\n\u003c/li>\n\u003cli>\u003ca href=\"http://www.natlawreview.com/article/theranos-sec-s-pursuit-unicorns-and-taking-reins-internal-controls\">Theranos, the SEC’s Pursuit of Unicorns, and Taking the Reins of Internal Controls\u003c/a> (The National Law Review)\u003cbr>\n\u003cblockquote>\u003cp>Even beyond potential misrepresentation issues, we believe the SEC may also be focused on the adequacy of internal controls at privately-held companies, potentially viewing governance and control problems as contributing factors to other issues. ...(I)n a recent speech addressing issues relating to pre-IPO companies, SEC Chair Mary Jo White noted that the SEC was looking closely at privately-held “unicorns”, even where the investors appeared to be venture capital and private equity funds. She stated that control issues were a major risk factor that could lead to opportunities to misstate financial results: “The risk of distortion and inaccuracy is amplified because start-up companies, even quite mature ones, often have far less robust internal controls and governance procedures than most public companies.”\u003c/p>\u003c/blockquote>\n\u003c/li>\n\u003c/ul>\n\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/157362/theranos-from-all-angles",
"authors": [
"80"
],
"categories": [
"futureofyou_452",
"futureofyou_1",
"futureofyou_73"
],
"tags": [
"futureofyou_814",
"futureofyou_617"
],
"featImg": "futureofyou_148281",
"label": "futureofyou"
},
"futureofyou_166491": {
"type": "posts",
"id": "futureofyou_166491",
"meta": {
"index": "posts_1716263798",
"site": "futureofyou",
"id": "166491",
"score": null,
"sort": [
1463675853000
]
},
"parent": 0,
"labelTerm": {
"site": "futureofyou"
},
"blocks": [],
"publishDate": 1463675853,
"format": "standard",
"disqusTitle": "Theranos Corrects Tens of Thousands of Blood Tests",
"title": "Theranos Corrects Tens of Thousands of Blood Tests",
"headTitle": "KQED Future of You | KQED Science",
"content": "\u003cp>The Wall Street Journal reported last night that the company has told its regulator, the Centers for Medicare & Medicaid Services, that it has \u003ca href=\"http://www.wsj.com/articles/theranos-voids-two-years-of-edison-blood-test-results-1463616976\" target=\"_blank\">voided tens of thousands\u003c/a> -- two years worth -- of patient blood test results. The tests were run on both the company's proprietary Edison machines and conventional testing equipment, the paper said. Some results were thrown out and some revised.\u003c/p>\n\u003cp>The Journal, which owns this story in a big way, cited its usual source: \"a person familiar with the matter.\" Forcing Theranos to issue its usual confirmation, plus this statement:\u003c/p>\n\u003caside class=\"pullquote alignright\">One physician received a corrected report for a patient who was unnecessarily sent to the ER based on erroneous test results, The Wall Street Journal said.\u003c/aside>\n\u003cp>\"Excellence in quality and patient safety is our top priority and we’ve taken comprehensive corrective measures to address the issues CMS raised in their observations,\" Theranos spokesperson Brooke Buchanan said in an email to KQED. \"As these matters are currently under review, we have no further comment at this time.\"\u003c/p>\n\u003cp>If you've been following this story -- which has unfolded like some sort of Silicon Valley morality tale -- you know that Theranos made a splash with investors and the media by claiming it was going to remake the diagnostic testing industry with more efficient and cheaper blood tests. The company said it could sample just a finger-prick's worth of blood, collected in a device it called a \"nanotainer;\" that small amount of blood, the company claimed, was enough to run a host of tests. The FDA, however, approved the process for just one of those tests, and the company collects samples for all others the traditional way -- from a patient's vein.\u003c/p>\n\u003cp>In March, The Wall Street Journal reported Theranos had run tests measuring blood-clotting time on 81 patients despite erratic results from quality-control checks. Around the time the story came out, Theranos released a statement saying it had contacted any patients potentially affected by inaccurate tests.\u003c/p>\n\u003cp>[ad fullwidth]\u003c/p>\n\u003cp>“We have conducted assessments to identify any patients affected or having the potential to be affected by the issues identified by CMS, and we have no reason to believe that these issues have affected patients’ health,\" said Theranos’ Newark, California lab director, Dr. Kingshuk Das, in a \u003ca href=\"https://www.theranos.com/news/posts/statement-regarding-newark-california-lab-survey\">statement\u003c/a>.\u003c/p>\n\u003cp>Apparently, Theranos has expanded that group of patients. From the Journal:\u003c/p>\n\u003cblockquote>\u003cp>[The corrections mean] some patients received erroneous results that might have thrown off health decisions made with their doctors. ...\u003c/p>\n\u003cp>Several physician practices in the Phoenix area confirmed receiving corrected test reports from Theranos in recent weeks. ...\u003c/p>\n\u003cp>There have been massive recalls of single tests in the past, but I’m not aware of one where a company recalled the entirety of the results from its testing platform,” said Geoffrey Baird, associate professor in the department of laboratory medicine at the University of Washington in Seattle. “I believe that’s unprecedented.”\u003c/p>\u003c/blockquote>\n\u003cp>One Phoenix-area physician received a corrected report for a patient who was unnecessarily sent to the ER based on the original test results, the paper said.\u003c/p>\n\u003cp>These revised or voided tests may or may not satisfy CMS, which has been weighing whether to drop the hammer on Theranos since March, when the agency informed the company it had not submitted credible evidence of correcting serious deficiencies at its Newark, California lab. Those deficiencies, which CMS had uncovered during an inspection, were potentially life-threatening to patients, CMS said.\u003c/p>\n\u003cp>Among the penalties CMS threatened: revoking the lab's federal license to operate and suspending Theranos founder and CEO Elizabeth Holmes from involvement in the blood-testing industry for two years. CMS also named president and COO Sunny Balwani as subject to suspension, but Balwani last week announced his departure from the company.\u003c/p>\n\u003cp>At the same time it informed Theranos of potential penalties, CMS gave the company one last chance to submit additional proof of its compliance with regulations. Theranos responsed to CMS with additional information, and there's been no word from CMS since that story broke in April.\u003c/p>\n\u003cp>If CMS declines to accept Theranos' filing as valid proof of compliance, the company will still have options for administrative appeal. So it's possible the final resolution of the case may not come for months.\u003c/p>\n\u003cp>But even if Theranos manages to avoid sanctions from CMS, it still faces investigations by both the SEC and the U.S. Attorney’s Office for the Northern District of California. It also faces what many assume will be the end of its \u003ca href=\"http://www.nytimes.com/2016/04/22/business/a-once-avid-ally-walgreens-is-struggling-to-shake-off-theranos.html?_r=0\">high-profile deal\u003c/a> with the Walgreens Boots Alliance, which put dozens of Theranos \"Wellness Centers\" in Walgreens stores in Arizona, giving the secretive company and its unproven technology a needed dose of credibility.\u003c/p>\n\u003cp>That has now been wiped out by the one-two punch of the Journal's investigative reports and the failed federal inspection. Last October, the Journal reported allegations by Theranos employees that the company may have violated reporting rules related to proficiency tests run on Edison.\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>Theranos' Buchanan says federal regulators have issued no findings related to allegations of cheating on proficiency testing or manipulating data. The struggling company recently added a group of doctors and medical scientists to its advisory board to comb through data and help Theranos publish its results publicly.\u003c/p>\n\n",
"disqusIdentifier": "166491 http://ww2.kqed.org/futureofyou/?p=166491",
"disqusUrl": "https://ww2.kqed.org/futureofyou/2016/05/19/theranos-corrects-tens-of-thousands-of-blood-tests/",
"stats": {
"hasVideo": false,
"hasChartOrMap": false,
"hasAudio": false,
"hasPolis": false,
"wordCount": 917,
"hasGoogleForm": false,
"hasGallery": false,
"hasHearkenModule": false,
"iframeSrcs": [],
"paragraphCount": 20
},
"modified": 1463705805,
"excerpt": "The company confirms a report in The Wall Street Journal that two years worth of test results have been either voided or revised.",
"headData": {
"twImgId": "",
"twTitle": "",
"ogTitle": "",
"ogImgId": "",
"twDescription": "",
"description": "The company confirms a report in The Wall Street Journal that two years worth of test results have been either voided or revised.",
"title": "Theranos Corrects Tens of Thousands of Blood Tests | KQED",
"ogDescription": "",
"schema": {
"@context": "https://schema.org",
"@type": "Article",
"headline": "Theranos Corrects Tens of Thousands of Blood Tests",
"datePublished": "2016-05-19T09:37:33-07:00",
"dateModified": "2016-05-19T17:56:45-07:00",
"image": "https://cdn.kqed.org/wp-content/uploads/2020/02/KQED-OG-Image@1x.png"
}
},
"guestAuthors": [],
"slug": "theranos-corrects-tens-of-thousands-of-blood-tests",
"status": "publish",
"path": "/futureofyou/166491/theranos-corrects-tens-of-thousands-of-blood-tests",
"audioTrackLength": null,
"parsedContent": [
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003cp>The Wall Street Journal reported last night that the company has told its regulator, the Centers for Medicare & Medicaid Services, that it has \u003ca href=\"http://www.wsj.com/articles/theranos-voids-two-years-of-edison-blood-test-results-1463616976\" target=\"_blank\">voided tens of thousands\u003c/a> -- two years worth -- of patient blood test results. The tests were run on both the company's proprietary Edison machines and conventional testing equipment, the paper said. Some results were thrown out and some revised.\u003c/p>\n\u003cp>The Journal, which owns this story in a big way, cited its usual source: \"a person familiar with the matter.\" Forcing Theranos to issue its usual confirmation, plus this statement:\u003c/p>\n\u003caside class=\"pullquote alignright\">One physician received a corrected report for a patient who was unnecessarily sent to the ER based on erroneous test results, The Wall Street Journal said.\u003c/aside>\n\u003cp>\"Excellence in quality and patient safety is our top priority and we’ve taken comprehensive corrective measures to address the issues CMS raised in their observations,\" Theranos spokesperson Brooke Buchanan said in an email to KQED. \"As these matters are currently under review, we have no further comment at this time.\"\u003c/p>\n\u003cp>If you've been following this story -- which has unfolded like some sort of Silicon Valley morality tale -- you know that Theranos made a splash with investors and the media by claiming it was going to remake the diagnostic testing industry with more efficient and cheaper blood tests. The company said it could sample just a finger-prick's worth of blood, collected in a device it called a \"nanotainer;\" that small amount of blood, the company claimed, was enough to run a host of tests. The FDA, however, approved the process for just one of those tests, and the company collects samples for all others the traditional way -- from a patient's vein.\u003c/p>\n\u003cp>In March, The Wall Street Journal reported Theranos had run tests measuring blood-clotting time on 81 patients despite erratic results from quality-control checks. Around the time the story came out, Theranos released a statement saying it had contacted any patients potentially affected by inaccurate tests.\u003c/p>\n\u003cp>\u003c/p>\u003c/div>",
"attributes": {
"named": {},
"numeric": []
}
},
{
"type": "component",
"content": "",
"name": "ad",
"attributes": {
"named": {
"label": "fullwidth"
},
"numeric": [
"fullwidth"
]
}
},
{
"type": "contentString",
"content": "\u003cdiv class=\"post-body\">\u003cp>\u003c/p>\n\u003cp>“We have conducted assessments to identify any patients affected or having the potential to be affected by the issues identified by CMS, and we have no reason to believe that these issues have affected patients’ health,\" said Theranos’ Newark, California lab director, Dr. Kingshuk Das, in a \u003ca href=\"https://www.theranos.com/news/posts/statement-regarding-newark-california-lab-survey\">statement\u003c/a>.\u003c/p>\n\u003cp>Apparently, Theranos has expanded that group of patients. From the Journal:\u003c/p>\n\u003cblockquote>\u003cp>[The corrections mean] some patients received erroneous results that might have thrown off health decisions made with their doctors. ...\u003c/p>\n\u003cp>Several physician practices in the Phoenix area confirmed receiving corrected test reports from Theranos in recent weeks. ...\u003c/p>\n\u003cp>There have been massive recalls of single tests in the past, but I’m not aware of one where a company recalled the entirety of the results from its testing platform,” said Geoffrey Baird, associate professor in the department of laboratory medicine at the University of Washington in Seattle. “I believe that’s unprecedented.”\u003c/p>\u003c/blockquote>\n\u003cp>One Phoenix-area physician received a corrected report for a patient who was unnecessarily sent to the ER based on the original test results, the paper said.\u003c/p>\n\u003cp>These revised or voided tests may or may not satisfy CMS, which has been weighing whether to drop the hammer on Theranos since March, when the agency informed the company it had not submitted credible evidence of correcting serious deficiencies at its Newark, California lab. Those deficiencies, which CMS had uncovered during an inspection, were potentially life-threatening to patients, CMS said.\u003c/p>\n\u003cp>Among the penalties CMS threatened: revoking the lab's federal license to operate and suspending Theranos founder and CEO Elizabeth Holmes from involvement in the blood-testing industry for two years. CMS also named president and COO Sunny Balwani as subject to suspension, but Balwani last week announced his departure from the company.\u003c/p>\n\u003cp>At the same time it informed Theranos of potential penalties, CMS gave the company one last chance to submit additional proof of its compliance with regulations. Theranos responsed to CMS with additional information, and there's been no word from CMS since that story broke in April.\u003c/p>\n\u003cp>If CMS declines to accept Theranos' filing as valid proof of compliance, the company will still have options for administrative appeal. So it's possible the final resolution of the case may not come for months.\u003c/p>\n\u003cp>But even if Theranos manages to avoid sanctions from CMS, it still faces investigations by both the SEC and the U.S. Attorney’s Office for the Northern District of California. It also faces what many assume will be the end of its \u003ca href=\"http://www.nytimes.com/2016/04/22/business/a-once-avid-ally-walgreens-is-struggling-to-shake-off-theranos.html?_r=0\">high-profile deal\u003c/a> with the Walgreens Boots Alliance, which put dozens of Theranos \"Wellness Centers\" in Walgreens stores in Arizona, giving the secretive company and its unproven technology a needed dose of credibility.\u003c/p>\n\u003cp>That has now been wiped out by the one-two punch of the Journal's investigative reports and the failed federal inspection. Last October, the Journal reported allegations by Theranos employees that the company may have violated reporting rules related to proficiency tests run on Edison.\u003c/p>\n\u003cp>\u003c/p>\n\u003cp>Theranos' Buchanan says federal regulators have issued no findings related to allegations of cheating on proficiency testing or manipulating data. The struggling company recently added a group of doctors and medical scientists to its advisory board to comb through data and help Theranos publish its results publicly.\u003c/p>\n\n\u003c/div>\u003c/p>",
"attributes": {
"named": {},
"numeric": []
}
}
],
"link": "/futureofyou/166491/theranos-corrects-tens-of-thousands-of-blood-tests",
"authors": [
"80"
],
"categories": [
"futureofyou_452",
"futureofyou_1",
"futureofyou_73"
],
"tags": [
"futureofyou_617"
],
"featImg": "futureofyou_152361",
"label": "futureofyou"
}
},
"podcastsReducer": {
"isFetching": false,
"fetchFailed": false,
"hasFetched": false,
"podcasts": {}
},
"radioProgramsReducer": {
"isFetching": false,
"fetchFailed": false,
"hasFetched": false,
"radioPrograms": {}
},
"radioSearchSegmentsReducer": {},
"programsReducer": {
"all-things-considered": {
"id": "all-things-considered",
"title": "All Things Considered",
"info": "Every weekday, \u003cem>All Things Considered\u003c/em> hosts Robert Siegel, Audie Cornish, Ari Shapiro, and Kelly McEvers present the program's trademark mix of news, interviews, commentaries, reviews, and offbeat features. Michel Martin hosts on the weekends.",
"airtime": "MON-FRI 1pm-2pm, 4:30pm-6:30pm\u003cbr />SAT-SUN 5pm-6pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/All-Things-Considered-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.npr.org/programs/all-things-considered/",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/all-things-considered"
},
"american-suburb-podcast": {
"id": "american-suburb-podcast",
"title": "American Suburb: The Podcast",
"tagline": "The flip side of gentrification, told through one town",
"info": "Gentrification is changing cities across America, forcing people from neighborhoods they have long called home. Call them the displaced. Now those priced out of the Bay Area are looking for a better life in an unlikely place. American Suburb follows this migration to one California town along the Delta, 45 miles from San Francisco. But is this once sleepy suburb ready for them?",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/American-Suburb-Podcast-Tile-703x703-1.jpg",
"officialWebsiteLink": "/news/series/american-suburb-podcast",
"meta": {
"site": "news",
"source": "kqed",
"order": 19
},
"link": "/news/series/american-suburb-podcast/",
"subscribe": {
"npr": "https://rpb3r.app.goo.gl/RBrW",
"apple": "https://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?mt=2&id=1287748328",
"tuneIn": "https://tunein.com/radio/American-Suburb-p1086805/",
"rss": "https://ww2.kqed.org/news/series/american-suburb-podcast/feed/podcast",
"google": "https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5tZWdhcGhvbmUuZm0vS1FJTkMzMDExODgxNjA5"
}
},
"baycurious": {
"id": "baycurious",
"title": "Bay Curious",
"tagline": "Exploring the Bay Area, one question at a time",
"info": "KQED’s new podcast, Bay Curious, gets to the bottom of the mysteries — both profound and peculiar — that give the Bay Area its unique identity. And we’ll do it with your help! You ask the questions. You decide what Bay Curious investigates. And you join us on the journey to find the answers.",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Bay-Curious-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED Bay Curious",
"officialWebsiteLink": "/news/series/baycurious",
"meta": {
"site": "news",
"source": "kqed",
"order": 3
},
"link": "/podcasts/baycurious",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/bay-curious/id1172473406",
"npr": "https://www.npr.org/podcasts/500557090/bay-curious",
"rss": "https://ww2.kqed.org/news/category/bay-curious-podcast/feed/podcast",
"amazon": "https://music.amazon.com/podcasts/9a90d476-aa04-455d-9a4c-0871ed6216d4/bay-curious",
"stitcher": "https://www.stitcher.com/podcast/kqed/bay-curious",
"spotify": "https://open.spotify.com/show/6O76IdmhixfijmhTZLIJ8k"
}
},
"bbc-world-service": {
"id": "bbc-world-service",
"title": "BBC World Service",
"info": "The day's top stories from BBC News compiled twice daily in the week, once at weekends.",
"airtime": "MON-FRI 9pm-10pm, TUE-FRI 1am-2am",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/BBC-World-Service-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.bbc.co.uk/sounds/play/live:bbc_world_service",
"meta": {
"site": "news",
"source": "BBC World Service"
},
"link": "/radio/program/bbc-world-service",
"subscribe": {
"apple": "https://itunes.apple.com/us/podcast/global-news-podcast/id135067274?mt=2",
"tuneIn": "https://tunein.com/radio/BBC-World-Service-p455581/",
"rss": "https://podcasts.files.bbci.co.uk/p02nq0gn.rss"
}
},
"californiareport": {
"id": "californiareport",
"title": "The California Report",
"tagline": "California, day by day",
"info": "KQED’s statewide radio news program providing daily coverage of issues, trends and public policy decisions.",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/The-California-Report-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED The California Report",
"officialWebsiteLink": "/californiareport",
"meta": {
"site": "news",
"source": "kqed",
"order": 8
},
"link": "/californiareport",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/kqeds-the-california-report/id79681292",
"amazon": "https://music.amazon.com/podcasts/26099305-72af-4542-9dde-ac1807fe36d5/kqed-s-the-california-report",
"npr": "https://www.npr.org/podcasts/432285393/the-california-report",
"stitcher": "https://www.stitcher.com/podcast/kqedfm-kqeds-the-california-report-podcast-8838",
"rss": "https://ww2.kqed.org/news/tag/tcram/feed/podcast"
}
},
"californiareportmagazine": {
"id": "californiareportmagazine",
"title": "The California Report Magazine",
"tagline": "Your state, your stories",
"info": "Every week, The California Report Magazine takes you on a road trip for the ears: to visit the places and meet the people who make California unique. The in-depth storytelling podcast from the California Report.",
"airtime": "FRI 4:30pm-5pm, 6:30pm-7pm, 11pm-11:30pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/The-California-Report-Magazine-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED The California Report Magazine",
"officialWebsiteLink": "/californiareportmagazine",
"meta": {
"site": "news",
"source": "kqed",
"order": 10
},
"link": "/californiareportmagazine",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/the-california-report-magazine/id1314750545",
"google": "https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5tZWdhcGhvbmUuZm0vS1FJTkM3NjkwNjk1OTAz",
"npr": "https://www.npr.org/podcasts/564733126/the-california-report-magazine",
"stitcher": "https://www.stitcher.com/podcast/kqed/the-california-report-magazine",
"rss": "https://ww2.kqed.org/news/tag/tcrmag/feed/podcast"
}
},
"city-arts": {
"id": "city-arts",
"title": "City Arts & Lectures",
"info": "A one-hour radio program to hear celebrated writers, artists and thinkers address contemporary ideas and values, often discussing the creative process. Please note: tapes or transcripts are not available",
"imageSrc": "https://ww2.kqed.org/radio/wp-content/uploads/sites/50/2018/05/cityartsandlecture-300x300.jpg",
"officialWebsiteLink": "https://www.cityarts.net/",
"airtime": "SUN 1pm-2pm, TUE 10pm, WED 1am",
"meta": {
"site": "news",
"source": "City Arts & Lectures"
},
"link": "https://www.cityarts.net",
"subscribe": {
"tuneIn": "https://tunein.com/radio/City-Arts-and-Lectures-p692/",
"rss": "https://www.cityarts.net/feed/"
}
},
"closealltabs": {
"id": "closealltabs",
"title": "Close All Tabs",
"tagline": "Your irreverent guide to the trends redefining our world",
"info": "Close All Tabs breaks down how digital culture shapes our world through thoughtful insights and irreverent humor.",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2025/02/CAT_2_Tile-scaled.jpg",
"imageAlt": "KQED Close All Tabs",
"officialWebsiteLink": "/podcasts/closealltabs",
"meta": {
"site": "news",
"source": "kqed",
"order": 1
},
"link": "/podcasts/closealltabs",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/close-all-tabs/id214663465",
"rss": "https://feeds.megaphone.fm/KQINC6993880386",
"amazon": "https://music.amazon.com/podcasts/92d9d4ac-67a3-4eed-b10a-fb45d45b1ef2/close-all-tabs",
"spotify": "https://open.spotify.com/show/6LAJFHnGK1pYXYzv6SIol6?si=deb0cae19813417c"
}
},
"code-switch-life-kit": {
"id": "code-switch-life-kit",
"title": "Code Switch / Life Kit",
"info": "\u003cem>Code Switch\u003c/em>, which listeners will hear in the first part of the hour, has fearless and much-needed conversations about race. Hosted by journalists of color, the show tackles the subject of race head-on, exploring how it impacts every part of society — from politics and pop culture to history, sports and more.\u003cbr />\u003cbr />\u003cem>Life Kit\u003c/em>, which will be in the second part of the hour, guides you through spaces and feelings no one prepares you for — from finances to mental health, from workplace microaggressions to imposter syndrome, from relationships to parenting. The show features experts with real world experience and shares their knowledge. Because everyone needs a little help being human.\u003cbr />\u003cbr />\u003ca href=\"https://www.npr.org/podcasts/510312/codeswitch\">\u003cem>Code Switch\u003c/em> offical site and podcast\u003c/a>\u003cbr />\u003ca href=\"https://www.npr.org/lifekit\">\u003cem>Life Kit\u003c/em> offical site and podcast\u003c/a>\u003cbr />",
"airtime": "SUN 9pm-10pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Code-Switch-Life-Kit-Podcast-Tile-360x360-1.jpg",
"meta": {
"site": "radio",
"source": "npr"
},
"link": "/radio/program/code-switch-life-kit",
"subscribe": {
"apple": "https://podcasts.apple.com/podcast/1112190608?mt=2&at=11l79Y&ct=nprdirectory",
"google": "https://podcasts.google.com/feed/aHR0cHM6Ly93d3cubnByLm9yZy9yc3MvcG9kY2FzdC5waHA_aWQ9NTEwMzEy",
"spotify": "https://open.spotify.com/show/3bExJ9JQpkwNhoHvaIIuyV",
"rss": "https://feeds.npr.org/510312/podcast.xml"
}
},
"commonwealth-club": {
"id": "commonwealth-club",
"title": "Commonwealth Club of California Podcast",
"info": "The Commonwealth Club of California is the nation's oldest and largest public affairs forum. As a non-partisan forum, The Club brings to the public airwaves diverse viewpoints on important topics. The Club's weekly radio broadcast - the oldest in the U.S., dating back to 1924 - is carried across the nation on public radio stations and is now podcasting. Our website archive features audio of our recent programs, as well as selected speeches from our long and distinguished history. This podcast feed is usually updated twice a week and is always un-edited.",
"airtime": "THU 10pm, FRI 1am",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Commonwealth-Club-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.commonwealthclub.org/podcasts",
"meta": {
"site": "news",
"source": "Commonwealth Club of California"
},
"link": "/radio/program/commonwealth-club",
"subscribe": {
"apple": "https://itunes.apple.com/us/podcast/commonwealth-club-of-california-podcast/id976334034?mt=2",
"google": "https://podcasts.google.com/feed/aHR0cDovL3d3dy5jb21tb253ZWFsdGhjbHViLm9yZy9hdWRpby9wb2RjYXN0L3dlZWtseS54bWw",
"tuneIn": "https://tunein.com/radio/Commonwealth-Club-of-California-p1060/"
}
},
"forum": {
"id": "forum",
"title": "Forum",
"tagline": "The conversation starts here",
"info": "KQED’s live call-in program discussing local, state, national and international issues, as well as in-depth interviews.",
"airtime": "MON-FRI 9am-11am, 10pm-11pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Forum-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED Forum with Mina Kim and Alexis Madrigal",
"officialWebsiteLink": "/forum",
"meta": {
"site": "news",
"source": "kqed",
"order": 9
},
"link": "/forum",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/kqeds-forum/id73329719",
"google": "https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5tZWdhcGhvbmUuZm0vS1FJTkM5NTU3MzgxNjMz",
"npr": "https://www.npr.org/podcasts/432307980/forum",
"stitcher": "https://www.stitcher.com/podcast/kqedfm-kqeds-forum-podcast",
"rss": "https://feeds.megaphone.fm/KQINC9557381633"
}
},
"freakonomics-radio": {
"id": "freakonomics-radio",
"title": "Freakonomics Radio",
"info": "Freakonomics Radio is a one-hour award-winning podcast and public-radio project hosted by Stephen Dubner, with co-author Steve Levitt as a regular guest. It is produced in partnership with WNYC.",
"imageSrc": "https://ww2.kqed.org/news/wp-content/uploads/sites/10/2018/05/freakonomicsRadio.png",
"officialWebsiteLink": "http://freakonomics.com/",
"airtime": "SUN 1am-2am, SAT 3pm-4pm",
"meta": {
"site": "radio",
"source": "WNYC"
},
"link": "/radio/program/freakonomics-radio",
"subscribe": {
"npr": "https://rpb3r.app.goo.gl/4s8b",
"apple": "https://itunes.apple.com/us/podcast/freakonomics-radio/id354668519",
"tuneIn": "https://tunein.com/podcasts/WNYC-Podcasts/Freakonomics-Radio-p272293/",
"rss": "https://feeds.feedburner.com/freakonomicsradio"
}
},
"fresh-air": {
"id": "fresh-air",
"title": "Fresh Air",
"info": "Hosted by Terry Gross, \u003cem>Fresh Air from WHYY\u003c/em> is the Peabody Award-winning weekday magazine of contemporary arts and issues. One of public radio's most popular programs, Fresh Air features intimate conversations with today's biggest luminaries.",
"airtime": "MON-FRI 7pm-8pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Fresh-Air-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.npr.org/programs/fresh-air/",
"meta": {
"site": "radio",
"source": "npr"
},
"link": "/radio/program/fresh-air",
"subscribe": {
"npr": "https://rpb3r.app.goo.gl/4s8b",
"apple": "https://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?s=143441&mt=2&id=214089682&at=11l79Y&ct=nprdirectory",
"tuneIn": "https://tunein.com/radio/Fresh-Air-p17/",
"rss": "https://feeds.npr.org/381444908/podcast.xml"
}
},
"here-and-now": {
"id": "here-and-now",
"title": "Here & Now",
"info": "A live production of NPR and WBUR Boston, in collaboration with stations across the country, Here & Now reflects the fluid world of news as it's happening in the middle of the day, with timely, in-depth news, interviews and conversation. Hosted by Robin Young, Jeremy Hobson and Tonya Mosley.",
"airtime": "MON-THU 11am-12pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Here-And-Now-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "http://www.wbur.org/hereandnow",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/here-and-now",
"subsdcribe": {
"apple": "https://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?mt=2&id=426698661",
"tuneIn": "https://tunein.com/radio/Here--Now-p211/",
"rss": "https://feeds.npr.org/510051/podcast.xml"
}
},
"hidden-brain": {
"id": "hidden-brain",
"title": "Hidden Brain",
"info": "Shankar Vedantam uses science and storytelling to reveal the unconscious patterns that drive human behavior, shape our choices and direct our relationships.",
"imageSrc": "https://ww2.kqed.org/radio/wp-content/uploads/sites/50/2018/05/hiddenbrain.jpg",
"officialWebsiteLink": "https://www.npr.org/series/423302056/hidden-brain",
"airtime": "SUN 7pm-8pm",
"meta": {
"site": "news",
"source": "NPR"
},
"link": "/radio/program/hidden-brain",
"subscribe": {
"apple": "https://itunes.apple.com/us/podcast/hidden-brain/id1028908750?mt=2",
"tuneIn": "https://tunein.com/podcasts/Science-Podcasts/Hidden-Brain-p787503/",
"rss": "https://feeds.npr.org/510308/podcast.xml"
}
},
"how-i-built-this": {
"id": "how-i-built-this",
"title": "How I Built This with Guy Raz",
"info": "Guy Raz dives into the stories behind some of the world's best known companies. How I Built This weaves a narrative journey about innovators, entrepreneurs and idealists—and the movements they built.",
"imageSrc": "https://ww2.kqed.org/news/wp-content/uploads/sites/10/2018/05/howIBuiltThis.png",
"officialWebsiteLink": "https://www.npr.org/podcasts/510313/how-i-built-this",
"airtime": "SUN 7:30pm-8pm",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/how-i-built-this",
"subscribe": {
"npr": "https://rpb3r.app.goo.gl/3zxy",
"apple": "https://itunes.apple.com/us/podcast/how-i-built-this-with-guy-raz/id1150510297?mt=2",
"tuneIn": "https://tunein.com/podcasts/Arts--Culture-Podcasts/How-I-Built-This-p910896/",
"rss": "https://feeds.npr.org/510313/podcast.xml"
}
},
"hyphenacion": {
"id": "hyphenacion",
"title": "Hyphenación",
"tagline": "Where conversation and cultura meet",
"info": "What kind of no sabo word is Hyphenación? For us, it’s about living within a hyphenation. Like being a third-gen Mexican-American from the Texas border now living that Bay Area Chicano life. Like Xorje! Each week we bring together a couple of hyphenated Latinos to talk all about personal life choices: family, careers, relationships, belonging … everything is on the table. ",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2025/03/Hyphenacion_FinalAssets_PodcastTile.png",
"imageAlt": "KQED Hyphenación",
"officialWebsiteLink": "/podcasts/hyphenacion",
"meta": {
"site": "news",
"source": "kqed",
"order": 15
},
"link": "/podcasts/hyphenacion",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/hyphenaci%C3%B3n/id1191591838",
"spotify": "https://open.spotify.com/show/2p3Fifq96nw9BPcmFdIq0o?si=39209f7b25774f38",
"youtube": "https://www.youtube.com/c/kqedarts",
"amazon": "https://music.amazon.com/podcasts/6c3dd23c-93fb-4aab-97ba-1725fa6315f1/hyphenaci%C3%B3n",
"rss": "https://feeds.megaphone.fm/KQINC2275451163"
}
},
"jerrybrown": {
"id": "jerrybrown",
"title": "The Political Mind of Jerry Brown",
"tagline": "Lessons from a lifetime in politics",
"info": "The Political Mind of Jerry Brown brings listeners the wisdom of the former Governor, Mayor, and presidential candidate. Scott Shafer interviewed Brown for more than 40 hours, covering the former governor's life and half-century in the political game and Brown has some lessons he'd like to share. ",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/The-Political-Mind-of-Jerry-Brown-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED The Political Mind of Jerry Brown",
"officialWebsiteLink": "/podcasts/jerrybrown",
"meta": {
"site": "news",
"source": "kqed",
"order": 18
},
"link": "/podcasts/jerrybrown",
"subscribe": {
"npr": "https://www.npr.org/podcasts/790253322/the-political-mind-of-jerry-brown",
"apple": "https://itunes.apple.com/us/podcast/id1492194549",
"rss": "https://ww2.kqed.org/news/series/jerrybrown/feed/podcast/",
"tuneIn": "http://tun.in/pjGcK",
"stitcher": "https://www.stitcher.com/podcast/kqed/the-political-mind-of-jerry-brown",
"spotify": "https://open.spotify.com/show/54C1dmuyFyKMFttY6X2j6r?si=K8SgRCoISNK6ZbjpXrX5-w",
"amazon": "https://music.amazon.com/podcasts/44420f75-3b0e-4301-ab3b-16da6b09e543/the-political-mind-of-jerry-brown"
}
},
"latino-usa": {
"id": "latino-usa",
"title": "Latino USA",
"airtime": "MON 1am-2am, SUN 6pm-7pm",
"info": "Latino USA, the radio journal of news and culture, is the only national, English-language radio program produced from a Latino perspective.",
"imageSrc": "https://ww2.kqed.org/radio/wp-content/uploads/sites/50/2018/04/latinoUsa.jpg",
"officialWebsiteLink": "http://latinousa.org/",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/latino-usa",
"subscribe": {
"npr": "https://rpb3r.app.goo.gl/xtTd",
"apple": "https://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?s=143441&mt=2&id=79681317&at=11l79Y&ct=nprdirectory",
"tuneIn": "https://tunein.com/radio/Latino-USA-p621/",
"rss": "https://feeds.npr.org/510016/podcast.xml"
}
},
"marketplace": {
"id": "marketplace",
"title": "Marketplace",
"info": "Our flagship program, helmed by Kai Ryssdal, examines what the day in money delivered, through stories, conversations, newsworthy numbers and more. Updated Monday through Friday at about 3:30 p.m. PT.",
"airtime": "MON-FRI 4pm-4:30pm, MON-WED 6:30pm-7pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Marketplace-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.marketplace.org/",
"meta": {
"site": "news",
"source": "American Public Media"
},
"link": "/radio/program/marketplace",
"subscribe": {
"apple": "https://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?s=143441&mt=2&id=201853034&at=11l79Y&ct=nprdirectory",
"tuneIn": "https://tunein.com/radio/APM-Marketplace-p88/",
"rss": "https://feeds.publicradio.org/public_feeds/marketplace-pm/rss/rss"
}
},
"masters-of-scale": {
"id": "masters-of-scale",
"title": "Masters of Scale",
"info": "Masters of Scale is an original podcast in which LinkedIn co-founder and Greylock Partner Reid Hoffman sets out to describe and prove theories that explain how great entrepreneurs take their companies from zero to a gazillion in ingenious fashion.",
"airtime": "Every other Wednesday June 12 through October 16 at 8pm (repeats Thursdays at 2am)",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Masters-of-Scale-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://mastersofscale.com/",
"meta": {
"site": "radio",
"source": "WaitWhat"
},
"link": "/radio/program/masters-of-scale",
"subscribe": {
"apple": "http://mastersofscale.app.link/",
"rss": "https://rss.art19.com/masters-of-scale"
}
},
"mindshift": {
"id": "mindshift",
"title": "MindShift",
"tagline": "A podcast about the future of learning and how we raise our kids",
"info": "The MindShift podcast explores the innovations in education that are shaping how kids learn. Hosts Ki Sung and Katrina Schwartz introduce listeners to educators, researchers, parents and students who are developing effective ways to improve how kids learn. We cover topics like how fed-up administrators are developing surprising tactics to deal with classroom disruptions; how listening to podcasts are helping kids develop reading skills; the consequences of overparenting; and why interdisciplinary learning can engage students on all ends of the traditional achievement spectrum. This podcast is part of the MindShift education site, a division of KQED News. KQED is an NPR/PBS member station based in San Francisco. You can also visit the MindShift website for episodes and supplemental blog posts or tweet us \u003ca href=\"https://twitter.com/MindShiftKQED\">@MindShiftKQED\u003c/a> or visit us at \u003ca href=\"/mindshift\">MindShift.KQED.org\u003c/a>",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Mindshift-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED MindShift: How We Will Learn",
"officialWebsiteLink": "/mindshift/",
"meta": {
"site": "news",
"source": "kqed",
"order": 12
},
"link": "/podcasts/mindshift",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/mindshift-podcast/id1078765985",
"google": "https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5tZWdhcGhvbmUuZm0vS1FJTkM1NzY0NjAwNDI5",
"npr": "https://www.npr.org/podcasts/464615685/mind-shift-podcast",
"stitcher": "https://www.stitcher.com/podcast/kqed/stories-teachers-share",
"spotify": "https://open.spotify.com/show/0MxSpNYZKNprFLCl7eEtyx"
}
},
"morning-edition": {
"id": "morning-edition",
"title": "Morning Edition",
"info": "\u003cem>Morning Edition\u003c/em> takes listeners around the country and the world with multi-faceted stories and commentaries every weekday. Hosts Steve Inskeep, David Greene and Rachel Martin bring you the latest breaking news and features to prepare you for the day.",
"airtime": "MON-FRI 3am-9am",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Morning-Edition-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.npr.org/programs/morning-edition/",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/morning-edition"
},
"onourwatch": {
"id": "onourwatch",
"title": "On Our Watch",
"tagline": "Deeply-reported investigative journalism",
"info": "For decades, the process for how police police themselves has been inconsistent – if not opaque. In some states, like California, these proceedings were completely hidden. After a new police transparency law unsealed scores of internal affairs files, our reporters set out to examine these cases and the shadow world of police discipline. On Our Watch brings listeners into the rooms where officers are questioned and witnesses are interrogated to find out who this system is really protecting. Is it the officers, or the public they've sworn to serve?",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/On-Our-Watch-Podcast-Tile-703x703-1.jpg",
"imageAlt": "On Our Watch from NPR and KQED",
"officialWebsiteLink": "/podcasts/onourwatch",
"meta": {
"site": "news",
"source": "kqed",
"order": 11
},
"link": "/podcasts/onourwatch",
"subscribe": {
"apple": "https://podcasts.apple.com/podcast/id1567098962",
"google": "https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5ucHIub3JnLzUxMDM2MC9wb2RjYXN0LnhtbD9zYz1nb29nbGVwb2RjYXN0cw",
"npr": "https://rpb3r.app.goo.gl/onourwatch",
"spotify": "https://open.spotify.com/show/0OLWoyizopu6tY1XiuX70x",
"tuneIn": "https://tunein.com/radio/On-Our-Watch-p1436229/",
"stitcher": "https://www.stitcher.com/show/on-our-watch",
"rss": "https://feeds.npr.org/510360/podcast.xml"
}
},
"on-the-media": {
"id": "on-the-media",
"title": "On The Media",
"info": "Our weekly podcast explores how the media 'sausage' is made, casts an incisive eye on fluctuations in the marketplace of ideas, and examines threats to the freedom of information and expression in America and abroad. For one hour a week, the show tries to lift the veil from the process of \"making media,\" especially news media, because it's through that lens that we see the world and the world sees us",
"airtime": "SUN 2pm-3pm, MON 12am-1am",
"imageSrc": "https://ww2.kqed.org/radio/wp-content/uploads/sites/50/2018/04/onTheMedia.png",
"officialWebsiteLink": "https://www.wnycstudios.org/shows/otm",
"meta": {
"site": "news",
"source": "wnyc"
},
"link": "/radio/program/on-the-media",
"subscribe": {
"apple": "https://itunes.apple.com/us/podcast/on-the-media/id73330715?mt=2",
"tuneIn": "https://tunein.com/radio/On-the-Media-p69/",
"rss": "http://feeds.wnyc.org/onthemedia"
}
},
"pbs-newshour": {
"id": "pbs-newshour",
"title": "PBS NewsHour",
"info": "Analysis, background reports and updates from the PBS NewsHour putting today's news in context.",
"airtime": "MON-FRI 3pm-4pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/PBS-News-Hour-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.pbs.org/newshour/",
"meta": {
"site": "news",
"source": "pbs"
},
"link": "/radio/program/pbs-newshour",
"subscribe": {
"apple": "https://itunes.apple.com/us/podcast/pbs-newshour-full-show/id394432287?mt=2",
"tuneIn": "https://tunein.com/radio/PBS-NewsHour---Full-Show-p425698/",
"rss": "https://www.pbs.org/newshour/feeds/rss/podcasts/show"
}
},
"perspectives": {
"id": "perspectives",
"title": "Perspectives",
"tagline": "KQED's series of daily listener commentaries since 1991",
"info": "KQED's series of daily listener commentaries since 1991.",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2025/01/Perspectives_Tile_Final.jpg",
"imageAlt": "KQED Perspectives",
"officialWebsiteLink": "/perspectives/",
"meta": {
"site": "radio",
"source": "kqed",
"order": 14
},
"link": "/perspectives",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/id73801135",
"npr": "https://www.npr.org/podcasts/432309616/perspectives",
"rss": "https://ww2.kqed.org/perspectives/category/perspectives/feed/",
"google": "https://podcasts.google.com/feed/aHR0cHM6Ly93dzIua3FlZC5vcmcvcGVyc3BlY3RpdmVzL2NhdGVnb3J5L3BlcnNwZWN0aXZlcy9mZWVkLw"
}
},
"planet-money": {
"id": "planet-money",
"title": "Planet Money",
"info": "The economy explained. Imagine you could call up a friend and say, Meet me at the bar and tell me what's going on with the economy. Now imagine that's actually a fun evening.",
"airtime": "SUN 3pm-4pm",
"imageSrc": "https://ww2.kqed.org/radio/wp-content/uploads/sites/50/2018/04/planetmoney.jpg",
"officialWebsiteLink": "https://www.npr.org/sections/money/",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/planet-money",
"subscribe": {
"npr": "https://rpb3r.app.goo.gl/M4f5",
"apple": "https://itunes.apple.com/us/podcast/planet-money/id290783428?mt=2",
"tuneIn": "https://tunein.com/podcasts/Business--Economics-Podcasts/Planet-Money-p164680/",
"rss": "https://feeds.npr.org/510289/podcast.xml"
}
},
"politicalbreakdown": {
"id": "politicalbreakdown",
"title": "Political Breakdown",
"tagline": "Politics from a personal perspective",
"info": "Political Breakdown is a new series that explores the political intersection of California and the nation. Each week hosts Scott Shafer and Marisa Lagos are joined with a new special guest to unpack politics -- with personality — and offer an insider’s glimpse at how politics happens.",
"airtime": "THU 6:30pm-7pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Political-Breakdown-2024-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED Political Breakdown",
"officialWebsiteLink": "/podcasts/politicalbreakdown",
"meta": {
"site": "radio",
"source": "kqed",
"order": 5
},
"link": "/podcasts/politicalbreakdown",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/political-breakdown/id1327641087",
"amazon": "https://music.amazon.com/podcasts/e0c2d153-ad36-4c8d-901d-f1da6a724824/political-breakdown",
"npr": "https://www.npr.org/podcasts/572155894/political-breakdown",
"stitcher": "https://www.stitcher.com/podcast/kqed/political-breakdown",
"spotify": "https://open.spotify.com/show/07RVyIjIdk2WDuVehvBMoN",
"rss": "https://ww2.kqed.org/news/tag/political-breakdown/feed/podcast"
}
},
"possible": {
"id": "possible",
"title": "Possible",
"info": "Possible is hosted by entrepreneur Reid Hoffman and writer Aria Finger. Together in Possible, Hoffman and Finger lead enlightening discussions about building a brighter collective future. The show features interviews with visionary guests like Trevor Noah, Sam Altman and Janette Sadik-Khan. Possible paints an optimistic portrait of the world we can create through science, policy, business, art and our shared humanity. It asks: What if everything goes right for once? How can we get there? Each episode also includes a short fiction story generated by advanced AI GPT-4, serving as a thought-provoking springboard to speculate how humanity could leverage technology for good.",
"airtime": "SUN 2pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Possible-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.possible.fm/",
"meta": {
"site": "news",
"source": "Possible"
},
"link": "/radio/program/possible",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/possible/id1677184070",
"spotify": "https://open.spotify.com/show/730YpdUSNlMyPQwNnyjp4k"
}
},
"pri-the-world": {
"id": "pri-the-world",
"title": "PRI's The World: Latest Edition",
"info": "Each weekday, host Marco Werman and his team of producers bring you the world's most interesting stories in an hour of radio that reminds us just how small our planet really is.",
"airtime": "MON-FRI 2pm-3pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/The-World-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.pri.org/programs/the-world",
"meta": {
"site": "news",
"source": "PRI"
},
"link": "/radio/program/pri-the-world",
"subscribe": {
"apple": "https://itunes.apple.com/us/podcast/pris-the-world-latest-edition/id278196007?mt=2",
"tuneIn": "https://tunein.com/podcasts/News--Politics-Podcasts/PRIs-The-World-p24/",
"rss": "http://feeds.feedburner.com/pri/theworld"
}
},
"radiolab": {
"id": "radiolab",
"title": "Radiolab",
"info": "A two-time Peabody Award-winner, Radiolab is an investigation told through sounds and stories, and centered around one big idea. In the Radiolab world, information sounds like music and science and culture collide. Hosted by Jad Abumrad and Robert Krulwich, the show is designed for listeners who demand skepticism, but appreciate wonder. WNYC Studios is the producer of other leading podcasts including Freakonomics Radio, Death, Sex & Money, On the Media and many more.",
"airtime": "SUN 12am-1am, SAT 2pm-3pm",
"imageSrc": "https://ww2.kqed.org/radio/wp-content/uploads/sites/50/2018/04/radiolab1400.png",
"officialWebsiteLink": "https://www.wnycstudios.org/shows/radiolab/",
"meta": {
"site": "science",
"source": "WNYC"
},
"link": "/radio/program/radiolab",
"subscribe": {
"apple": "https://itunes.apple.com/us/podcast/radiolab/id152249110?mt=2",
"tuneIn": "https://tunein.com/radio/RadioLab-p68032/",
"rss": "https://feeds.wnyc.org/radiolab"
}
},
"reveal": {
"id": "reveal",
"title": "Reveal",
"info": "Created by The Center for Investigative Reporting and PRX, Reveal is public radios first one-hour weekly radio show and podcast dedicated to investigative reporting. Credible, fact based and without a partisan agenda, Reveal combines the power and artistry of driveway moment storytelling with data-rich reporting on critically important issues. The result is stories that inform and inspire, arming our listeners with information to right injustices, hold the powerful accountable and improve lives.Reveal is hosted by Al Letson and showcases the award-winning work of CIR and newsrooms large and small across the nation. In a radio and podcast market crowded with choices, Reveal focuses on important and often surprising stories that illuminate the world for our listeners.",
"airtime": "SAT 4pm-5pm",
"imageSrc": "https://ww2.kqed.org/radio/wp-content/uploads/sites/50/2018/04/reveal300px.png",
"officialWebsiteLink": "https://www.revealnews.org/episodes/",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/reveal",
"subscribe": {
"apple": "https://itunes.apple.com/us/podcast/reveal/id886009669",
"tuneIn": "https://tunein.com/radio/Reveal-p679597/",
"rss": "http://feeds.revealradio.org/revealpodcast"
}
},
"rightnowish": {
"id": "rightnowish",
"title": "Rightnowish",
"tagline": "Art is where you find it",
"info": "Rightnowish digs into life in the Bay Area right now… ish. Journalist Pendarvis Harshaw takes us to galleries painted on the sides of liquor stores in West Oakland. We'll dance in warehouses in the Bayview, make smoothies with kids in South Berkeley, and listen to classical music in a 1984 Cutlass Supreme in Richmond. Every week, Pen talks to movers and shakers about how the Bay Area shapes what they create, and how they shape the place we call home.",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Rightnowish-Podcast-Tile-500x500-1.jpg",
"imageAlt": "KQED Rightnowish with Pendarvis Harshaw",
"officialWebsiteLink": "/podcasts/rightnowish",
"meta": {
"site": "arts",
"source": "kqed",
"order": 16
},
"link": "/podcasts/rightnowish",
"subscribe": {
"npr": "https://www.npr.org/podcasts/721590300/rightnowish",
"rss": "https://ww2.kqed.org/arts/programs/rightnowish/feed/podcast",
"apple": "https://podcasts.apple.com/us/podcast/rightnowish/id1482187648",
"stitcher": "https://www.stitcher.com/podcast/kqed/rightnowish",
"google": "https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5tZWdhcGhvbmUuZm0vS1FJTkMxMjU5MTY3NDc4",
"spotify": "https://open.spotify.com/show/7kEJuafTzTVan7B78ttz1I"
}
},
"science-friday": {
"id": "science-friday",
"title": "Science Friday",
"info": "Science Friday is a weekly science talk show, broadcast live over public radio stations nationwide. Each week, the show focuses on science topics that are in the news and tries to bring an educated, balanced discussion to bear on the scientific issues at hand. Panels of expert guests join host Ira Flatow, a veteran science journalist, to discuss science and to take questions from listeners during the call-in portion of the program.",
"airtime": "FRI 11am-1pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Science-Friday-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.wnycstudios.org/shows/science-friday",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/science-friday",
"subscribe": {
"apple": "https://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?s=143441&mt=2&id=73329284&at=11l79Y&ct=nprdirectory",
"tuneIn": "https://tunein.com/radio/Science-Friday-p394/",
"rss": "http://feeds.wnyc.org/science-friday"
}
},
"snap-judgment": {
"id": "snap-judgment",
"title": "Snap Judgment",
"tagline": "Real stories with killer beats",
"info": "The Snap Judgment radio show and podcast mixes real stories with killer beats to produce cinematic, dramatic radio. Snap's musical brand of storytelling dares listeners to see the world through the eyes of another. This is storytelling... with a BEAT!! Snap first aired on public radio stations nationwide in July 2010. Today, Snap Judgment airs on over 450 public radio stations and is brought to the airwaves by KQED & PRX.",
"airtime": "SAT 1pm-2pm, 9pm-10pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/05/Snap-Judgment-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED Snap Judgment",
"officialWebsiteLink": "https://snapjudgment.org",
"meta": {
"site": "arts",
"source": "kqed",
"order": 4
},
"link": "https://snapjudgment.org",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/snap-judgment/id283657561",
"npr": "https://www.npr.org/podcasts/449018144/snap-judgment",
"stitcher": "https://www.pandora.com/podcast/snap-judgment/PC:241?source=stitcher-sunset",
"spotify": "https://open.spotify.com/show/3Cct7ZWmxHNAtLgBTqjC5v",
"rss": "https://snap.feed.snapjudgment.org/"
}
},
"soldout": {
"id": "soldout",
"title": "SOLD OUT: Rethinking Housing in America",
"tagline": "A new future for housing",
"info": "Sold Out: Rethinking Housing in America",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Sold-Out-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED Sold Out: Rethinking Housing in America",
"officialWebsiteLink": "/podcasts/soldout",
"meta": {
"site": "news",
"source": "kqed",
"order": 13
},
"link": "/podcasts/soldout",
"subscribe": {
"npr": "https://www.npr.org/podcasts/911586047/s-o-l-d-o-u-t-a-new-future-for-housing",
"apple": "https://podcasts.apple.com/us/podcast/introducing-sold-out-rethinking-housing-in-america/id1531354937",
"rss": "https://feeds.megaphone.fm/soldout",
"spotify": "https://open.spotify.com/show/38dTBSk2ISFoPiyYNoKn1X",
"stitcher": "https://www.stitcher.com/podcast/kqed/sold-out-rethinking-housing-in-america",
"tunein": "https://tunein.com/radio/SOLD-OUT-Rethinking-Housing-in-America-p1365871/"
}
},
"spooked": {
"id": "spooked",
"title": "Spooked",
"tagline": "True-life supernatural stories",
"info": "",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/10/Spooked-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED Spooked",
"officialWebsiteLink": "https://spookedpodcast.org/",
"meta": {
"site": "news",
"source": "kqed",
"order": 7
},
"link": "https://spookedpodcast.org/",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/spooked/id1279361017",
"npr": "https://www.npr.org/podcasts/549547848/snap-judgment-presents-spooked",
"spotify": "https://open.spotify.com/show/76571Rfl3m7PLJQZKQIGCT",
"rss": "https://feeds.simplecast.com/TBotaapn"
}
},
"tech-nation": {
"id": "tech-nation",
"title": "Tech Nation Radio Podcast",
"info": "Tech Nation is a weekly public radio program, hosted by Dr. Moira Gunn. Founded in 1993, it has grown from a simple interview show to a multi-faceted production, featuring conversations with noted technology and science leaders, and a weekly science and technology-related commentary.",
"airtime": "FRI 10pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Tech-Nation-Radio-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "http://technation.podomatic.com/",
"meta": {
"site": "science",
"source": "Tech Nation Media"
},
"link": "/radio/program/tech-nation",
"subscribe": {
"rss": "https://technation.podomatic.com/rss2.xml"
}
},
"ted-radio-hour": {
"id": "ted-radio-hour",
"title": "TED Radio Hour",
"info": "The TED Radio Hour is a journey through fascinating ideas, astonishing inventions, fresh approaches to old problems, and new ways to think and create.",
"airtime": "SUN 3pm-4pm, SAT 10pm-11pm",
"imageSrc": "https://ww2.kqed.org/radio/wp-content/uploads/sites/50/2018/04/tedRadioHour.jpg",
"officialWebsiteLink": "https://www.npr.org/programs/ted-radio-hour/?showDate=2018-06-22",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/ted-radio-hour",
"subscribe": {
"npr": "https://rpb3r.app.goo.gl/8vsS",
"apple": "https://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?s=143441&mt=2&id=523121474&at=11l79Y&ct=nprdirectory",
"tuneIn": "https://tunein.com/radio/TED-Radio-Hour-p418021/",
"rss": "https://feeds.npr.org/510298/podcast.xml"
}
},
"thebay": {
"id": "thebay",
"title": "The Bay",
"tagline": "Local news to keep you rooted",
"info": "Host Devin Katayama walks you through the biggest story of the day with reporters and newsmakers.",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/The-Bay-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED The Bay",
"officialWebsiteLink": "/podcasts/thebay",
"meta": {
"site": "radio",
"source": "kqed",
"order": 2
},
"link": "/podcasts/thebay",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/the-bay/id1350043452",
"amazon": "https://music.amazon.com/podcasts/d800ea4c-7a2c-42f2-b861-edaf78a5db0b/the-bay",
"npr": "https://www.npr.org/podcasts/586725995/the-bay",
"stitcher": "https://www.stitcher.com/podcast/kqed/the-bay",
"spotify": "https://open.spotify.com/show/4BIKBKIujizLHlIlBNaAqQ",
"rss": "https://feeds.megaphone.fm/KQINC8259786327"
}
},
"thelatest": {
"id": "thelatest",
"title": "The Latest",
"tagline": "Trusted local news in real time",
"info": "",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2025/05/The-Latest-2025-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED The Latest",
"officialWebsiteLink": "/thelatest",
"meta": {
"site": "news",
"source": "kqed",
"order": 6
},
"link": "/thelatest",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/the-latest-from-kqed/id1197721799",
"npr": "https://www.npr.org/podcasts/1257949365/the-latest-from-k-q-e-d",
"spotify": "https://open.spotify.com/show/5KIIXMgM9GTi5AepwOYvIZ?si=bd3053fec7244dba",
"rss": "https://feeds.megaphone.fm/KQINC9137121918"
}
},
"theleap": {
"id": "theleap",
"title": "The Leap",
"tagline": "What if you closed your eyes, and jumped?",
"info": "Stories about people making dramatic, risky changes, told by award-winning public radio reporter Judy Campbell.",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/The-Leap-Podcast-Tile-703x703-1.jpg",
"imageAlt": "KQED The Leap",
"officialWebsiteLink": "/podcasts/theleap",
"meta": {
"site": "news",
"source": "kqed",
"order": 17
},
"link": "/podcasts/theleap",
"subscribe": {
"apple": "https://podcasts.apple.com/us/podcast/the-leap/id1046668171",
"npr": "https://www.npr.org/podcasts/447248267/the-leap",
"stitcher": "https://www.stitcher.com/podcast/kqed/the-leap",
"spotify": "https://open.spotify.com/show/3sSlVHHzU0ytLwuGs1SD1U",
"rss": "https://ww2.kqed.org/news/programs/the-leap/feed/podcast"
}
},
"the-moth-radio-hour": {
"id": "the-moth-radio-hour",
"title": "The Moth Radio Hour",
"info": "Since its launch in 1997, The Moth has presented thousands of true stories, told live and without notes, to standing-room-only crowds worldwide. Moth storytellers stand alone, under a spotlight, with only a microphone and a roomful of strangers. The storyteller and the audience embark on a high-wire act of shared experience which is both terrifying and exhilarating. Since 2008, The Moth podcast has featured many of our favorite stories told live on Moth stages around the country. For information on all of our programs and live events, visit themoth.org.",
"airtime": "SAT 8pm-9pm and SUN 11am-12pm",
"imageSrc": "https://ww2.kqed.org/radio/wp-content/uploads/sites/50/2018/04/theMoth.jpg",
"officialWebsiteLink": "https://themoth.org/",
"meta": {
"site": "arts",
"source": "prx"
},
"link": "/radio/program/the-moth-radio-hour",
"subscribe": {
"apple": "https://itunes.apple.com/us/podcast/the-moth-podcast/id275699983?mt=2",
"tuneIn": "https://tunein.com/radio/The-Moth-p273888/",
"rss": "http://feeds.themoth.org/themothpodcast"
}
},
"the-new-yorker-radio-hour": {
"id": "the-new-yorker-radio-hour",
"title": "The New Yorker Radio Hour",
"info": "The New Yorker Radio Hour is a weekly program presented by the magazine's editor, David Remnick, and produced by WNYC Studios and The New Yorker. Each episode features a diverse mix of interviews, profiles, storytelling, and an occasional burst of humor inspired by the magazine, and shaped by its writers, artists, and editors. This isn't a radio version of a magazine, but something all its own, reflecting the rich possibilities of audio storytelling and conversation. Theme music for the show was composed and performed by Merrill Garbus of tUnE-YArDs.",
"airtime": "SAT 10am-11am",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/The-New-Yorker-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.wnycstudios.org/shows/tnyradiohour",
"meta": {
"site": "arts",
"source": "WNYC"
},
"link": "/radio/program/the-new-yorker-radio-hour",
"subscribe": {
"apple": "https://itunes.apple.com/us/podcast/id1050430296",
"tuneIn": "https://tunein.com/podcasts/WNYC-Podcasts/New-Yorker-Radio-Hour-p803804/",
"rss": "https://feeds.feedburner.com/newyorkerradiohour"
}
},
"the-sam-sanders-show": {
"id": "the-sam-sanders-show",
"title": "The Sam Sanders Show",
"info": "One of public radio's most dynamic voices, Sam Sanders helped launch The NPR Politics Podcast and hosted NPR's hit show It's Been A Minute. Now, the award-winning host returns with something brand new, The Sam Sanders Show. Every week, Sam Sanders and friends dig into the culture that shapes our lives: what's driving the biggest trends, how artists really think, and even the memes you can't stop scrolling past. Sam is beloved for his way of unpacking the world and bringing you up close to fresh currents and engaging conversations. The Sam Sanders Show is smart, funny and always a good time.",
"airtime": "FRI 12-1pm AND SAT 11am-12pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2025/11/The-Sam-Sanders-Show-Podcast-Tile-400x400-1.jpg",
"officialWebsiteLink": "https://www.kcrw.com/shows/the-sam-sanders-show/latest",
"meta": {
"site": "arts",
"source": "KCRW"
},
"link": "https://www.kcrw.com/shows/the-sam-sanders-show/latest",
"subscribe": {
"rss": "https://feed.cdnstream1.com/zjb/feed/download/ac/28/59/ac28594c-e1d0-4231-8728-61865cdc80e8.xml"
}
},
"the-splendid-table": {
"id": "the-splendid-table",
"title": "The Splendid Table",
"info": "\u003cem>The Splendid Table\u003c/em> hosts our nation's conversations about cooking, sustainability and food culture.",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/The-Splendid-Table-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.splendidtable.org/",
"airtime": "SUN 10-11 pm",
"meta": {
"site": "radio",
"source": "npr"
},
"link": "/radio/program/the-splendid-table"
},
"this-american-life": {
"id": "this-american-life",
"title": "This American Life",
"info": "This American Life is a weekly public radio show, heard by 2.2 million people on more than 500 stations. Another 2.5 million people download the weekly podcast. It is hosted by Ira Glass, produced in collaboration with Chicago Public Media, delivered to stations by PRX The Public Radio Exchange, and has won all of the major broadcasting awards.",
"airtime": "SAT 12pm-1pm, 7pm-8pm",
"imageSrc": "https://ww2.kqed.org/radio/wp-content/uploads/sites/50/2018/04/thisAmericanLife.png",
"officialWebsiteLink": "https://www.thisamericanlife.org/",
"meta": {
"site": "news",
"source": "wbez"
},
"link": "/radio/program/this-american-life",
"subscribe": {
"apple": "https://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?s=143441&mt=2&id=201671138&at=11l79Y&ct=nprdirectory",
"rss": "https://www.thisamericanlife.org/podcast/rss.xml"
}
},
"tinydeskradio": {
"id": "tinydeskradio",
"title": "Tiny Desk Radio",
"info": "We're bringing the best of Tiny Desk to the airwaves, only on public radio.",
"airtime": "SUN 8pm and SAT 9pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2025/04/300x300-For-Member-Station-Logo-Tiny-Desk-Radio-@2x.png",
"officialWebsiteLink": "https://www.npr.org/series/g-s1-52030/tiny-desk-radio",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/tinydeskradio",
"subscribe": {
"rss": "https://feeds.npr.org/g-s1-52030/rss.xml"
}
},
"wait-wait-dont-tell-me": {
"id": "wait-wait-dont-tell-me",
"title": "Wait Wait... Don't Tell Me!",
"info": "Peter Sagal and Bill Kurtis host the weekly NPR News quiz show alongside some of the best and brightest news and entertainment personalities.",
"airtime": "SUN 10am-11am, SAT 11am-12pm, SAT 6pm-7pm",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Wait-Wait-Podcast-Tile-300x300-1.jpg",
"officialWebsiteLink": "https://www.npr.org/programs/wait-wait-dont-tell-me/",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/wait-wait-dont-tell-me",
"subscribe": {
"npr": "https://rpb3r.app.goo.gl/Xogv",
"apple": "https://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?s=143441&mt=2&id=121493804&at=11l79Y&ct=nprdirectory",
"tuneIn": "https://tunein.com/radio/Wait-Wait-Dont-Tell-Me-p46/",
"rss": "https://feeds.npr.org/344098539/podcast.xml"
}
},
"weekend-edition-saturday": {
"id": "weekend-edition-saturday",
"title": "Weekend Edition Saturday",
"info": "Weekend Edition Saturday wraps up the week's news and offers a mix of analysis and features on a wide range of topics, including arts, sports, entertainment, and human interest stories. The two-hour program is hosted by NPR's Peabody Award-winning Scott Simon.",
"airtime": "SAT 5am-10am",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Weekend-Edition-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.npr.org/programs/weekend-edition-saturday/",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/weekend-edition-saturday"
},
"weekend-edition-sunday": {
"id": "weekend-edition-sunday",
"title": "Weekend Edition Sunday",
"info": "Weekend Edition Sunday features interviews with newsmakers, artists, scientists, politicians, musicians, writers, theologians and historians. The program has covered news events from Nelson Mandela's 1990 release from a South African prison to the capture of Saddam Hussein.",
"airtime": "SUN 5am-10am",
"imageSrc": "https://cdn.kqed.org/wp-content/uploads/2024/04/Weekend-Edition-Podcast-Tile-360x360-1.jpg",
"officialWebsiteLink": "https://www.npr.org/programs/weekend-edition-sunday/",
"meta": {
"site": "news",
"source": "npr"
},
"link": "/radio/program/weekend-edition-sunday"
}
},
"racesReducer": {},
"racesGenElectionReducer": {},
"racesGenElection2026Reducer": {},
"racesGeneralEl2026Reducer": {},
"radioSchedulesReducer": {},
"listsReducer": {
"posts/futureofyou?tag=theranos": {
"isFetching": false,
"latestQuery": {
"from": 12,
"size": 12
},
"vitalsOnly": false,
"totalRequested": 12,
"isLoading": false,
"isLoadingMore": true,
"total": {
"value": 41,
"relation": "eq"
},
"items": [
"futureofyou_257644",
"futureofyou_240541",
"futureofyou_234211",
"futureofyou_231240",
"futureofyou_216744",
"futureofyou_210797",
"futureofyou_206905",
"futureofyou_199691",
"futureofyou_190748",
"futureofyou_182744",
"futureofyou_157362",
"futureofyou_166491"
],
"complete": true
}
},
"recallGuideReducer": {
"intros": {},
"policy": {},
"candidates": {}
},
"savedArticleReducer": {
"articles": [],
"status": {}
},
"newslettersReducer": {
"isFetching": false,
"fetchFailed": false,
"hasFetched": false,
"newsletters": {},
"isSubscribing": false,
"isUnsubscribing": false,
"subscribedNewsletters": {}
},
"termsReducer": {
"about": {
"name": "About",
"type": "terms",
"id": "about",
"slug": "about",
"link": "/about",
"taxonomy": "site"
},
"arts": {
"name": "Arts & Culture",
"grouping": [
"arts",
"pop",
"trulyca"
],
"description": "KQED Arts provides daily in-depth coverage of the Bay Area's music, art, film, performing arts, literature and arts news, as well as cultural commentary and criticism.",
"type": "terms",
"id": "arts",
"slug": "arts",
"link": "/arts",
"taxonomy": "site"
},
"artschool": {
"name": "Art School",
"parent": "arts",
"type": "terms",
"id": "artschool",
"slug": "artschool",
"link": "/artschool",
"taxonomy": "site"
},
"bayareabites": {
"name": "KQED food",
"grouping": [
"food",
"bayareabites",
"checkplease"
],
"parent": "food",
"type": "terms",
"id": "bayareabites",
"slug": "bayareabites",
"link": "/food",
"taxonomy": "site"
},
"bayareahiphop": {
"name": "Bay Area Hiphop",
"type": "terms",
"id": "bayareahiphop",
"slug": "bayareahiphop",
"link": "/bayareahiphop",
"taxonomy": "site"
},
"campaign21": {
"name": "Campaign 21",
"type": "terms",
"id": "campaign21",
"slug": "campaign21",
"link": "/campaign21",
"taxonomy": "site"
},
"careers": {
"name": "Careers",
"type": "terms",
"id": "careers",
"slug": "careers",
"link": "/careers",
"taxonomy": "site"
},
"checkplease": {
"name": "KQED food",
"grouping": [
"food",
"bayareabites",
"checkplease"
],
"parent": "food",
"type": "terms",
"id": "checkplease",
"slug": "checkplease",
"link": "/food",
"taxonomy": "site"
},
"education": {
"name": "Education",
"grouping": [
"education"
],
"type": "terms",
"id": "education",
"slug": "education",
"link": "/education",
"taxonomy": "site"
},
"elections": {
"name": "Elections",
"type": "terms",
"id": "elections",
"slug": "elections",
"link": "/elections",
"taxonomy": "site"
},
"events": {
"name": "Events",
"type": "terms",
"id": "events",
"slug": "events",
"link": "/events",
"taxonomy": "site"
},
"event": {
"name": "Event",
"alias": "events",
"type": "terms",
"id": "event",
"slug": "event",
"link": "/event",
"taxonomy": "site"
},
"filmschoolshorts": {
"name": "Film School Shorts",
"type": "terms",
"id": "filmschoolshorts",
"slug": "filmschoolshorts",
"link": "/filmschoolshorts",
"taxonomy": "site"
},
"food": {
"name": "KQED food",
"grouping": [
"food",
"bayareabites",
"checkplease"
],
"type": "terms",
"id": "food",
"slug": "food",
"link": "/food",
"taxonomy": "site"
},
"forum": {
"name": "Forum",
"relatedContentQuery": "posts/forum?",
"parent": "news",
"type": "terms",
"id": "forum",
"slug": "forum",
"link": "/forum",
"taxonomy": "site"
},
"futureofyou": {
"name": "Future of You",
"grouping": [
"science",
"futureofyou"
],
"parent": "science",
"type": "terms",
"id": "futureofyou",
"slug": "futureofyou",
"link": "/futureofyou",
"taxonomy": "site"
},
"jpepinheart": {
"name": "KQED food",
"relatedContentQuery": "posts/food,bayareabites,checkplease",
"parent": "food",
"type": "terms",
"id": "jpepinheart",
"slug": "jpepinheart",
"link": "/food",
"taxonomy": "site"
},
"liveblog": {
"name": "Live Blog",
"type": "terms",
"id": "liveblog",
"slug": "liveblog",
"link": "/liveblog",
"taxonomy": "site"
},
"livetv": {
"name": "Live TV",
"parent": "tv",
"type": "terms",
"id": "livetv",
"slug": "livetv",
"link": "/livetv",
"taxonomy": "site"
},
"lowdown": {
"name": "The Lowdown",
"relatedContentQuery": "posts/lowdown?",
"parent": "news",
"type": "terms",
"id": "lowdown",
"slug": "lowdown",
"link": "/lowdown",
"taxonomy": "site"
},
"mindshift": {
"name": "Mindshift",
"parent": "news",
"description": "MindShift explores the future of education by highlighting the innovative – and sometimes counterintuitive – ways educators and parents are helping all children succeed.",
"type": "terms",
"id": "mindshift",
"slug": "mindshift",
"link": "/mindshift",
"taxonomy": "site"
},
"news": {
"name": "News",
"grouping": [
"news",
"forum"
],
"type": "terms",
"id": "news",
"slug": "news",
"link": "/news",
"taxonomy": "site"
},
"newsletters": {
"name": "newsletters",
"type": "terms",
"id": "newsletters",
"slug": "newsletters",
"link": "/newsletters",
"taxonomy": "site"
},
"perspectives": {
"name": "Perspectives",
"parent": "radio",
"type": "terms",
"id": "perspectives",
"slug": "perspectives",
"link": "/perspectives",
"taxonomy": "site"
},
"podcasts": {
"name": "Podcasts",
"type": "terms",
"id": "podcasts",
"slug": "podcasts",
"link": "/podcasts",
"taxonomy": "site"
},
"pop": {
"name": "Pop",
"parent": "arts",
"type": "terms",
"id": "pop",
"slug": "pop",
"link": "/pop",
"taxonomy": "site"
},
"pressroom": {
"name": "Pressroom",
"type": "terms",
"id": "pressroom",
"slug": "pressroom",
"link": "/pressroom",
"taxonomy": "site"
},
"quest": {
"name": "Quest",
"parent": "science",
"type": "terms",
"id": "quest",
"slug": "quest",
"link": "/quest",
"taxonomy": "site"
},
"radio": {
"name": "Radio",
"grouping": [
"forum",
"perspectives"
],
"description": "Listen to KQED Public Radio – home of Forum and The California Report – on 88.5 FM in San Francisco, 89.3 FM in Sacramento, 88.3 FM in Santa Rosa and 88.1 FM in Martinez.",
"type": "terms",
"id": "radio",
"slug": "radio",
"link": "/radio",
"taxonomy": "site"
},
"root": {
"name": "KQED",
"image": "https://ww2.kqed.org/app/uploads/2020/02/KQED-OG-Image@1x.png",
"imageWidth": 1200,
"imageHeight": 630,
"headData": {
"title": "KQED | News, Radio, Podcasts, TV | Public Media for Northern California",
"description": "KQED provides public radio, television, and independent reporting on issues that matter to the Bay Area. We’re the NPR and PBS member station for Northern California."
},
"type": "terms",
"id": "root",
"slug": "root",
"link": "/root",
"taxonomy": "site"
},
"science": {
"name": "Science",
"grouping": [
"science",
"futureofyou"
],
"description": "KQED Science brings you award-winning science and environment coverage from the Bay Area and beyond.",
"type": "terms",
"id": "science",
"slug": "science",
"link": "/science",
"taxonomy": "site"
},
"stateofhealth": {
"name": "State of Health",
"parent": "science",
"type": "terms",
"id": "stateofhealth",
"slug": "stateofhealth",
"link": "/stateofhealth",
"taxonomy": "site"
},
"support": {
"name": "Support",
"type": "terms",
"id": "support",
"slug": "support",
"link": "/support",
"taxonomy": "site"
},
"thedolist": {
"name": "The Do List",
"parent": "arts",
"type": "terms",
"id": "thedolist",
"slug": "thedolist",
"link": "/thedolist",
"taxonomy": "site"
},
"trulyca": {
"name": "Truly CA",
"grouping": [
"arts",
"pop",
"trulyca"
],
"parent": "arts",
"type": "terms",
"id": "trulyca",
"slug": "trulyca",
"link": "/trulyca",
"taxonomy": "site"
},
"tv": {
"name": "TV",
"type": "terms",
"id": "tv",
"slug": "tv",
"link": "/tv",
"taxonomy": "site"
},
"voterguide": {
"name": "Voter Guide",
"parent": "elections",
"alias": "elections",
"type": "terms",
"id": "voterguide",
"slug": "voterguide",
"link": "/voterguide",
"taxonomy": "site"
},
"guiaelectoral": {
"name": "Guia Electoral",
"parent": "elections",
"alias": "elections",
"type": "terms",
"id": "guiaelectoral",
"slug": "guiaelectoral",
"link": "/guiaelectoral",
"taxonomy": "site"
},
"futureofyou_tag_theranos": {
"isLoading": true
},
"futureofyou_617": {
"type": "terms",
"id": "futureofyou_617",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "617",
"found": true
},
"relationships": {},
"featImg": null,
"name": "theranos",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "theranos Archives | KQED Arts",
"ogDescription": null
},
"ttid": 617,
"slug": "theranos",
"isLoading": false,
"link": "/futureofyou/tag/theranos"
},
"source_futureofyou_257644": {
"type": "terms",
"id": "source_futureofyou_257644",
"meta": {
"override": true
},
"name": "Future of You",
"isLoading": false
},
"source_futureofyou_231240": {
"type": "terms",
"id": "source_futureofyou_231240",
"meta": {
"override": true
},
"name": "Future of You",
"isLoading": false
},
"source_futureofyou_210797": {
"type": "terms",
"id": "source_futureofyou_210797",
"meta": {
"override": true
},
"name": "Future of You",
"isLoading": false
},
"source_futureofyou_199691": {
"type": "terms",
"id": "source_futureofyou_199691",
"meta": {
"override": true
},
"name": "Future of You",
"isLoading": false
},
"source_futureofyou_190748": {
"type": "terms",
"id": "source_futureofyou_190748",
"meta": {
"override": true
},
"name": "Future of You",
"isLoading": false
},
"futureofyou_1060": {
"type": "terms",
"id": "futureofyou_1060",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "1060",
"found": true
},
"relationships": {},
"featImg": null,
"name": "DIY Health",
"description": null,
"taxonomy": "category",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "DIY Health Archives | KQED Arts",
"ogDescription": null
},
"ttid": 1060,
"slug": "diy-health",
"isLoading": false,
"link": "/futureofyou/category/diy-health"
},
"futureofyou_452": {
"type": "terms",
"id": "futureofyou_452",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "452",
"found": true
},
"relationships": {},
"featImg": null,
"name": "Health Policy",
"description": null,
"taxonomy": "category",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "Health Policy Archives | KQED Arts",
"ogDescription": null
},
"ttid": 452,
"slug": "health-policy",
"isLoading": false,
"link": "/futureofyou/category/health-policy"
},
"futureofyou_1062": {
"type": "terms",
"id": "futureofyou_1062",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "1062",
"found": true
},
"relationships": {},
"featImg": null,
"name": "Hope/Hype",
"description": null,
"taxonomy": "category",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "Hope/Hype Archives | KQED Arts",
"ogDescription": null
},
"ttid": 1062,
"slug": "hopehype",
"isLoading": false,
"link": "/futureofyou/category/hopehype"
},
"futureofyou_1": {
"type": "terms",
"id": "futureofyou_1",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "1",
"found": true
},
"relationships": {},
"featImg": null,
"name": "KQED Future Of You",
"description": null,
"taxonomy": "category",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "KQED Future Of You Archives | KQED Arts",
"ogDescription": null
},
"ttid": 1,
"slug": "future-of-you",
"isLoading": false,
"link": "/futureofyou/category/future-of-you"
},
"futureofyou_73": {
"type": "terms",
"id": "futureofyou_73",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "73",
"found": true
},
"relationships": {},
"featImg": null,
"name": "KQED News",
"description": null,
"taxonomy": "category",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "KQED News Archives | KQED Arts",
"ogDescription": null
},
"ttid": 73,
"slug": "kqed-news",
"isLoading": false,
"link": "/futureofyou/category/kqed-news"
},
"futureofyou_814": {
"type": "terms",
"id": "futureofyou_814",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "814",
"found": true
},
"relationships": {},
"featImg": null,
"name": "Elizabeth Holmes",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "Elizabeth Holmes Archives | KQED Arts",
"ogDescription": null
},
"ttid": 814,
"slug": "elizabeth-holmes",
"isLoading": false,
"link": "/futureofyou/tag/elizabeth-holmes"
},
"futureofyou_38": {
"type": "terms",
"id": "futureofyou_38",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "38",
"found": true
},
"relationships": {},
"featImg": null,
"name": "FDA",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "FDA Archives | KQED Arts",
"ogDescription": null
},
"ttid": 38,
"slug": "fda",
"isLoading": false,
"link": "/futureofyou/tag/fda"
},
"futureofyou_1032": {
"type": "terms",
"id": "futureofyou_1032",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "1032",
"found": true
},
"relationships": {},
"featImg": null,
"name": "Zika",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "Zika Archives | KQED Arts",
"ogDescription": null
},
"ttid": 1032,
"slug": "zika",
"isLoading": false,
"link": "/futureofyou/tag/zika"
},
"futureofyou_971": {
"type": "terms",
"id": "futureofyou_971",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "971",
"found": true
},
"relationships": {},
"featImg": null,
"name": "CMS",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "CMS Archives | KQED Arts",
"ogDescription": null
},
"ttid": 971,
"slug": "cms",
"isLoading": false,
"link": "/futureofyou/tag/cms"
},
"futureofyou_865": {
"type": "terms",
"id": "futureofyou_865",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "865",
"found": true
},
"relationships": {},
"featImg": null,
"name": "AACC",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "AACC Archives | KQED Arts",
"ogDescription": null
},
"ttid": 865,
"slug": "aacc",
"isLoading": false,
"link": "/futureofyou/tag/aacc"
},
"futureofyou_80": {
"type": "terms",
"id": "futureofyou_80",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "80",
"found": true
},
"relationships": {},
"featImg": null,
"name": "kqedscience",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "kqedscience Archives | KQED Arts",
"ogDescription": null
},
"ttid": 80,
"slug": "kqedscience",
"isLoading": false,
"link": "/futureofyou/tag/kqedscience"
},
"futureofyou_964": {
"type": "terms",
"id": "futureofyou_964",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "964",
"found": true
},
"relationships": {},
"featImg": null,
"name": "Brooke Buchanan",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "Brooke Buchanan Archives | KQED Arts",
"ogDescription": null
},
"ttid": 964,
"slug": "brooke-buchanan",
"isLoading": false,
"link": "/futureofyou/tag/brooke-buchanan"
},
"futureofyou_245": {
"type": "terms",
"id": "futureofyou_245",
"meta": {
"index": "terms_1716263798",
"site": "futureofyou",
"id": "245",
"found": true
},
"relationships": {},
"featImg": null,
"name": "walgreens",
"description": null,
"taxonomy": "tag",
"headData": {
"twImgId": null,
"twTitle": null,
"ogTitle": null,
"ogImgId": null,
"twDescription": null,
"description": null,
"title": "walgreens Archives | KQED Arts",
"ogDescription": null
},
"ttid": 245,
"slug": "walgreens",
"isLoading": false,
"link": "/futureofyou/tag/walgreens"
}
},
"userPermissionsReducer": {
"wpLoggedIn": false
},
"eventsReducer": {},
"fssReducer": {},
"tvDailyScheduleReducer": {},
"tvWeeklyScheduleReducer": {},
"tvPrimetimeScheduleReducer": {},
"tvMonthlyScheduleReducer": {},
"userAccountReducer": {
"user": {
"email": null,
"emailStatus": "EMAIL_UNVALIDATED",
"loggedStatus": "LOGGED_OUT",
"loggingChecked": false,
"articles": [],
"firstName": null,
"lastName": null,
"phoneNumber": null,
"fetchingMembership": false,
"membershipError": false,
"memberships": [
{
"id": null,
"startDate": null,
"firstName": null,
"lastName": null,
"familyNumber": null,
"memberNumber": null,
"memberSince": null,
"expirationDate": null,
"pfsEligible": false,
"isSustaining": false,
"membershipLevel": "Prospect",
"membershipStatus": "Non Member",
"lastGiftDate": null,
"renewalDate": null,
"lastDonationAmount": null
}
]
},
"authModal": {
"isOpen": false,
"view": "LANDING_VIEW"
},
"error": null
},
"youthMediaReducer": {},
"checkPleaseReducer": {
"filterData": {
"region": {
"key": "Restaurant Region",
"filters": [
"Any Region"
]
},
"cuisine": {
"key": "Restaurant Cuisine",
"filters": [
"Any Cuisine"
]
}
},
"restaurantDataById": {},
"restaurantIdsSorted": [],
"error": null
},
"userAgentReducer": {
"userAgent": "Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)",
"isBot": true
},
"requestOutcomesReducer": {
"notFound": []
},
"navPromosReducer": {
"isFetching": false,
"fetchFailed": false,
"hasFetched": true,
"promos": {
"news": {},
"podcasts-radio": {},
"video-tv": {},
"events": {},
"support": {
"name": "Shop exclusive Bay Area offers",
"link": "https://shop.kqed.org/",
"imageURL": "https://cdn.kqed.org/wp-content/uploads/2026/11/Nav-Support-KQED-Marketplace@2x-e29b8111.png",
"description": "100% of net proceeds go to support KQED’s mission."
}
}
}
}